Publications/Abstracts

Scientific Journals

· 2021 ·
  1. S Nozza, L Timelli , A Saracino, N Gianotti, C Lazzaretti, A Tavelli, M Puoti, S Lo Caputo, A Antinori, A d'Arminio Monforte, C Mussini, E Girardi Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy J Clin Med. 2021 Jul 30;10(15):3391. doi: 10.3390/jcm10153391
  2. R Gagliardini, N Gianotti, F Maggiolo, A Cozzi-Lepri, A Antinori, S Nozza, G Lapadula, A De Luca, C Mussini, A Gori, A Saracino, M Andreoni, A d'Arminio Monforte Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy Int J Antimicrob Agents. 2021 Jul 19:106406. doi: 10.1016/j.ijantimicag.2021.106406. Online ahead of print. PMID: 34293454
  3. M Spaziante, G Taliani, G Marchetti, A Tavelli, M Lichtner, A Cingolani, S Cicalini, E Biliotti, E Girardi, A Antinori, M Puoti, A d'Arminio Monforte, A Cozzi-Lepri Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study Viruses. 2021 Jul 19;13(7):1402. doi: 10.3390/v13071402
  4. E Merlini, A Cozzi-Lepri, A Castagna, A Costantini, S Lo Caputo, S Carrara, E Quiros Roldan, M Ursitti, A Antinori, A d'Arminio Monforte, G Marchetti Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV BMC Infect Dis. 2021 Jun 12; 21(1):557. doi: 10.1186/s12879-021-06260-y
  5. C Mussini, P Lorenzini, A Cozzi-Lepri, A Mammone, G Guaraldi, G Marchetti, M Lichtner, G Lapadula, S Lo Caputo, A Antinori, A d'Arminio Monforte, E Girardi Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss Sci Rep. 2021 May 5; 11(1):9632. doi: 10.1038/s41598-021-88367-5.
  6. A Giacomelli, A Cozzi-Lepri, A Cingolani, A Tavelli, V Mazzotta, D Tesoro, M Bassetti, A Castagna, A Di Biagio, M Lichtner, A d'Arminio Monforte, S Rusconi Does syphilis increase the risk of HIV-RNA elevation >200 copies/mL in HIV positive patients under effective antiretroviral treatment? Data from the ICONA cohort J Acquir Immune Defic Syndr. 2021 Jun 15. doi: 10.1097/QAI.0000000000002749
  7. A Bandera, P Lorenzini, L Taramasso, A Cozzi-Lepri, G Lapadula, C Mussini, A Saracino, F Ceccherini-Silberstein, M Puoti, E Quiros-Roldan, F Montagnani, A Antinori, A d'Arminio Monforte, A Gori The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort J Viral Hepat. 2021 May;28(5):779-786. doi: 10.1111/jvh.13488. Epub 2021 Mar 11.PMID: 33600068
  8. G Madeddu, A De Vito, A Cozzi-Lepri, A Cingolani , F Maggiolo, CF Perno, R Gagliardini , G Marchetti, A Saracino, A d' Arminio Monforte, A Antinori, E Girardi Time spent with viral load 200 copies/mL in a cohort of people with HIV seen for care in Italy during the U=U prevention campaign era AIDS. 2021 Jan 29. doi: 10.1097/QAD.0000000000002825. Online ahead of print.PMID: 33534204
· 2020 ·
  1. V Malagnino, C Cerva, A Cingolani, F Ceccherini-Silberstein, A Vergori, G Cuomo, CF Perno, M Puoti, A d'Arminio Monforte, A Cozzi-Lepri, M Andreoni, L Sarmati HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients Open Forum Infect Dis. 2020 Nov 18;8(1):ofaa566. doi: 10.1093/ofid/ofaa566. eCollection 2021 Jan.PMID: 33447635
  2. A Vergori, R Gagliardini, N Gianotti, A Gori, M Lichtner, A Saracino, A De Vito, A Cascio, A Di Biagio, A d'Arminio Monforte, A Antinori, A Cozzi-Lepri Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? Int J Antimicrob Agents. 2020 Sep 9:106154. doi: 10.1016/j.ijantimicag.2020.106154
  3. E M Lori, A Cozzi-Lepri, A Tavelli, V Mercurio, S V Ibba, S Lo Caputo, F Castelli, A Castagna, A Gori, G Marchetti, C Venditti, M Clerici, A d'Arminio Monforte, M Biasin Evaluation of the effect of protective genetic variants on cART success in HIV - 1 - infected patients. J Biol Regul Homeost Agents. 2020 Aug 4;34(4). doi: 10.23812/19-527-L
  4. L Fabeni, MM Santoro, P Lorenzini, S Rusconi, N Gianotti, A Costantini, L Sarmati, A Antinori, F Ceccherini-Silberstein, A d'Arminio Monforte, A Saracino, E Girardi Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy Viruses. 2020 Jul 23;12(8):791. doi: 10.3390/v12080791.PMID: 32718024
  5. A d'Arminio Monforte, A Tavelli, A Cozzi-Lepri, A Castagna, S Passerini, D Francisci, A Saracino, F Maggiolo, G Lapadula, E Girardi, CF Perno, A Antinori Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort J Antimicrob Chemother. 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512.PMID: 31865395
  6. R Rossotti, A Tavelli, S Bonora, A Cingolani, S Lo Caputo, A Saracino, A Soria, L Marinaro, C Uberti-Foppa, C Mussini, M Puoti, A d'Arminio Monforte Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts  Dig Liver Dis. 2020 Apr;52(4):447-451. doi: 10.1016/j.dld.2019.12.007. Epub 2020 Jan 17.PMID: 31959479
· 2019 ·
  1. S Leone, P Lorenzini, A Cozzi-Lepri, G Orofino, D Bernacchia, A Castagna, M Menozzi, G Guaraldi, G Madeddu, A Di Biagio, M Puoti, A Gori, A d'Arminio Monforte; ICONA Foundation Study Group. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study.  Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1857-1865. doi: 10.1007/s10096-019-03618-8. Epub 2019 Jun 22.
  2. L Taramasso, P Lorenzini, A Di Biagio, M Lichtner, G Marchetti, R Rossotti, G Lapadula, A Cozzi-Lepri, F Vichi, A Antinori, S Bonora, A d'Arminio Monforte; ICONA Foundation Study Group. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.  J Antimicrob Chemother. 2019 Nov 1;74(11):3295-3304. doi: 10.1093/jac/dkz353.
  3. M Shanyinde, E Girardi, M Puoti, A De Luca, L Sighinolfi, UF Caterina, P Caramello, FC Lampe, A d’Arminio Monforte, A Cozzi-Lepri; ICONA Foundation Study Group. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? BMC Public Health. 2019 Oct 15;19(1):1291. doi: 10.1186/s12889-019-7608-1.
  4. D Armenia, D Di Carlo, A Cozzi-Lepri, A Calcagno, V Borghi, C Gori, A Bertoli, W Gennari, R Bellagamba, A Castagna, A Latini, C Pinnetti, S Cicalini, A Saracino, G Lapadula, S Rusconi, F Castelli, S Di Giambenedetto, M Andreoni, G Di Perri, A Antinori, C Mussini, F Ceccherini-Silberstein, A d’Arminio Monforte, CF Perno, MM Santoro; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.  Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3309. [Epub ahead of print].
  5. S Rusconi, MM Santoro, N Gianotti, A Antinori, S Bonora, A Cingolani, F Ceccherini-Silberstein, A Tavelli, A d’Arminio Monforte, A Cozzi-Lepri for the ICONA Foundation Study Group. Is the rate of virological failure to cART continuing to decline in recent calendar years?  Journal of Clinical Virology, Volume 116, July 2019, Pages 23-28
  6. N Gianotti, P Lorenzini, A Cozzi-Lepri, a De Luca, G Madeddu, L Sighinolfi, C Pinnetti, C Santoro, P Meraviglia, C Mussini, A Antinori, A d'Arminio Monforte; ICONA Foundation Study Group. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. Antimicrob Chemother. 2019 Jun 7. pii: dkz237. doi: 10.1093/jac/dkz237. [Epub ahead of print]
  7. A d'Arminio Monforte, A Cozzi-Lepri, A Di Biagio,G Marchetti, S Lo Caputo, S Rusconi, N Gianotti, V Mazzotta, G Mazzarello, A Costantini, A Castagna, A Antinori; ICONA Foundation Study Group. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 Jan 29. doi: 10.1093/jac/dky566. [Epub ahead of print.
  8. A Mondi , A Cozzi-Lepri, A Tavelli, S Rusconi, F Vichi, F Ceccherini-Silberstein, A Calcagno, A De Luca, F Maggiolo, G Marchetti, A Antinori, A d’Arminio Monforte and on behalf of Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.  Journal of the International AIDS Society 2019, 22:e25227
  9. A d'Arminio Monforte, A Tavelli, A Cozzi-Lepri, A Castagna, S Passerini, D Francisci, A Saracino, F Maggiolo, G Lapadula, E Girardi, CF Perno, A Antinori for the ICONA Foundation Study Group. Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. J Antimicrob Chemother. 2019 Dec 22. pii: dkz512. doi: 10.1093/jac/dkz512
· 2018 ·
  1. A d'Arminio Monforte, H Diaz-Cuervo, A De Luca, F Maggiolo, A Cingolani, S Bonora, A Castagna, E Girardi, A Antinori, S Lo Caputo, G Guaraldi, A Cozzi-Lepri; ICONA Foundation Study Group. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014.  HIV Med. 2018 Nov 21. doi: 10.1111/hiv.12683. [Epub ahead of print]
  2. C Dentone, A Di Biagio, A Cozzi-Lepri, D Fenoglio, G Filaci, M Lichtner, S Carrara, A Giacometti, L Sighinolfi, G Marchetti, A Antinori, A d'Arminio Monforte; ICONA Foundation Study Group. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.  HIV Clin Trials. 2018 Nov 13:1-5. doi: 10.1080/15284336.2018.1488453. [Epub ahead of print]
  3. F Ceccherini-Silberstein, A Cozzi Lepri, C Alteri, E Merlini, M Surdo, G Marchetti, MR Capobianchi, A De Luca, N Gianotti, P Viale, M Andreoni, A Antinori, CF Perno, A d'Arminio Monforte; ICONA Foundation Study Group. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART.  J Antimicrob Chemother. 2018 Sep 20. doi: 10.1093/jac/dky350. [Epub ahead of print]
  4. M Franzetti, A De Luca, F Ceccherini-Silberstein, V Spagnuolo, E Nicastri, C Mussini, A Antinori, L Monno, J Vecchiet, I Fanti, A d'Arminio Monforte, C Balotta; ICONA Foundation Study Group. Evolution of HIV-1 transmitted drug resistance in Italy in the 2007-2014 period: A weighted analysis.  J Clin Virol. 2018 Sep;106:49-52. doi: 10.1016/j.jcv.2018.07.009. Epub 2018 Jul 26
  5. A Saracino, M Zaccarelli, P Lorenzini, A Bandera, G Marchetti, F Castelli, A Gori, E Girardi, C Mussini, P Bonfanti, A Ammassari, A d'Arminio Monforte; Icona Foundation Study Group. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy.  BMC Public Health. 2018 Jul 13;18(1):870. doi: 10.1186/s12889-018-5804-z.
  6. L Taramasso, A Di Biagio, F Maggiolo, A Tavelli, S Lo Caputo, S Bonora, M Zaccarelli, P Caramello, A Costantini, C Viscoli, A d’Arminio Monforte and A Cozzi-Lepri on behalf of the Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.  DOI: 10.1111/hiv.12628,2018 British HIV Association HIV Medicine (2018)
  7. C Mussini, P Lorenzini, A Cozzi-Lepri, G Marchetti, S Rusconi, A Gori, S Nozza, M Lichtner, A Antinori, A Cossarizza, A d’Arminio Monforte and for the Icona Foundation Study Group. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine (2018) 16:79 https://doi.org/10.1186/s12916-018-1046-2
  8. A d'Arminio Monforte, P Lorenzini, A Cozzi-Lepri3, C Mussini, A Castagna5, F Baldelli, M Puoti, F Vichi, A Maddaloni, S Lo Caputo, Nicola Gianotti, A Antinori on behalf of the Icona Foundation Study Group. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.  HIV Clin Trials. 2018 Apr;19(2):52-60. doi: 10.1080/15284336.2018.1440691. Epub 2018 Mar 1.
  9. A Saracino, A Cozzi-Lepri, M Shanyinde, F Ceccherini Silberstein, S Nozza, A Di Biagio, G Cassola, G Bruno, M Capobianchi, M Puoti, L Monno, A d'Arminio Monforte; ICONA Foundation Study. HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients.  PLoS One. 2018 Jan 11;13(1):e0190302. doi: 10.1371/journal.pone.0190302. eCollection 2018.
  10. S Leone, M Shanyinde, A Cozzi Lepri, FC Lampe, P Caramello, A Costantini, A Giacometti, A De Luca, A Cingolani, F Ceccherini Silberstein, M Puoti M, A Gori, A d'Arminio Monforte; ICONA Foundation Cohort Study. Incidence and predictors of single drug discontinuation according to the presence of HCVcoinfection in HIV patients from the ICONA Foundation Cohort Study.  Eur J Clin Microbiol Infect Dis. 2018 Jan 9. doi: 10.1007/s10096-017-3180-8. [Epub ahead of print]
· 2017 ·
  1. M Smit, R Cassidy, A Cozzi-Lepri, E Quiros-Roldan, E Girardi, A Mammone, A Antinori, A Saracino, F Bai, S Rusconi, G Magnani, F Castelli, P Hsue, A d'Arminio Monforte, TB Hallett. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017 Oct 23;12(10):e0186638. doi: 10.1371/journal.pone.0186638. eCollection 2017.
  2. N Gianotti, G Marchetti, A Antinori, A Saracino, A Gori, G Rizzardini, M Lichtner, A Bandera, C Mussini, E Girardi, A d’Arminio Monforte, A Cozzi-Lepri; ICONA Foundation Study Group. Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):417-422. doi: 10.1097/QAI.0000000000001522
  3. B Rossetti, F Bai, A Tavelli, M Galli, A Antinori, F Castelli, G Pellizzer, A Cozzi-Lepri, S Bonora, A d’Arminio Monforte, M Puoti, A De Luca; ICONA Foundation study group. Evolution of the prevalence of HCV infection and HCV genotype distribution in HIV-infected patients in Italy between 1997 and 2015. Clin Microbiol Infect. 2017 Jul 29. pii: S1198-743X(17)30405-6. doi: 10.1016/j.cmi.2017.07.021. [Epub ahead of print]
  4. A De Luca, P Lorenzini, A Castagna, M Puoti, N Gianotti, F Castelli, C Mastroianni, F Maggiolo, A Antinori, G Guaraldi, M Lichtner, A dʼArminio Monforte; ICONA Foundation Study. Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):465-471. doi: 10.1097/QAI.0000000000001443.
  5. N Gianotti, A Cozzi-Lepri, A Antinori, A Castagna, A De Luca, BM Celesia, M Galli, C Mussini, C Pinnetti, V Spagnuolo, A d'Arminio Monforte, F Ceccherini-Silberstein, M Andreoni; Icona Foundation Study and mono-PI/r database Study Cohorts. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.  PLoS One. 2017 Feb 13;12(2):e0171611. doi: 10.1371/journal.pone.0171611. eCollection 2017.
  6. A d'Arminio Monforte , A Cozzi-Lepri, F Ceccherini-Silberstein, A De Luca, S Lo Caputo, A Castagna, C Mussini, A Cingolani, A Tavelli, M Shanyinde, A Gori, E Girardi, M Andreoni, A Antinori, M Puoti; Icona Foundation and HepaIcona Study Group. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.  PLoS One. 2017 May 17;12(5):e0177402. doi: 10.1371/journal.pone.0177402. eCollection 2017.
  7. M Puoti, P Lorenzini , A Cozzi-Lepri, A Gori, C Mastroianni, G Rizzardini, G Mazzarello, A Antinori , A d'Arminio Monforte, E Girardi, The Icona Foundation Study Group. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.  Clinical Microbiology and Infection 23 (2017) 267.e1e267.e4
  8. G Madeddu; S Rusconi; A Cozzi-Lepri; S Di Giambenedetto; S Bonora; A Carbone; A De Luca; N Gianotti; A Di Biagio; A Antinori for the Icona Foundation Study Group. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.  Infection (2017). 5 maggio 2017 - doi:10.1007/s15010-017-1018-z.
  9. S Vita, M Lichtner, G Marchetti, C Mascia, E Merlini, P Cicconi, V Vullo, P Viale, A Costantini, A dʼArminio Monforte; ICONA Foundation Study Group. Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort.  J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):347-352. doi: 10.1097/QAI.0000000000001232.
  10. Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, Hohaus S, Bandera A, Alba L, Galizzi N, Castagna A, D'arminio Monforte A, Antinori A; ICONA Foundation Study group. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS One. 2017 Oct 31;12(10):e0186549. doi: 10.1371/journal.pone.0186549.
  11. Di Biagio A, Lorenzini P, Gustinetti G, Rusconi S, De Luca A, Lapadula G, Lo Caputo S, Cicalini S, Castelli F, Marchetti G, Antinori A, Monforte AD. Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation.  AIDS Patient Care STDS. 2017 Dec;31(12):487-494. doi: 10.1089/apc.2017.0140.
  12. Nozza S, Cozzi-Lepri A, Bai F, Rusconi S, Gori A, Cinque P, Ammassari A, Caramello P, Tambussi G, D'Arminio Monforte A, Marchetti G; Icona Foundation Study Group. Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort.  PLoS One. 2017 Dec 5;12(12):e0189045. doi: 10.1371/journal.pone.0189045.
· 2016 ·
  1. S Costarelli, A Cozzi-Lepri, G Lapadula, S Bonora, G Madeddu, F Maggiolo, A Antinori, M Galli, G Di Perri, P Viale, A d'Arminio Monforte, A Gori; ICONA Foundation Study Group. Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.  PLoS One. 2016 Oct 7;11(10):e0160761. doi: 10.1371/journal.pone.0160761.
  2. N Squillace; P Lorenzini; G Lapadula; A Bandera; A Cozzi-Lepri; S Rusconi; M Puoti; A Castagna; A Antinori; A Gori; A d'Arminio Monforte. Triglycerides/HDL Ratio And Its Impact On Risk Of Diabetes Mellitus Development During Antiretroviral Therapy. J Antimicrob Chemother. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185
  3. A Castagna, L Monno, S Carta, L Galli, S Carrara, V Fedele, G Punzi, I Fanti, P Caramello, AC LepriC, A De Luca, F Ceccherini-Silberstein, A d’Arminio Monforte; ICONA Foundation Study Group. Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. Medicine (Baltimore). 2016 Nov;95(44):e5222.
  4. N Squillace, L Galli, A Bandera, A Castagna, G Madeddu, P Caramello, A Antinori, AM Cattelan, F Maggiolo, A Cingolani, A Gori, A d’Arminio Monforte, on behalf of the ICONA Foundation Study Group. High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. Data from the ICONA Foundation Cohort. Medicine (Baltimore). 2016 Sep;95(36):e4434. doi: 10.1097/MD.0000000000004434.
  5. A d'Arminio Monforte, A Cozzi-Lepri, F Maggiolo, G Rizzardini, PE Manconi, N Gianotti, T Quirino, C Pinnetti, S Rusconi, A De Luca, A Antinori;Icona Foundation Study cohort. Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS One. 2016 Jun 27;11(6):e0156360. doi: 10.1371/journal.pone.0156360. eCollection 2016.
  6. A Di Biagio; A Cozzi-Lepri; R Prinapori; G Angarano; A Gori; T Quirino; A De Luca; A Costantini; C Mussini; G Rizzardini; A Castagna; A Antinori; A d'Arminio Monforte; for the ICONA Foundation Study Group. Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.  JAIDS Journal of Acquired Immune Deficiency Syndromes: 1 March 2016 - Volume 71 - Issue 3 - p 263–271.
  7. A Saracino, P Lorenzini, S Lo Caputo, E Girardi, F Castelli, P Bonfanti, S Rusconi, P Caramello, N Abrescia, C Mussini, L Monno, A d’Arminio Monforte. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.  Clin Microbiol Infect. 2016 Mar;22(3):288.e1-8. doi: 10.1016/j.cmi.2015.10.026. Epub 2015 Nov 10.
· 2015 ·
  1. C Mussini, P Lorenzini, M Puoti, M Lichtner, G Lapadula, S Di Giambenedetto, A Antinori, G Madeddu, A Cozzi-Lepri, A d’Arminio Monforte and A De Luca on behalf of the ICONA Foundation study group. Prognostic value of the fibrosis-4 index in human immunodeficiency virus type-1 infected patients initiating antiretroviral therapy with or without hepatitis C virus.  Plos ONE 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015
  2. A Bandera, A Gori, F Sabbatini, G Madeddu, S Bonora, R Libertone, C Mastroianni, P Bonfanti, A d'Arminio Monforte, A Cozzi-Lepri; Icona Foundation Study Group. Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS One. 2015 May 1;10(5):e0124252. doi: 10.1371/journal.pone.0124252. eCollection 2015.
  3. M Lichtner, P Cicconi, S Vita, A Cozzi-Lepri, M Galli, S Lo Caputo, A Saracino, A De Luca, MC Moioli, F Maggiolo, G Marchetti, V Vullo, A d'Arminio Monforte. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients J Infect Dis. 2015 Jan 15;211(2):178-86. doi: 10.1093/infdis/jiu417. Epub 2014 Jul 31.
  4. A Cingolani, S Zona, E Girardi, ACozzi-Lepri, L Monno, E Quiros Roldan, G Guaraldi, A Antinori, A d'Arminio Monforte, S Marcotullio; Community-Oriented Study Group of the Icona Foundation Study Group. Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort.  HIV Med. 2015 May 11. doi: 10.1111/hiv.12226.
  5. C Mussini, P Lorenzini, A Cozzi-Lepri, G Lapadula, G Marchetti, E Nicastri, A Cingolani, M Lichtner, A Antinori, A Gori, A d’Arminio Monforte, for the Icona Foundation Study Group. CD4/CD8 ratio normalisation and non-AIDS related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. The Lancet HIV 2015; 2 (3): e98-e106
· 2014 ·
  1. A Saracino, P Lorenzini, S Lo Caputo, E Girardi, F Castelli, P Bonfanti, M Galli, P Caramello, N Abrescia, C Mussini, L Monno, A d’Arminio Monforte. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared tonatives: data from the ICONA cohort. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19769. doi: 10.7448/IAS.17.4.19769. eCollection 2014.
  2. A d'Arminio Monforte, L Galli, S Lo Caputo, M Lichtner, C Pinnetti, N Bobbio, D Francisci, A Costantini, A Cingolani, F Castelli, E Girardi and A Castagna for the ICONA Foundation Study Group. Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013. J Acquir Immune Defic Syndr 2014;67:258-267
  3. A Di Biagio, LA Nicolini, P Lorenzini, M Puoti, A Antinori A, A Cozzi-Lepri, A Gori, J Vecchiet, C Mussini, M Andreoni, C Viscoli, A d'Arminio Monforte, For The Icona Foundation Study Group. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C co-infection: data from the ICONA Foundation cohort HIV Clinical Trials. HIV Clin Trials. 2014 Jul Aug;15(4):151-60. doi: 10.1310/hct1504-151
  4. G Rozera, I Abbate, E Giombini, A Castagna, A De Luca, F Ceccherini-Silberstein, A Cozzi Lepri, G Cassola, C Torti, A d'Arminio Monforte, G Ippolito and M R. Capobianchi on behalf of the ICONA Foundation Group. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. J Antimicrob Chemother. 2014 Jul 10. doi:10.1093/jac/dku255. Epub 2014 Jul 10
  5. A d'Arminio Monforte, N Gianotti, A Cozzi-Lepri, C Pinnetti, M Andreoni, G di Perri, M Galli, A Poli, A Costantini, G Orofino, F Maggiolo, G Mazzarello, BM Celesia, F Luciani, ALazzarin, L Sighinolfi, G Rizzardini, P Bonfanti, CF Perno, A Antinori; ICONA Foundation Cohort. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting. Antivir Ther. 2014;19(3):319-24. doi: 10.3851/IMP2687. Epub 2013 Sep 13
  6. G Marchetti, A Cozzi-Lepri, C Tincati, A Calcagno, F Ceccherini-Silberstein, A De Luca, A Antinori, A Castagna, M Puoti, A d'Arminio Monforte for Icona Foundation Study group Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. BMC Infectious Diseases 2014, 14:79 doi:10.1186/1471-2334-14-79
  7. A Cingolani, A Cozzi-Lepri, A Ammassari, C Mussini, MA Ursitti, P Caramello, G Angarano, P Bonfanti, A De Luca, MS Mura, E Girardi, A Antinori, A d'Arminio Monforte, for Icona Foundation Study group. Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort. Plos One 2014; Feb 27;9(2):e89861
  8. G Meini, B Rossetti, C Bianco, F Ceccherini-Silberstein, S Di Giambenedetto, L Sighinolfi, L Monno, A Castagna, G Rozera, A d'Arminio Monforte, M Zazzi and A De Luca on behalf of the ICONA Foundation Group. Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. J Antimicrob Chemother. 2014 Mar;69(3):735-41
· 2013 ·
  1. C Mussini, L Galli, A Cozzi-Lepri, A De Luca, A Antinori, V Tozzi, G Angarano, P Bonfanti, A Castagna and A d'Arminio Monforte for the ICONA Foundation Study Group. Incidence, time and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation cohort. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):339-45
  2. M Bibas, A d'Arminio Monforte, A Antinori. Free Light Chains and the risk of nonmalignant AIDS events in HIV-infected patients treated with combination antiretroviral therapy. Clin Infect Dis. 2013 May;56(9):1349-50
  3. G Lapadula, A Cozzi-Lepri, G Marchetti, A Antinori, A Chiodera, E Nicastri, G Parruti, M Galli, A Gori, A d'Arminio Monforte; ICONA Foundation Study. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS. 2013 Mar 13;27(5):769-79
  4. V Cento, C Mirabelli, S Dimonte, R Salpini, Y Han, P Trimoulet, A Bertoli, V Micheli, G Gubertini, G Cappiello, A Spano, R Longo, M Bernassola, F Mazzotta, GM De Sanctis, XX Zhang, J Verheyen, A d'Arminio Monforte, F Ceccherini-Silberstein, CF Perno, V Svicher. Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. J Gen Virol. 2013 Jan;94(Pt 1):143-9
  5. Alteri C, Artese A, Beheydt G, Santoro MM, Costa G, Parrotta L, Bertoli A, Gori C, Orchi N, Girardi E, Antinori A, Alcaro S, d'Arminio Monforte A, Theys K, Vandamme AM, Ceccherini-Silberstein F, Svicher V, Perno CF. Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. J Antimicrob Chemother. 2013 Oct;68(10):2205-9
· 2012 ·
  1. M Bibas, P Lorenzini, A Cozzi-Lepri, A Calcagno, S di Giambenedetto, A Costantini, A Castagna, V Manfrin, A d'Arminio Monforte and A Antinori for the ICONA Cohort Study Group. Polyclonal serum free light chains elevation in HIV-infected patients. AIDS 2012, 23 October 2012; 16:2107-2110
  2. M Bibas, MP Trotta, A Cozzi-Lepri, P Lorenzini, C Pinnetti, G Rizzardini, G Angarano, P Caramello, L Sighinolfi, CM Mastroianni, G Mazzarello, A Di Caro, C Di Giacomo, A d'Arminio Monforte, and A Antinori; for the ICONA Foundation Study Group. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol. 2012 Aug;87(8):749-53
  3. A De Luca, K de Gaetano Donati, A Cozzi-Lepri, M Colafigli, A De Curtis, MR Capobianchi, A Antinori, A Giacometti, G Magnani, V Vullo, R Cauda, L Iacoviello, A d'Arminio Monforte, and The ICoNA Foundation Study Group. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. JAIDS 2012; 60 (3): e98-e101
  4. S Nozza, F Canducci, L Galli, A Cozzi-Lepri, MR Capobianchi, ER Ceresola, P Narciso, R Libertone, P Castelli, M Moioli, A d'Arminio Monforte, A Castagna; on behalf of the ICONA Foundation. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naïve patients with high CD4 counts. J Antimicrob Chemother 2012 May;67(5):1224-1227
  5. E Girardi, P Scognamiglio, C Angeletti, A Gori, D Buonfrate, M Arlotti, G Mazzarello, A Castagna, M Andreoni, A d'Arminio Monforte, A Antinori and G Ippolito, for the I.Co.Na Foundation Study. Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. BMC Health Services Research 2012, 12:38
  6. A Cingolani, A Cozzi-Lepri, A Castagna, D Goletti, A De Luca, P Scarpellini, I Fanti, A Antinori, A d'Arminio Monforte, and E Girardi. Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. Clin Infect Dis. 2012 Mar;54(6):853-61
· 2011 ·
  1. F Vescini, A Cozzi-Lepri, M Borderi, MC Re, F Maggiolo, A De Luca, G Cassola, V Vullo, G Carosi, A Antinori, V Tozzi and A d'Arminio Monforte for the Icona Foundation Study Group. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):163-72
  2. A d'Arminio Monforte, A Cozzi-Lepri, E Girardi, A Castagna, C Mussini, S Di Giambenedetto, M Galli, G Cassola, V Vullo, E Quiros-Roldan, S Lo Caputo, A Antinori for the Icona Foundation Study Group. Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antiviral Therapy 2011;16(7):1103-12
  3. C Torti, A d'Arminio Monforte, AL Pozniak, G Lapadula, G Cologni, A Antinori, A De Luca, C Mussini, A Castagna, P Cicconi, L Minoli, A Costantini, G Carosi, H Liang, BM Cesana; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. BMC Infect Dis. 2011 Jan 25;11:23
  4. G Marchetti, A CozziI-Lepri, E Merlini, GM Bellistrì, A Castagna, M Galli, G Verucchi, A Antinori, A Costantini, A Giacometti, A Di Caro, and A d'Arminio Monforte for the Icona Foundation Study Group. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 2011 Jul 17;25(11):1385-94
  5. F Tordato, A Cozzi-Lepri, P Cicconi, A De Luca, A Antinori, G Verucchi, A castagna, P Nasta, N ladisa, A Giacometti, A d'Arminio Monforte, and A Gori for the Icona Foundation Study Group. Evaluation of glomerular filtrationrate in HIV-1 infected patients before anf after combined antiretroviral therapy exposure. HIV Med. 2011 Jan;12(1):4-13
  6. MCF Prosperi, A Cozzi-Lepri, A Antinori, G Cassola, C Torti, G Magnani, G Pellizzer, A Giacometti, A d'Arminio Monforte and A De Luca for the Icona Foundation Study Group. Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008. HIV Med. 2011 Mar;12(3):174-82
  7. C Alteri, MM Santoro, I Abbate, G Rozera, A Bruselles, B Bartolini, C Gori, F Forbici, N Orchi, V Tozzi, G Palamara, A Antinori, P Narciso, E Girardi, V Svicher, F Ceccherini-Silberstein, MR Capobianchi, CF Perno 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. J Antimicrob Chemother. 2011 Nov;66(11):2615-23
· 2010 ·
  1. MP Trotta, A Cozzi-Lepri, A Ammassari, J Vecchiet, G Cassola, P Caramello, V Vullo, F Soscia, A Chiodera, N Ladisa, C Abeli, R Cauda, AR Buonuomi, A Antinori, and A d'Arminio Monforte for the Icona Foundation Study Group. Rate of CD4+ Cell Count Increase Over Periods of Viral Load Suppression: Relationship with the Number of Previous Virological Failures. Clin Infect Dis. 2010, Aug 15; 51(4):456-464
  2. P Cicconi, A Cozzi-Lepri, A Castagna, EM Trecarichi, A Antinori, F Gatti, G Cassola, L Sighinolfi, P Castelli, A d'Arminio Monforte for the I.Co.N.A. Foundation Study Group. Insights into the reasons for discontinuation according to year of starting the first HAART in a cohort of antiretroviral naïve patients. HIV Medicine 2010, Feb;11(2):104-13
  3. M Zaccarelli, A Antinori, A Cozzi-Lepri, C Mussini, G Palamara, MM Santoro, V Spagnuolo, A d'Arminio Monforte, CF Perno, F Ceccherini-Silberstein. Is there any potential for first line Etravirine use? Analysis from a large dataset of ART-naïve HIV infected patients undergoing resistance test. J Acq Immune Def Syndr 2010, Jan 1;53(1):150-1
  4. MCF Prosperi, A Cozzi-Lepri, A Castagna, C Mussini, R Murri, A Giacometti, C Torti, A Costantini, P Narciso, F Ghinelli, A Antinori and A d'Arminio Monforte for the Icona Foundation Study Group. The incidence of malignancies in HIV-infected patients and postic role of current CD4 cell count: evidence from a Italian study. Clin Infect Dis. 2010 May 1;50(9):1316-21
  5. F Ceccherini-Silberstein, I Malet, L Fabeni, S Dimonte, V Svicher, R D'Arrigo, A Artese, G Costa, S Bono, S Alcaro, A d'Arminio Monforte, C Katlama, V Calvez, A Antinori, AG Marcelin, CF Perno Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother. 2010 Nov;65(11):2305-18
· 2009 ·
  1. G Morsica, F Ancarani, S Bagaglio, M Maracci, P Cicconi, A Cozzi-Lepri, G Antonucci, R Bruno, T Santantonio, L Tacconi, F Baldelli, R Piscopo, D Santoro, A Lazzarin, A d'Arminio Monforte for the Hepa I.C.o.N.A and the Icona Study Groups. Occult Hepatitis B Virus Infection in a Cohort of HIV-Positive Patients: Correlation with Hepatitis C Virus Coinfection, Virological and Immunological Features. Infection 2009, 37(5):445-9
  2. A d'Arminio Monforte, A Cozzi-Lepri, A Castagna, A Antinori, A De Luca, C Mussini, S Lo Caputo, M Arlotti, G Magnani, G Pellizzer, F Maggiolo and M Puoti, for the ICONA Foundation Study Group. Risk of developing specific AIDS defining illnesses in HIV(/HCV co-infected patients with or without liver cirrhosis. Clin Infect Dis 2009, 49(4):612-22
  3. G Morsica, S Bagaglio, P Cicconi, MR. Capobianchi, G Pellizzer, P Caramello, A Orani, C Moioli, G Rizzardini, C Uberti-Foppa, M Puoti, A d'Arminio Monforte for the Hepa I.C.o.N.A and the Icona Foundation Study Groups. Viral Interference between Hepatitis B, C and D Viruses in Dual and Triple Infections in HIV Positive Patients. J Acq Immune Def Syndr 2009, 51:574-581.
· 2008 ·
  1. B Zanone Poma, A Riva, M Nasi, P Cicconi, V Broggini, A Cozzi-Lepri, D Mologni, F Mazzotta, C Mussini, A d'Arminio Monforte, A Cossarizza, M Galli. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008, 12;22(14):1769-78
  2. P Cicconi, A Cozzi-Lepri, G Orlando, A Matteelli, E Girardi, A Degli Esposti, C Moioli, G Rizzardini, A Chiodera, G Ballardini, A d'Arminio Monforte for the I.Co.N.A. Study Group. Recent acquired STD and the use of HAART in I.Co.N.A.: analysis of the incidence of acute hepatitis B and syphilis. Infection. 2008; 36(1):46-53
  3. MP Trotta, A Ammassari, R Murri, P Marconi, M Maccarelli, A Cozzi-Lepri, R Acinapura, N Abrescia, P De Longis, V Tozzi, A Scalzini, V Vullo, E Boumis, P Nasta, A d'Arminio Monforte, and A Antinori for the AdICoNA and AdeSpall Study Group. Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons And Is Associated With Sub-Optimal Adherence To Antiretrovirals. AIDS Pat Care STD, 2008 Apr;22(4):291-9
  4. S de Wit, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, W El-Sadr, A d´Arminio Monforte, E Fontas, MG Law, N Friis-Møller, JD Lundgren. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study.  Diabetes Care. 2008 Jun;31(6):1224-9
· 2007 ·
  1. M Bongiovanni, A Gori, A Cozzi-Lepri, A Antinori, A de Luca, G Pagano, A Chiodera, M Puoti, A d'Arminio Monforte for the ICONA Cohort. Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? Clin Infect Dis. 2007 ;45(5):650-3
  2. F Ceccherini-Silberstein, V Svicher, T Sing, A Artese, MM Santoro, F Forbici, A Bertoli, S Alcaro, G Palamara, A d'Arminio Monforte, J Balzarini, A Antinori, T Lengauer, CF Perno. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol. 2007 Oct;81(20):11507-19
  3. B Larder, D Wang, A Revell, J Montaner, R Harrigan, F De Wolf, J Lange, S Wegner, L Ruiz, MJ Pérez-Elìas, S Emery, J Gatell, A d'Arminio Monforte, C Torti, M Zazzi and C Lane. The development of artificial neural networks to predict virological response to combination HIV therapy. Antiviral Therapy 2007; 12:15-24
  4. MP Trotta, A Ammassari, R Murri, A d'Arminio Monforte, A Antinori. Sexual dysfunction in HIV infection. Lancet 2007;369(9565):905-6
  5. P Cicconi, A Cozzi-Lepri, A Phillips, M Puoti, G Antonucci, PE Manconi, G Tositti, V Colangeli, M Lichtner, A d'Arminio Monforte for the HepaI.Co.N.A. and I.Co.N.A. Study Groups. Is the raised risk of liver enzyme elevation in hepatitis co-infected patients any greater in those on antiretroviral therapy than in naïve patients? AIDS 2007; 21(5):599-606
· 2006 ·
  1. A Cozzi-Lepri, A De Luca, AN Phillips, M Bongiovanni, S Di Giambenedetto, M Mena, MC Moioli, M Arlotti, L Sighinolfi, P Narciso, M Lichtner, R Cauda, A d'Arminio Monforte; ICoNA Study Group; UCSC-Roma HIV Cohort Study Group; IMIT Study Group. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. J Infect Dis 2006;194(1):20-8
  2. A De Luca, A Cozzi-Lepri, A Antinori, M Zaccarelli, M Bongiovanni, S Di Giambenedetto, P Marconi, P Cicconi, F Resta, B Grisorio, M Ciardi, A d'Arminio Monforte. Lopinavir/ritonavir or efavirenz plus two nucleosides analogues as first-line antiretroviral therapy: a non-randomized comparison. Antiviral Therapy 2006;11(5):609-618
  3. M Puoti, A Cozzi-Lepri, F Castelli, G Paraninfo, N Friis Moller, J D Lundgren, B Ledergerber, M Rickenbach, I Suarez-Lozano, M Garrido, F Dabis, M Winnock, L Milazzo, A Gervais, F Raffi, J Gill, J Rockstroh, N Qurishi, C Mussini, A Castagna, A De Luca, A d'Arminio Monforte for the HBV-HIV international intercohort study group. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis Antiviral Therapy 2006; 11 567-574
  4. M Solmone, E Girardi, El Lalle, I Abbate, A d'Arminio Monforte, A Cozzi-Lepri, A Alessandrini, R Piscopo, F Ebo, L Cosco, G Antonucci, G Ippolito, MR Capobianchi for the HepaI.Co.N.A. and the I.Co.N.A. Study Group. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCVcoinfected patients according to the pattern of response to highly active antiretroviral therapy. Antiviral Therapy 2006; 11: 87-94
  5. V Svicher, T Sing A d'Arminio Monforte, A Antinori, T Lengauer,F Ceccherini-Silberstein, CF Perno. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006: 80 (14):7186-7198
  6. R Murri, A Cozzi-Lepri, P Cicconi, A Poggio, M Arlotti, G Tositti, D Santoro, ML Soranzo, G Rizzardini, V Colangeli, M Montroni, A d'Arminio Monforte; ICoNA Study Group. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naïve patients study. J Acquir Immune Defic Syndr. 2006;41(1):23-30
  7. P Biswas, A Cozzi-Lepri, F Delfanti, A Galli, V Colangeli, MC Moioli, A Scarchilli, N Abrescia, G Vigevani, A d'Arminio Monforte, R Novati, A Lazzarin. Significant link between sCD30 changes and HIV viremia in patients treated with HAART. J Med Virol. 2006;78(12):1513-1519
  8. V Svicher, T Sing, MM Santoro, A Bertoli, F Forbici, A Artese, A d'Arminio Monforte, A Antinori, CF Perno and F Ceccherini-Silberstein Additional mutations in HIV-1 reverse transcriptase involved in regulation of NNRTI resistance. Antiviral Therapy, 2006 11:S165
· 2005 ·
  1. G Antonucci, E Girardi, A Cozzi-Lepri, MR Capobianchi, G Morsica, P Pizzaferri, N Ladisa, L Sighinolfi, A Chiodera, M Solmone, E Lalle, G Ippolito, A d'Arminio Monforte for the HepaI.Co.N.A., and the I.Co.N.A. Study Group. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral naïve HIV-infected individuals. Antiviral Therapy 2005, 10:109-117
  2. A d'Arminio Monforte, A Cozzi-Lepri, A Phillips, A De Luca, R Murri, C Mussini, P Grossi, A Galli, G Ballardini, M Montoni, P Tundo, M Moroni for the I.Co.N.A Study Group. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the I.Co.N.A study. J Acquir Immune Defic Syndr 2005; 38:407-416
  3. V Svicher, F Ceccherini-Silberstein, F Erba, M Santoro, C Gori, MC Bellocchi, S Giannella, MP Trotta, A d'Arminio Monforte, A Antinori, and CF Perno. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. J Antimicrob Agents Chemother 2005; 49:2015-2025
  4. CF Perno, A Cozzi-Lepri, F Ceccherini-Silberstein, A d'Arminio Monforte, for ICONA Study Group. Correlation between M36I in HIV protease and selection/maintenance of L90M after treatment with protease inhibitors. J Infect Dis 2005; 191:1779-80
  5. G Antonucci, E Girardi, A Cozzi-Lepri, MR Capobianchi, A De Luca, M Puoti, E Petrelli, G Carnevale, G Rizzardini, PA Grossi, P Viganò, MC Moioli, F Carletti, M Solmone, G Ippolito, A d'Arminio Monforte for the HepaI.Co.N.A., and the I.Co.N.A. Study Group. Role of HCV viraemia and HCV genotype in the immune recovery from HAART in a cohort of antiretroviral naïve HIV-infected individuals. Clin Infect Dis 2005; 40:e101-109
  6. MS Aloisi, R Murri, A d'Arminio Monforte, D Bertelli, V Colangeli, F Leoncini, G Ippolito, E Girardi. for the I.CO.N.A. Study Group. Partnership of HIV-infected women and health status. J Acquir Immune Defic Syndr 2005; 39(4):502-503
  7. M Merito, A Bonaccorsi, F Pammolli, M Riccaboni, G Baio, C Arici, A d'Arminio Monforte, P Pezzotti, D Corsini, A Tramarin, R Cauda, V Colangeli, G Pastore. Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. Health policy 2005; 74(3):304-313
  8. G Antonucci, A Cozzi-Lepri, E Girardi, MR Capobianchi, A De Luca, A d'Arminio Monforte for the HepaI.Co.N.A. Study Group. Effect of HCV genotype on CD4+ cell count in a cohort of antiretroviral naïve HIV-infected individuals. J Infect Dis 2005; 192(4):703-704
  9. F Ceccherini-Silberstein, F Gago, M Santoro, C Gori, V Svicher, F Rodriguez-Barrios, R d'Arrigo, M Ciccozzi, A Bertoli, A d'Arminio Monforte, J Balzarini, A Antinori and CF Perno for the I.CO.N.A. Study Group. High sequence conservation of HIV-1 reverse transcriptase under drug pressure despite a continuous appearance of mutations. J Virol 2005; 79:10718-10729
  10. F Ceccherini-Silberstein, V Svicher, T Sing, M Santoro, N Beerenwikel, F Gago, A Bertoli, F Forbici, MC Bellocchi, P Narciso, A d'Arminio Monforte, A Antinori and CF Perno for the I.CO.N.A. Study Group Involvement of novel HIV-1 reverse transcriptase mutations in the highly ordered regulation of NRTI resistance. Antiviral Therapy 2005; 10:S106
· 2004 ·
  1. M Violin, A Cozzi-Lepri, R Velleca, A Vincenti, S D'Elia, F Chiodo, F Ghinelli, A Bertoli, A d'Arminio Monforte, CF Perno, M Moroni, C Balotta for the I.CO.N.A. Study Group. Risk of virological failure in antiretroviral-naïve patients with HIV-1 revertants at RT position 215 starting thymidine analog-containing HAART: a cohort study. AIDS 2004; 18(2):227-235
  2. A Antinori, A Cozzi-Lepri, A Ammassari, MP Trotta, D Nauwelaers, R Murri, S Melzi, P Narciso, P Nasta, M Zaccarelli, P Santopadre, J Vecchiet, CM Izzo and A d'Arminio Monforte for the Ad.I.Co.N.A. Study Group. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antiviral Therapy 2004; 9:291-294
  3. CF Perno, A Cozzi-Lepri, F Forbici, A Bertoli, M Violin, MS Mura, GP Cadeo, A Orani, A Chirianni, C De Stefano, C Balotta, A d'Arminio Monforte for the I.CO.N.A Study Group. Minor Mutations in HIV-Protease at Baseline and Appearance of Primary Mutation 90M in Patients Failing Their First Protease-Inhibitor Antiretroviral Regimens. J Infect Dis 2004; 189(11):1983-7
  4. F Ceccherini-Silberstein, F Erba, F Gago, A Bertoli, F Forbici, MC Bellocchi, C Gori, R d'Arrigo, L Marcon, C Balotta, A Antinori, A d'Arminio Monforte, and Carlo-Federico Perno for the I.CO.N.A. Study Group. Identification of the Minimal Conserved Structure of HIV-1. Protease in the Presence and Absence of Drug Pressure. AIDS 2004; 18(12):F11-9
  5. E Girardi, MS Aloisi, C Arici, P Pezzotti, D Serraino, R Balzano, GM Vigevani, F Alberici, M Ursitti, M D'Alessandro, A d'Arminio Monforte, G Ippolito for the I.CO.N.A. Study Group. Delayed presentation and late testing for HIV: demographic and behavioural risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr 2004; 36:951-959
  6. A De Luca, A Cozzi-Lepri, CF Perno, C Balotta, S Di Giambenedetto, A Poggio, G Pagano, G Tositti, R Piscopo, A Del Forno, F Chiodo, G Magnani and A d'Arminio Monforte for the I.Co.N.A drug resistance study group and the I.Co.N.A study group. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems. Antiviral Therapy 2004; 9: 743-752
  7. M Puoti, A Cozzi-Lepri, F Ancarani, R Bruno, S Ambu, T Ferraro, P Tundo, T Santantonio, M Toti, M Bonasso, A d'Arminio Monforte for the HepaI.Co.N.A. Study Group. The management of hepatitis B virus (HBV) / HIV-1 co-infected patients starting their first HAART regimen. Treating two infections at the price of one drug? Antiviral Therapy 2004; 9:811-817
  8. A Ammassari, A Antinori, MS Aloisi, MP Trotta, R Murri, L Bartoli, A d'Arminio Monforte, AW Wu, F Starace. The relationship of depressive symptoms, neurocognitive impairment and HAART adherence among HIV-infected persons. Psychosomatics 2004; 45: 394-402
  9. R Murri, A Ammassari, MP Trotta, A De Luca, S Melzi, C Minardi, M Zaccarelli, P Rellecati, P Santopadre, F Soscia, A Scasso, V Tozzi, M Ciardi, GC Orofino, P Noto, A d'Arminio Monforte, A Antinori, AW Wu for the AdICoNA Study Group. Patient-reported and physician estimated adherence to HAART: social and clinic center related factors are associated with discordance. J Gen Intern Med 2004; 19: 1104-1110
  10. M Violin, R Velleca, A Cozzi-Lepri, C Riva, PA Grossi, G Carnevale, G Rizzardini, E Petrelli, CF Perno, A d'Arminio Monforte, C Balotta. Prevalence of HIV-1 primary drug resistance in seroconverters of I.CO.N.A. cohort over the period 1996-2001. J Acquir Immune Defic Syndr 2004; 36 (2): 761-764
· 2003 ·
  1. MP Trotta, A Ammassari, A Cozzi-Lepri, M Zaccarelli, F Castelli, P Narciso, S Melzi, R Murri, F Baldelli, P Noto, J Vecchiet, A De Luca, A d'Arminio Monforte and A Antinori for the AdICONA and AdeSpall Study Group. Adherence to HAART is better in patients receiving NNRTI-containing regimens than in those receiving PI-containing regimens. AIDS 2003; 17:1099-1102.
  2. E Riva, G Antonelli, C Scagnolari, M Pistello, MR Capobianchi, A d'Arminio Monforte, P Pezzotti, F Dianzani for the I.CO.N.A Study Group. Human Immunodeficiency Virus (HIV) DNA Load and Level of Immunosuppression in Treatment-Naive HIV-1-Infected Patients. J Infect Dis 2003; 187:1826-1827
  3. G Nasti, R Talamini, A Antinori, F Martellotta, G Jacchetti, F Chiodo, G Ballardini, L Stoppini, G Di Perri, M Mena, M Tavio, E Vaccher, A d'Arminio Monforte and U Tirelli for GICAT and ICONA Study Groups. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS clinical trial group staging system in the HAART era. J Clin Oncol 2003; 21:2876-2882
  4. R Murri, A Cozzi-Lepri, AN Phillips, E Girardi, G Nasti, S Ferrara, MS Mura, C Mussini, E Petrelli, M Arlotti, C De Stefano, P Vigano, R Novati, A Cargnel, A d'Arminio Monforte for the I.CO.N.A. Study Group. Access to antiretroviral treatment, incidence of sustained therapy interruptions and risk of clinical events according to sex: evidence from the I.CO.N.A study. J Acquir Immune Defic Syndr 2003; 34:184-191
  5. A Ammassari, F Starace, MS Aloisi, MP Trotta, R Murri, A d'Arminio Monforte, A Antinori. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2003; 61:723-724
  6. G Nasti, F Martellotta, M Berretta, M Mena, M Fasan, G Di Perri, R Talamini, G Pagano, M Montroni, R Cinelli, E Vaccher, A d'Arminio Monforte, U Tirelli. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 11:2440-2446
· 2002 ·
  1. A Cozzi-Lepri, AN Phillips, A d'Arminio Monforte, N Piersantelli, A Orani, N Petrosillo, F Leoncini, T Ferraro, P Grima, N Abrescia and M Moroni for the I.CO.N.A. study group. Virological and immunological response to regimens containing nevirapine or efavirenz in combination with two nucleoside analogues in the I.CO.N.A. Study. J Infect Dis 2002; 185: 1062-1069
  2. CF Perno, A Cozzi-Lepri, C Balotta, M Violin, A Bertoli, L Monno, T Zauli, M Montroni, G Ippolito, A d'Arminio Monforte, for the I.CO.N.A. Study Group. Low prevalence of primary mutations associated to drug resitance in antiretroviral-naïve patients at initiation of HAART. AIDS 2002; 16:619-624
  3. M Violin, F Forbici, A Cozzi-Lepri, R Velleca, A Bertoli, PE Manconi, A Lazzarin, S Pasquinucci, L Tacconi, G Carnevale, F Mazzotta, L Bonazzi, M Montroni, A Chirianni, MR Capobianchi, G Ippolito, M Moroni, CF Perno, A d'Arminio Monforte, C Balotta for the I.CO.N.A. Study Group. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals. J Biol Regulat Homeost Agents 2002; 16: 37-43
  4. F Starace, L Bartoli, MS Aloisi, A Antinori, P Narciso, G Ippolito, L Ravasio, MC Moioli, D Vangi, L Gennero, O Coronado, A Giacometti, S Nappa, ML Perulli, V Montesarchio, A La Gala, F Ricci, L Cristiano, M De Marco, CM Izzo, P Pezzotti and A d'Arminio Monforte for the NeuroI.Co.N.A. Study Group. Cognitive and affective disorders associated to HIV infection in the HAART era. Findings from the NeuroICONA Study. Acta Psych Scand 2002; 106: 20-26
  5. A De Luca, R Bugarini, A Cozzi-Lepri, M Puoti, E Girardi, A Antinori, A Poggio, G Pagano G Tositti, GP Cadeo, A Macor, M Toti and A d'Arminio Monforte for the I.CO.N.A. Study Group. Coinfection with hepatitis viruses and outcome of the first antiretroviral regimen in previously naïve HIV-infected subjects. Arch Intern Med 2002; 162: 2125-2132
  6. M Galli, A Cozzi-Lepri, AL Ridolfo, C Gervasoni, L Ravasio, L Corsico, E Gianelli, M Vaccarezza, V Vullo, A Cargnel, L Minoli, O Coronado, A Giacometti, A Antinori, G Antonucci, A d'Arminio Monforte, M Moroni for the LipoICoNa study. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LIPOICONA study. Arch Intern Med 2002; 162:2621-2628
  7. MS Aloisi, C Arici, R Balzano, P Noto, R Piscopo, G Filice, F Menichetti, A d'Arminio Monforte, G Ippolito, E Girardi for the I.Co.N.A. Behavioural Epidemiology Study Group. Behavioural correlates of adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31(3):S145-S148
  8. A Ammassari, A Antinori, A Cozzi-Lepri, MP Trotta, G Nasti, AL Ridolfo, F Mazzotta, AW Wu, A d'Arminio Monforte, M Galli for the AdI.Co.N.A. and the LipoI.Co.N.A. Study Groups. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31(3):S140-S144
  9. A Ammassari, MP Trotta, R Murri, F Castelli, P Narciso, P Noto, J Vecchiet, A d'Arminio Monforte, AW Wu, A Antinori for the AdICONA Study Group. Correlates and predictors of adherence to HAART: overview of published literature. J Acquir Immune Defic Syndr 2002; 31(3):S123-S127
  10. R Murri, A Antinori, A Ammassari, S Nappa, G Orofino, N Abrescia, C Mussini, A d'Arminio Monforte, AW Wu for the AdICoNA Study Group. Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretrovirals. J Acquir Immune Defic Syndr 2002; 31(3):S158-S162
  11. CF Perno, F Ceccherini-Silberstein, A De Luca, A Cozzi-Lepri, C Gori, A Cingolani, MC Bellocchi, MP Trotta, P Piano, F Forbici, A Scasso, V Vullo, A d'Arminio Monforte, A Antinori, for the AdICoNA Study Group. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr 2002; 31(3):S118-S122
  12. F Starace, A Ammassari, MP Trotta, R Murri, P De Longis, C Izzo, A Scalzini, A d'Arminio Monforte, AW Wu, A Antinori. Depression is a risk factor for sub-optimal adherence to HAART. J Acquir Immune Defic Synd 2002; 31(3):S136-S139
  13. MP Trotta, A Ammassari, S Melzi, M Zaccarelli, N Ladisa, L Sighinolfi, MS Mura, A d'Arminio Monforte and A Antinori for the AdICoNA Study Group. Treatment related factors and HAART adherence. J Acquir Immune Defic Synd 2002; 31(3):S128-S131
  14. M Guarinieri for the I.CO.N.A. Community Advisory Board. Highly Active Antiretroviral Therapy: the patient's point of view. J Acquir Immune Defic Synd 2002; 31(3):S167-S169
· 2001 ·
  1. E Girardi, MS Aloisi, D Serraino, M Carballo, A d'Arminio Monforte, G Rezza, M Moroni, GP Carosi, A Alessandrini, D Giacobbi, L Cremonini, S Ranieri, M Montroni, G Ippolito for the I.CO.N.A. Study Group. Sexual behaviour of heterosexual individuals with HIV infection naïve for antiretroviral therapy in Italy. Sex Transm Infect 2001; 77:130-134
  2. B Ledergerber, A Mocroft, P Reiss, H Furrer, O Kirk, M Bickel, C Uberti-Foppa, C Pradier, A d'Arminio Monforte, MME Schneider, and JD Lundgren, for eight European HIV Cohorts. Discontinuation of Secondary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. N Engl J Med 2001; 344 (3):168-174
  3. A Cozzi-Lepri, AN Phillips, A d'Arminio Monforte, F Castelli, A Antinori, A De Luca, P Pezzotti, F Alberici, A Cargnel, P Grima, R Piscopo, T Prestileo, G Scalise, M Vigevani and M Moroni for the I.CO.N.A. Study Group. When to start highly active antiretroviral therapy in chronically HIV infected patients: evidence from the I.CO.N.A. Study. AIDS 2001; 15:983-990
  4. C Balotta, G Facchi, M Violin, S Van Dooren, A Cozzi-Lepri, F Forbici, A Bertoli, D Senese, P Caramello, G Carnevale, G Rizzardini, L Cremonini, L Monno, G Rezza, CF Perno, G Ippolito, A d'Arminio Monforte, AM Vandamme, M Moroni for the I.CO.N.A. Study Group. Increasing prevalence of non-clade B HIV-1 strains in heterosexuals, as monitored by the analysis of the RT and protease sequences. J Acquir Immune Defic Syndr 2001; 27:499-505
  5. M Dorrucci, P Pezzotti, B Grisorio, C Minardi, MS Mura, V Vullo, A d'Arminio Monforte, for the I.CO.N.A. Study Group. Time to discontinuation of the first HAART regimen: a comparison between PI- and NNRTI-containing regimens. AIDS 2001; 15:1733-1736
  6. CF Perno, A d'Arminio Monforte, C Balotta, A Cozzi-Lepri, F Forbici, M Violin, A Bertoli, G Facchi, P Pezzotti, GP Cadeo, G Tositti, S Pasquinucci, S Pauluzzi, A Scalzini, B Salassa, A Vincenti, AN Phillips, F Dianzani, A Appice, G Angarano, L Monno, G Ippolito, M Moroni for the I.CO.N.A. Study Group. Secondary mutations in the protease region are predictors of virological failure in antiretroviral-naïve patients treated with protease inhibitors-containing HAART regimens. J Infect Dis 2001; 184: 983-991
  7. A d'Arminio Monforte, R Bugarini, P Pezzotti, A De Luca, A Antinori, C Mussini, F Milazzo, U Tirelli, R Bruno, F Gritti, M Piazza, S Chigiotti, A Chirianni, C De Stefano, E Pizzigallo, O Perrella, and M Moroni, for the I.CO.N.A. Study Group. Low frequency of severe hepatic cytolysis and strong association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28(2):114-123
  8. CF Perno, A Cozzi-Lepri, C Balotta, F Forbici, M Violin, A Bertoli, G Facchi, P Pezzotti, G Angarano, C Arici, P Narciso, A Orani, E Raise, A Scalzini, A Poggio, G Ippolito, M Moroni, A d'Arminio Monforte and the ICONA Study Group. Impact of mutations conferring reduced susceptibility to lamivudine (3TC) on the response to antiretroviral therapy. Antiviral Therapy 2001; 6 (3):195-198
  9. A Ammassari, R Murri, P Pezzotti, MP Trotta, L Ravasio, P De Longis, S Lo Caputo, P Narciso, S Pauluzzi, G Carosi, S Nappa, P Piano, CM Izzo, M Lichtner, G Rezza, G Ippolito, A d'Arminio Monforte, AW Wu, A Antinori for the AdICONA Study Group. Self-reported symptoms and medication side effects influence adherence to HAART in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-449
  10. E Girardi, C Arici, M Ferrara, D Ripamonti, MS Aloisi, A Alessandrini, A Scalzini, A d'Arminio Monforte, D Serraino, and G Ippolito, for the I.CO.N.A. Behavioural Epidemiology Study. Estimating duration of HIV infection with CD4 count and HIV-1 RNA at presentation. AIDS 2001; 15: 2201-2203
· 2000 ·
  1. A d'Arminio Monforte, A Cozzi-Lepri, G Rezza, P Pezzotti, A Antinori, AN Phillips, G Angarano, V Colangeli, A De Luca, G Ippolito, L Caggese, F Soscia, G Filice, F Gritti, P Narciso, U Tirelli, M Moroni for the I.CO.N.A. Study Group. Insights into the reasons for discontinuation of the first highly active antiretrovial therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000; 14:499-507
  2. G Rezza, A Cozzi-Lepri, A d'Arminio Monforte, P Pezzotti, F Castelli, F Dianzani, A Lazzarin, A De Luca, M Arlotti, F Leoncini, PE Manconi, F Milazzo, L Minoli, A Poggio, G Ippolito, A N Phillips, M Moroni for the I.CO.N.A. Study Group. Plasma viral load concentrations in women and men from different exposure categories and known duration of HIV infection. J Acquir Immune Defic Syndr 2000; 25:56-62
  3. MS Aloisi, D Serraino, E Girardi, A d'Arminio Monforte, A Cargnel, L Bonazzi, N Petrosillo, N Abrescia, F Mazzotta, V Vullo, T Ferraro, F Suter, G Rezza, G Ippolito for the I.CO.N.A. Study Group. Sexual behaviour of women living with HIV/AIDS naïve for antiretroviral therapy: the ICONA-BEHEPI Study. AIDS Care 2000; 12 (6): 789-795
  4. P Pezzotti, A d'Arminio Monforte, R Bugarini, G Rezza, C Arici, G Angarano, C Fiorini, F Alberici, O Armignacco, F Menichetti, T Prestileo, L Sighinolfi, A Sinicco, F Resta, M Vigevani, G Ippolito, for the I.CO.N.A. Study Group. Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic parameters? Eur J Epidem 2000; 16(10):219-226
· 1999 ·
  1. M Moroni on the behalf of I.CO.N.A. Study Group. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet 1999; 353:589-590

Congressi

· 2021 ·
  1. N Gianotti, A Tavelli, A Antinori, F Maggiolo, G Madeddu, A Saracino, S Bonora, L Taramasso, R Gagliardini, G Lapadula, A Cozzi-Lepri, A d’Arminio Monforte Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine?  11th IAS Conference on HIV Science, 18-21 luglio 2021 (PEB145 pag. 148/455)
  2. G Madeddu, A De Vito, A Cozzi-Lepri, A Cingolani, N Gianotti, R Gagliardini, G Marchetti, M Santoro, F Maggiolo, E. Girardi, A d’Arminio Monforte, A Antinori Low risk of losing the undetectable viral load status in people with HIV switching to dual therapy 11th IAS Conference on HIV Science, 18-21 luglio 2021 (PEB165 pag. 158/455)
  3. A Antinori, A Tavelli, C Mussini, A Gori, F Maggiolo, A Castagna, F Ceccherini-Silberstein, S Lo Caputo, M Puoti, C Pinnetti, V Calvino, E Girardi, C F. Perno, A d'Arminio Monforte, A Cozzi-Lepri Impact of lockdown restrictions due to COVID-19 pandemic on HIV care in Italy Virtual CROI 2021, Conference on Retroviruses and opportunistic Infections, 6-10 marzo 2021
· 2020 ·
  1. E Merlini, P Lorenzini, C Mussini, A Cozzi-Lepri, S Truffa, E Quiros Roldan, C Muccini, E S Cannizzo, M Lichtner, A Antinori, A d'Arminio Monforte, G Marchetti Residual Inflammation and CD4/CD8 Recovery After Switching to Dual Therapy 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  2. A d'Arminio Monforte, A Tavelli, A Cozzi-Lepri, A Vergori, E Quiros-Roldan, R Rossotti, B M Celesia, F Bai, F Maggiolo, E Girardi, A Antinori, M Puoti Decrease of prevalence of subjects harboring replicating HCV among PLWHIV in Italy: results from the NoCo study 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  3. A Giacomelli, A Cozzi-Lepri, A Cingolani, A Tavelli, V Mazzotta, D Tesoro, M Bassetti, A Castagna, A Di Biagio, M Lichtner, A d'Arminio Monforte, S Rusconi Impact of syphilis on the risk of HIV positive patients under effective antiretroviral treatment: data from the ICONA cohort 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  4. A Vergori, A Cozzi-Lepri, N Gianotti, A Calcagno, G Guaraldi, G Orofino, M C Moioli, I Gentile, L Sarmati, S Cicalini, A d'Arminio Monforte, A Antinori Durability of F/TAF regimens in the era of integrase inhibitors in a large cohort of PLWH seen for care in Italy 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  5. A Saracino, P Lorenzini, M M Santoro, A Tavelli, S Rusconi, N Bobbio, A Mondi, S Lo Caputo, A Antinori, E Girardi, A d'Arminio Monforte, L Monno Post-migration HIV infection in the foreign-born population enrolled in the ICONA cohort  12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  6. C Alteri, A Cozzi-Lepri, R Scutari, Y Bouba, E S Cannizzo, A Tavelli, M Prato, F Bai, A Antinori, A d'Arminio Monforte, F Ceccherini-Silberstein, G Marchetti Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  7. V Mazzotta, P Lorenzini, A Bandera, A Gori, L Sighinolfi, S Rusconi, P Bonfanti, A Cingolani, G Marchetti, C Mussini, A d'Arminio Monforte, A Antinori Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH) 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  8. E S Cannizzo, A Cozzi-Lepri, F Ceccherini S, R Scutari, C Alteri, A Tavelli, D Bernacchia, E Merlini, A Castagna, A Antinori, A d’Arminio Monforte, G Marchetti Reduced Bone catabolism and inflammation in patients switching TAF-containing cART 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  9. S Nozza, L Timelli, A Saracino, N Gianotti, C Lazzaretti, A Tavelli, M Puoti, S Lo Caputo, A Antinori, A d'Arminio Monforte, C Mussini, E Girardi Causes and incidence of hospitalization in patients enrolled in the ICONA cohort 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  10. S Cicalini, P Lorenzini, A Di Biagio, L Taramasso, A Cozzi-Lepri, D Canetti, A Saracino, G Lapadula, R Rossotti, G Guaraldi, G Madeddu, A d'Arminio Monforte, A Antinori Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
  11. S Cicalini, P Lorenzini, A Di Biagio, L Taramasso, A Cozzi-Lepri, D Canetti, A Saracino, G Lapadula, R Rossotti, G Guaraldi, G Madeddu, A d'Arminio Monforte, A Antinori Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA  IAS Annual Meeting 2020, 11 - 15 ottobre 2020
  12. S Nozza, L Timelli, A Saracino, N Gianotti, C Lazzaretti, A Tavelli, M Puoti, S Lo Caputo, A Antinori, A d'Arminio Monforte, C Mussini, E Girardi Causes and incidence of hospitalization in patients enrolled in the ICONA cohort IAS Annual Meeting 2020, 11 - 15 ottobre 2020
  13. R Gagliardini, A Cozzi Lepri, M Zazzi, A Tavelli, MM Santoro, D Armenia, A Castagna, Gennari, S Rusconi, C Mussini, Laghetti, CF Perno, a D'Arminio, A Antinori Impact of multi-drug resistance on mortality: a multi-cohort Italian study HIV 2020 - Glasgow, 5 - 8 ottobre 2020
  14. A Cingolani, A Tavelli, V Calvino, F Maggiolo, E Girardi, A Cozzi Lepri, A Perziano, A Camposeragna, R Gagliardini, S Nozza, A Antinori, A d'Arminio Monforte Awareness and perception of accuracy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA), in Italy and correlation with the level of confidence in reference physicians HIV 2020 - Glasgow, 5 - 8 ottobre 2020
  15. A Vergori, A Cozzi Lepri, N Gianotti, A Calcagno, G Guaraldi, G Orofino, MC Moioli, I Gentile, L Sarmati, S Cicalini, A d'Arminio Monforte, A Antinori Durability of F/TAF in a large cohort of PLWH seen for care in Italy  HIV 2020 - Glasgow, 5 - 8 ottobre 2020
  16. R Rossotti, A Tavelli, MG Quaranta, L Ferrigno, F Bai, F Barbaro, A Cingolani, M Dallio, M Loi, E Zappullo, A d'Arminio Monforte, M Puoti HIV/HCV co-infected sujects show better thrombocytopenia improvement after Sustained Virologic Response than HCV mono-infected cirrhotics. Data from the HepaICONA and PITER cohorts EASL International Liver Congress, 27 - 29 agosto 2020
  17. A Antinori, F Maggiolo, N Gianotti, S R Cole, J K Edwards, S Lo Caputo, A Calcagno, D Francisci, P Blanc, C Mussini, A d'Arminio Monforte, A Cozzi-Lepri Emulation of an RCT of dolutegravir vs. boosted-darunavir in advanced ART-naive CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 - 11 marzo 2020
  18. G Madeddu, A De Vito, A Cozzi-Lepri, A Cingolani, F Maggiolo, C F Perno, R Gagliardini, G Marchetti, A Saracino, A d'Arminio Monforte, A Antinori, E Girardi Implementation of U=U in real life in Italy: results fron the ICONA cohort CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 -11 marzo 2020
  19. R Gagliardini, P Lorenzini, A Cozzi-Lepri, A Tavelli, V Borghi, L Galli, G Tagliaferri, F Maggiolo, C Mussini, A Castagna, A d'Arminio Monforte, A Antinori Effect of past virological failure on dolutegravir+lamivudine as manteinance regimen CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 - 11 marzo 2020
  20. L Fabeni, M M Santoro, P Lorenzini, S Rusconi, N Gianotti, A Costantini, L Sarmati, A Antinori, F Ceccherini Silberstein, A d'Arminio Monforte, A Saracino, E Girardi Evaluation of HIV transmission clusters among natives and foreigners living in Italy CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 - 11 marzo 2020
  21. A Mondi, P Lorenzini, A Cozzi-Lepri, A Cingolani, M Farenga, S Rusconi, G De Girolamo, A Gori, M Camici, C Mussini, A d'Arminio Monforte, A Antinori Persistent poor clinical outcomes for AIDS presentation in Italy over the last decade CROI - Conference on Retroviruses and opportunistic Infections - Boston, 8 - 11 marzo 2020
  22. A Bandera, A Cozzi-Lepri, A Cingolani, F Ceccherini-Silberstein, G Marchetti, S Rusconi, V Svicher, R Cauda, F Castelli, A Gori, A Antinori, A d'Arminio Monforte Impact of universal ART access on Kaposi Sarcoma burden: results from the ICONA cohort CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 -11 marzo 2020
· 2019 ·
  1. R. Rossotti, G. Guaraldi, A. Cozzi Lepri, V. Spagnuolo, S. Cicalini, J. Vecchiet, E. Quiros Roldan, G. Madeddu, S. Lo Caputo, A. Antinori, M. Puoti, A. d’Arminio Monforte on behalf of the ICONA Foundation Study Group. Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virologic failure and drug discontinuation: data from the ICONA Foundation cohort.  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
  2. R Rossotti, A Saracino, P Lorenzini, C Alcantarini, A Latini, G Lapadula, S Nozza, L Sarmati, E Girardi, A Castagna, A d’Arminio Monforte, M Puoti on behalfof the ICONA Foundation StudyGroup. Long term response to mandatory anti-HBV vaccination: risks for disease acquisition and opportunities for re-vaccination within the ICONA cohort.  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
  3. A. d’Arminio Monforte, A. Tavelli, A. Cozzi-Lepri, S. Cicalini, A. Calcagno, R. Rossotti, E. Grilli, F. Bai, E. Quiros-Roldan, E. Girardi, A. Antinori, M. Puoti, for the NoCo Study of the Icona cohort. Road to hcv elimination in hiv/hcv coinfected patients by screening and universal access to daa: baseline data from the first screening of noco (no coinfection) study.  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
  4. A. Mondi, A. Cozzi-Lepri, A. Cingolani, A. Tavelli, M. Puoti, V. Barocci, A. Londero, F. Bai, C. Pinnetti, P. Cinque, A. d’Arminio Monforte8, A. Antinori on behalf of the Icona Foundation Study Group. Comparative neuropsychiatric toxicity profile of dolutegravir versus efavirenz versus other antiretroviral third drugs used either in first-line or switch antiretroviral therapies (art): data from icona foundation study cohort.  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
  5. A Antinori, A Mondi, P Lorenzini, A Cozzi-Lepri, A Cingolani, F Maggiolo, A Saracino, A Bandera, G Marchetti, C Mussini, E Girardi, A d’Arminio Monforte. Change of prevalence, diseases distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018).  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
  6. A Gabrieli, L Galli, M Tarkowski, C De Giuli, A Saracino, G Marchetti, S Bonora, E Lattuada, M Mena, A d'Arminio Monforte, A Castagna, A Riva, S Rusconi on behalf of ICONA Foundation and ELVIS cohort. HIV-DNA LEVELS, HLA-B*27 and HLA-DRB1*13 AMONG LTNPs, ECs and HIV controllers.  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
  7. A Vergori, R Gagliardini, N Gianotti, A Gori, M Lichtner, A Saracino, A De Vito, A Cascio, A di Biagio, A d’Arminio Monforte, A Antinori, A Cozzi-Lepri on behalfof ICONA Foundation StudyGroup. Determinants of switchingto TAF-basedcARTor dualcombinations(DC) from TDF-basedregimensin a cohort of HIV-infectedindividualswith controlledviralload≤50 copies/mL. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
  8. A Cingolani, J Romaine, A Tavelli, F Maggiolo, M Camici, F Bai, S Rusconi, AM Cattelan, A Antinori, R Cauda, A d’Arminio Monforte & C Bradley. Well-being in people living with hiv/aids (plwha): data from icona cohort.  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland
  9. C Mussini, P Lorenzini, A Cingolani, M Lichtner, S Di Giambenedetto, AM Cattelan, M Malena, G d’Ettorre, A d’Arminio Monforte. Virological outcomesof first line regimensin womenliving with HIV from Icona cohort: comparisonwith clinicaltrials data.  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland
  10. E Merlini, A Cozzi-Lepri, C Alteri, R Scutari, A Cingolani, F Bai, F Petroni, S Lo Caputo, A Antinori, CF Perno, A d'Arminio Monforte, G Marchetti. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir.  The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland
  11. S. Leone, P. Lorenzini, A. Cozzi-Lepri, G. Orofino, D. Bernacchia, A. Castagna, M. Menozzi, G. Guaraldi, G. Madeddu, A. Di Biagio, A. Gori, A. d'Arminio Monforte, for the ICONA Foundation Cohort Study Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  12. A. Antinori, A. Mondi, P. Lorenzini, A. Cozzi-Lepri, A. Cingolani, A. Latini, A. Saracino, A. Bandera, G. Marchetti, C. Mussini, E. Girardi, A. d’Arminio Monforte Change of prevalence and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018). 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  13. S. Lo Caputo, A. Antinori, A. Tavelli, F. Ceccherini-Silberstein, C.F. Perno, A. Castagna, N. Bobbio, G. Parruti, R. Gagliardini, S. Bonora, A. d’Arminio Monforte, A. Cozzi Lepri for the ICONA Foundation Study Group Variables related to becoming Heavily Treated Experienced (HTE) patients in a large Italian cohort. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  14. A. Antinori, A. Cozzi-Lepri, D. Moschese, S. Nozza, L. Comi, M. Santoro, L. Sarmati, C. Pinnetti, F. Ceccherini Silberstein, G. Marchetti, F. Maggiolo, A. d’Arminio Monforte for the Icona Foundation Study Group Viral potency and durability of emtricitabine/tenofovir alafenamide (F/TAF) based regimens in the real life setting 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  15. A. Vergori, R. Gagliardini, N. Gianotti, A. Gori, M. Lichtner, A. Saracino, A. De Vito, A. Cascio, A. Di Biagio, A. d’Arminio Monforte, A. Antinori, A. Cozzi- Lepri Determinants of switching to TAF-based cART or dual combinations (DT) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load≤50 copies/mL 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  16. C. Mussini, P. Lorenzini, A. Cingolani, M. Lichtner, S. Di Giambenedetto, A.M. Cattelan, E. Balletto, L. Sighinolfi, C. Abeli, M. Malena, G. d’Ettorre, A. d’Arminio Monforte Virological outcomes of first line regimens in women living with HIV from Icona cohort: comparison with clinical trials data. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  17. A. Mondi, P. Lorenzini, A. Cozzi-Lepri, A. Cingolani, M. Farenga, S. Rusconi, G. Di Girolamo, A. Gori, M. Camici, C. Mussini, A. d’Arminio Monforte, A. Antinori1 on behalf of the Icona Foundation Study Cohort Lower response to antiretroviral therapy (ART) and persistently poor survival for AIDS presentation in people seen for care in Italy from 2009 to 2018. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  18. E. Suardi, A. Cozzi Lepri, G. Madeddu, V. Spagnuolo, S. Vita, V. Manfrin, A. Bandera, A. Cingolani, A. Antinori, C. Mussini, G. Marchetti, A. d'Arminio Monforte, for the Icona Foundation Study Group CD4/CD8 ratio predicts the onset of virus-related cancers in HIV-positive patients on effective cART. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  19. A. d’Arminio Monforte, A. Tavelli, A. Cozzi-Lepri, A. Castagna, S. Passerini, D. Francisci, A. Saracino, F. Maggiolo, G. Lapadula, E. Girardi, C.F. Perno, A. Antinori for the Icona Foundation Study Group Is time from HIV diagnosis to ART initiation predictive of virological outcome and of retention in care? 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  20. P. Piselli, A. Tavelli, C. Cimaglia, G. Chiaradia, L. Rancilio, M. Oldrini, A. Cingolani, M.E. Quiros Roldan, V. Rizzo, S Rusconi, A. Caraglia, A. d’Arminio Monforte, E. Girardi for the ICONA Foundation Study Group and for the Working Group of the project “Linkage to Care in HIV: a further piece to the analysis of continuum of care in HIV in Italy” Time to Linkage to Care (LtC) in the ICONA COHORT: 2010-2018 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  21. A. Mondi, A. Cozzi-Lepri, A. Cingolani, A. Tavelli, M. Puoti, V. Barocci, A. Londero, F. Bai, C. Pinnetti, P. Cinque, A. d’Arminio Monforte, A. Antinori on behalf of the Icona Foundation Study Group Comparative neuropsychiatric toxicity profile of dolutegravir (DTG)-based versus efavirenz (EFV)-based versus other recommend first-line antiretroviral therapies (ART): data from Icona Foundation Study Cohort, 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  22. A. d’Arminio Monforte, A. Tavelli, A. Cozzi-Lepri, S. Cicalini, A. Calcagno, R. Rossotti, E. Grilli, F. Bai, E. Quiros-Roldan, E. Girardi, A. Antinori, M. Puoti for the NoCo Study of the Icona cohort Road to HCV elimination in HIV/HCV coinfected patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No Coinfection) study 11° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
  23. V Malagnino, A Cozzi-Lepri, L Sarmati, A Cingolani, C Cerva, F Ceccherini Silberstein, A Vergori, G Cuomo, CF Perno, M Puoti, M Andreoni, A d'Arminio Monforte, for the ICONA Foundation Study Group. Impact of HBcAb+ on advanced liver fibrosis development in HIV-HBV infected patients.  26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
  24. A Mondi, P Lorenzini, A Tavelli, A Cozzi-Lepri, F Maggiolo, N Gianotti, D Francisci, C Carcieri, A De Vito, A Di Biagio, A d'Arminio Monforte, A Antinori, for the ICONA Foundation Study Group. Effectiveness of single- vs multiple-tablet regimens as 1st-line ART in ICONA Cohort.  26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
  25. E Girardi, Y Caro-Vega, J Musaazi, G Carriquiry, A Cozzi-Lepri, B Castelnuovo, A Gori, Y C. Manabe, E Gotuzzo, A d'Arminio Monforte, B Crabtree-Ramírez, C Mussini, for the ICoNA Study Group, IMT AvH, INNSZ and IDI Cohorts. Timing and incidence of HIV-associated tuberculosis: a four-country study. Timing and incidence of HIV-associated tuberculosis: a four-country study.  26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
  26. V Spagnuolo, L Galli, A Cozzi-Lepri, G Lapadula, A Antinori, G Orofino, N Bobbio, MC Moioli, A Calcagno, A De Luca, A d'Arminio Monforte, A Castagna, for the ICONA Foundation Study Group. Time to undetectable viral load achievement after art start and risk of mortality. 26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
  27. R Gagliardini, P Lorenzini, A Cozzi-Lepri, N Gianotti, L Sarmati, S Rusconi, E Messina, A Capetti, A Saracino, G Madeddu, A d'Arminio Monforte, A Antinori, for the ICONA Foundation Study Group. Evolution and reversibility of renal function after switch from TDF to TAF regimens.  26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
· 2018 ·
  1. EM Lori, A Cozzi-Lepri, V Mercurio, SV Ibba, S Lo Caputo, F Castelli, A Castagna, A Gori, G Marchetti, C Venditti, M Clerici, A d’Arminio Monforte, M Biasin. Evaluation of Protective Genetic Variants in HIV-1-Infected cART Treated Patients. HIV Research for Prevention 2018: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P) - Madrid, 21–25 October 2018.
  2. A Vergori, P Lorenzini, A Cozzi-Lepri, F Maggiolo, G Lapadula, A De Luca, A Cingolani, M Galli, G Mazzarello, P Milini, A d’Arminio Monforte, A Antinori on behalf of ICONA Foundation Study Group. Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  3. A Cozzi-Lepri, A d'Arminio Monforte, A Capetti, A De Luca, A Castagna, D Bernacchia, F Bai, M Zaccarelli, A Cingolani, C Mussin, C F Perno and A Antinori for the Icona Foundation Study. Determinants of switching to taf-based cart or two-drug combinations with hivrna ≤50 copies/ml in a cohort of hiv-infected individuals seen for care in italy. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  4. G Taliani, G Marchetti, A Cingolani, M Lichtner, S Cicalini, E Quiros Roldan, M Ursitti, E Girardi, A Antinori, M Puoti, A d'Arminio Monforte, A Cozzi-Lepri. Increased total and ldl cholesterol plasma levels upon direct antiviral agents (daas) driven hcv eradication.  HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  5. A Calcagno, A Cozzi-Lepri, A Saracino, A De Luca, E Colella, A Cingolani, L Sarmati, F Ceccherini-Silberstein, A Antinori, M Puoti, CF Perno, A d'Arminio Monforte. Long-term Follow up of HIV-HBV Co-infected Patients According to the Use of Anti-HBV Active Drugs.  HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  6. A Cozzi-Lepri, H Diaz-Cuervo, N Gianotti, G Lapadula, A De Luca, F Maggiolo, S Rusconi, N Bobbio, V Esposito, MC Moioli, G Madeddu, A Antinori, A d'Arminio Monforte. Determinants of switching to two-drug combinations with hiv-rna ≤50 copies/ml in a cohort of hivinfected individuals seen for care in Italy.  HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  7. S Cicalini, P Lorenzini, A Cozzi-Lepri, F Maggiolo, N Gianotti, S Rusconi, G Lapadula, O Cirioni, A Castagna, C Mussini, S Lo Caputo, A Antinori. Incidence of dyslipidemia and modification of atherosclerotic cardiovascular disease (ASCVD) risk in HIV-infected patients who switch away from tenofovir disoproxil fumarate (TDF)-based to TDF-sparing regimens in the Icona Foundation Cohort.  HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  8. A Vergori, P Lorenzini, A Cozzi Lepri, F Maggiolo, G Lapadula, A De Luca, A Cingolani, M Galli, G Mazzarello, P Milini, A D'Arminio Monforte, A Antinori. Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort.  HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  9. S Vita, P Lorenzini, M Lichtner, G Marchetti, CM Mastroianni, A Bandera, A Di Biagio, C Pinnetti, A Calcagno, A Castagna, A Antinori, A d'Arminio Monforte. Impact of CMV on liver progression in HIV/HCV/CMV coinfected patients in a large cohort of HIV-infected patients. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  10. A Cingolani, J Romaine, A Tavelli, F Maggiolo, E Girardi, A Antinori, A Cascio, AM Cattelan, A De Luca, M Murray, A D'Arminio Monforte, C Bradley. Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  11. A Tavelli, M Palma, S Lo Caputo, G Madeddu, P Bonfanti, B Menzaghi, S Nozza, A Antinori, R Termini, A d'Arminio Monforte. Reasons for choosing darunavir/ritonavir 600/100 mg BID vs. 800/100 mg QD in ART-naive patients. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
  12. A. Tavelli, A. Cozzi-Lepri, C. Mussini, A. Castagna, A. Saracino, A. Cingolani, B. Menzaghi, G. Lapadula, S. Savinelli, A. Antinori, A. d'Arminio Monforte, M. Puoti. Response to DAA among HIV-HCV co-infected people who inject drugs (PWID) in clinical practice.  10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  13. A. Tavelli, M. Palma, S. Lo Caputo, G. Madeddu, P. Bonfanti, B. Menzaghi, S. Nozza , A. Antinori, R. Termini, A. d’Arminio Monforte. Reasons for choosing darunavir/ritonavir 600/100 mg twice daily vs. 800/100 mg once daily in treatment-naïve patients: 10 years data from the ICONA cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24
  14. L. Taramasso, P. Lorenzini, A. Di Biagio, M. Lichtner, G. Marchetti, R. Rossotti, G. Lapadula, D. Minisci, F. Vichi, A. Antinori, S. Bonora, A. d'Arminio Monforte. Liver enzyme elevations according to the first line cART regimen: real life data from the ICONA cohort.  10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  15. A. Cingolani, J. Romaine, A. Tavelli, F. Maggiolo, E. Girardi, A. Antinori, A. Cascio, A.M. Cattelan, A. De Luca, M. Murray, A. d’Arminio Monforte, A. Bradley. Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort.  10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  16. A. Cozzi-Lepri, M. Zaccarelli, A. Capetti, A. De Luca, A. Castagna, D. Bernacchia, F. Bai, A. Cingolani, C. Mussini, C.F. Perno, A. d'Arminio Monforte, A. Antinori. Use of TAF with a HIV-RNA≤50 copies/mL in clinical practice. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  17. P. Piselli, D. Serraino, A. Bandera, A. Antinori, E. Girardi, C. Cimaglia, A. Tavelli, F. Bai, G. Baldin, A. Calcagno, A. d'Arminio Monforte, A. Cingolani. Non-AIDS related cancer risk is not affected by cART in ICONA cohort.  10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018.
  18. G. Lapadula, A. d’Arminio Monforte, A. Castagna, S. Rusconi, C. Mussini, E. Colella, A. Gori, C. Fabrizio, V. Spagnuolo, E. Schiaroli, A. Antinori, A. Cozzi-Lepri. HIV viral load kinetcs during first-line antiretroviral treatment and risk of virological non-response or rebound among patient with high pre-treatment HIV-RNA. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  19. I. Mastrorosa, P. Lorenzini, A. Cozzi-Lepri, M. Puoti, R. Rossotti, G. Marchetti, G. Orofino, L. Sighinolfi, A. Raimondi, A. d'Arminio Monforte, A. Antinori, A. De Luca. Impact of HCV treatment with Direct-Acting Antivirals on glucose levels in diabetic HIV/HCV co-infected patients in the ICONA and HepaICONA cohorts.  10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  20. E. Girardi , A. Cozzi-Lepri , A. Gori , A Saracino, A Di Biagio, G Lapadula, G Orofino, M Lichtner, S Lo Caputo, A Antinori, A d'Arminio Monforte , C Mussini. Which is the current risk of tuberculosis in persons diagnosed with HIV in Italy? 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  21. A. Bandera, P. Lorenzini, G. Lapadula, C. Mussini, A. Saracino, F. Ceccherini-Silberstein, M. Puoti, E. Quiros-Roldan, F. Montagnani, A. Antinori, A. Gori, A. d’Arminio Monforte. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocytes trajectories in HIV/HCV coinfected patients: data from the Icona Foundation Cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  22. A. Mondi, A. Cozzi-Lepri, A. Tavelli, S. Rusconi, F. Vichi, B. Menzaghi, F. Ceccherini-Silberstein, A. Calcagno, F. Maggiolo, G.Marchetti, A. Antinori, A. d'Arminio Monforte. Effectiveness of dolutegravir (DTG)-based regimens as either first line or switch antiretroviral therapy (ART): data from the Icona cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018.
  23. I. Mastrorosa, A. Cozzi-Lepri, E. Girardi, A. Calcagno, G. Madeddu, A. Maddaloni, M. Farenga, A. Cristaudo, P. Meraviglia, A. Antinori, A. d'Arminio Monforte, A. Cingolani. Patient-Reported Outcomes (PROs) evaluation among HIV-infected (HIV+) patients (pts) starting elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF). 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  24. A. d'Arminio Monforte, A. Cozzi-Lepri, S. Lo Caputo, S. Rusconi, N. Gianotti, A. Di Biagio, G. Marchetti, V. Mazzotta, G. Mazzarello, A. Costantini, A. Castagna, A. Antinori. Durability of integrase inhibitors (INSTI) regimens in the clinical setting: data from the Icona Foundation Cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
  25. E Girardi, M Puoti, C Mussini, A Tavelli, I Mastrorosa, F Ceccherini Silberstein, G Madeddu, C Molteni, P Nasta, A Antinori, A d'Arminio Monforte, A Cozzi-Lepri. The Hepatitis C Continuum of Care among HIV infected individuals in the Icona study network.  The International Liver Congress 2018 (EASL) – Paris, 11/15 April 2017.
  26. R Rossotti, P Lorenzini, M Merli, A Castagna, A De Luca, A Antinori, M Chiamenti, I Mastrorosa, G Verucchi, F Maggiolo, A d'Arminio Monforte, M Puoti. Genotype 3 infection in HIV/HCV co-infected subjects in the DAA era: real life data from the Icona/Hepaicona foundation cohorts.  The International Liver Congress 2018 (EASL) – Paris, 11/15 April 2017.
  27. R Rossotti, A Tavelli, S Bonora, A Cingolani, S Lo Caputo, A Saracino, G Lapadula, L Marinaro, C Uberti-Foppa, C Mussini, M Puoti, A d'Arminio Monforte.s. Safety and Efficacy of Daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: data from the Icona/Hepaicona foundation cohort The International Liver Congress 2018 (EASL) – Paris, 11/15 April 2017.
  28. GB Gaeta, M Shanyinde, G Brancaccio, M Puoti, Ad'Arminio Monforte, A De Luca, A Vergori, S Rusconi, A Mazzarelli, A Castagna, A Antinori, A Cozzi-Lepri. Hepatitis Delta infection in patients with HIV/HBV coinfection.  25th CROI – Conference on Retrovirus and Opportunistic Infections. Boston, March 4-7, 2018
  29. P Piselli , D Serraino , A Bandera , A Antinori , E Girardi , C Cimaglia ,A Tavelli , F Bai , G Baldin , A Calcagno , A d'Arminio Monforte , A Cingolani for the Icona Foundation Study Group. Still high risk of Virus-related cancer despite 20 years of cART in Icona Cohort.  25th CROI – Conference on Retrovirus and Opportunistic Infections. Boston, March 4-7, 2018
  30. E Girardi , A Cozzi-Lepri , A Gori , A Saracino , A Di Biagio , G Lapadula , G Orofino , M Lichtner , S Lo Caputo , A Antinori , A d'Arminio Monforte , C Mussini , for the Icona Foundation Study Group. HIV-associated TB in a low burden country: is screening for latent TB still needed? 25th CROI – Conference on Retrovirus and Opportunistic Infections. Boston, March 4-7, 2018
  31. N Gianotti, P Lorenzini, A Cozzi-Lepri, A De Luca, G Madeddu, L Sighinolfi, C Pinnetti, C Santoro, P Meraviglia, C Mussini, A Antinori, A D'Arminio Monforte. Durability of initial regimens when starting ART with -200 CD4 and +5 Log HIV-RNA. 25th CROI  Conference on Retrovirus and Opportunistic Infections. Boston, March 4-7, 2018
· 2017 ·
  1. A Cingolani, L Galli, G Lapadula, S Bonora, C Uberti Foppa, A Di Biagio, G Verucchi, S Odolini, C Mussini, A Antinori, A d'Arminio Monforte, M Zaccarelli for Icona Foundation Study Group. Evolution of renal function during treatment with direct antiviral agents (DAA-t) in HIV/HCV infected patients in ICONA/HepaIcona cohorts.  16th European AIDS Conference from October 25-27, 2017.
  2. L Galli, A Castagna, A Vergori, G Baldin, N Galizzi, A Poli, E Girardi, MM Santoro, A Saracino, A Cingolani, C Mussini, A Lazzarin, A Antinori, A d’Arminio Monforte. High pre-ART viral load and risk of death in HIV-1 infected subjects: an Italian inter-cohort study.  16th European AIDS Conference from October 25-27, 2017.
  3. A Bandera, A Cozzi Lepri, L Galli, N Galizzi, G Baldin, L Teofili, V Mazzotta, L Alba, A Castagna, A Gori, A d'Arminio Monforte, A Antinori, A Cingolani for the Icona Foundation Study Group. Outcome of HIV-associated non-Hodgkin lymphomas can be predicted by lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio. 16th European AIDS Conference from October 25-27, 2017.
  4. A Mondi, A Cozzi-Lepri, A Tavelli, F Vichi, S Rusconi, T Quirino, F Ceccherini-Silberstein, A Calcagno, F Maggiolo, G Marchetti, A Antinori, A d'Arminio Monforte. Effectiveness and discontinuation rate of dolutegravir (DTG)-based regimensas either first line or switch antiretroviral therapy (ART): data from the Icona cohort. 16th European AIDS Conference from October 25-27, 2017.
  5. B Rossetti, P Lorenzini, A Cingolani, A Tavelli, M Puoti, I Mastrorosa, A Gori, S Lo Caputo, R Rosso, A Antnori, A d’Arminio Monforte, A De Luca on behalf of ICONA Foundation study group. Progression of liver disease, access to HCV treatment with direct acing anIvirals and eradicaIon rate according to sex in HIV/HCV coinfected paIents in Italy. 16th European AIDS Conference from October 25-27, 2017.
  6. A Cozzi-Lepri, M Zaccarelli, S Rusconi, N Gianotti, S Bonora, A De Luca, G Madeddu, N Galizi, VEsposito, M Puoti, A d’Arminio Monforte and A Antinori for the Icona Foundation Study cohort. Two years of exposure to elvitegravir/cobicistat/emtricitabine/tenofovir(E/C/FTC/TDF): an overview of the trend in laboratory parameters in clinical practice. 16th European AIDS Conference from October 25-27, 2017.
  7. A Mammone, A Tavelli, A Costantini, P Caramello, C Mussini, A Di Biagio, G Madeddu, A d’Arminio Monforte, E Girardi for the ICONA Foundation Study Group. Trends and determinants of viral suppression among persons on HIV care in Italy. 9th IAS 2017 conference, 23-26 July, Paris
  8. S Piconi, G Marchetti, A Gori, A Castagna, G Rizzardini, P Caramello, PE Manconi, A d’Arminio Monforte and A Cozzi-Lepri for Icona Foundation Study cohort. HIV-RNA, CD4/CD8 ratio and HDL-c concentration in a cohort of HIV+ ART-naïve patients: data from ICONA Foundation cohort. 9th IAS 2017 conference, 23-26 July, Paris
  9. A Di Biagio, L Taramasso, A Cozzi-Lepri, F Maggiolo, A Tavelli, S Lo Caputo, S Bonora, M Zaccarelli, P Caramello, A Costantini, C Viscoli, A d’Arminio Monforte A comparison of 2-year durability of efavirenz and rilpivirine based regimens in clinical practice: data from the ICONA Foundation cohort (P 97)  IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
  10. A Bandera, A Cozzi Lepri, L Galli, N Galizzi, GM Baldin, L Teofili, V Mazzotta, L Alba, A Castagna, A Gori, A d'Arminio Monforte, A Antinori, A Cingolani for the Icona Foundation Study Group Lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio predict survival in HIV-infected patients with non-Hodgkin lymphomas (PD 12)  IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
  11. A Saracino, M Zaccarelli, P Lorenzini, A Bandera, G Marchetti, F Castelli, A Gori, E Girardi, C Mussini, P Bonfanti, A Ammassari, A d’Arminio Monforte, for the Icona Foundation Study Group Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for HIV-infected people (OC 71) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
  12. B Rossetti, P Lorenzini, A Cingolani, A Tavelli, M Puoti, G Cassola, G Angarano, G Taliani, E Girardi, A Antinori, A d’Arminio Monforte, A De Luca Gender differences in HCV exposure, active replication and genotypes in HIV patients entering care in Italy (OC 60) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
  13. M Zaccarelli, A Antinori, A Saracino, G Madeddu, G Rizzardini, S Lo Caputo, A Castagna, A Tavelli, A d'Arminio Monforte, A Cozzi-Lepri Value of CD4 count nadir and of time since occurrence of CD4 count nadir to predict viral rebound in a selected population who underwent a therapy switch after achieving viral suppression (OC 19) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
  14. C Mussini, P Lorenzini, S Rusconi, G Marchetti, A Gori, S Nozza, MM Santoro, A Calcagno, A Saracino, M Lichtner, A Antinori, A d'Arminio Monforte for the Icona Foundation Study Group CD4/CD8 ratio in patients who switch therapy: better triple therapy than dual/mono? (OC 17) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
  15. S Rusconi, MM Santoro, A Cozzi-Lepri, A Antinori, S Bonora, A Cingolani, N Gianotti, F Ceccherini Silberstein, A Tavelli, A d'Arminio Monforte, for the Icona Foundation Study Group Factors related to over-time viral failure in HIV-infected patients with previous C-ART failures (OC 6) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
  16. A d'Arminio Monforte, A Antinori, A Cozzi-Lepri, F Ceccherini-Silberstein, E Girardi, A Castagna, S Lo Caputo, C Mussini, A De Luca, G Madeddu, A Cingolani, A Tavelli, G Taliani, A Gori, M Puoti and Icona Foundation Study Group. Predictors of access and response to DAA in a cohort of HIV/HCV co-infected patients in Italy.  The International Liver Congress (EASL) – Amsterdam, 19/23 April 2017.
· 2016 ·
  1. 1. GB Gaeta, M Shanyinde, M Puoti, A d’Arminio Monforte, A De Luca; A Castagna, A Antinori and A Cozzi-Lepri. Patients with HIV-HBV coinfection are an underestimated reservoir for Hepatitis Delta Virus. An analysis of the ICONA cohort.  67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston – November 11-15, 2016
  2. A Antinori, A Cozzi-Lepri , A Castagna , S Lo Caputo , C Mussini , S Rusconi , A Di Biagio, G Marchetti , S Nozza, A Cingolani, A De Luca and A d’Arminio Monforte, for the Icona Foundation Cohort Study. Prescription patterns and determinants of dolutegravir use in an antiretroviral naive HIV-infected population in Italy.  13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
  3. A Cingolani, A Cozzi Lepri, L Teofili, L Galli, V Mazzotta, G M Baldin, S Hohaus, A Bandera, L Alba, N Galizzi, A Castagna, A d'Arminio Monforte, A Antinori for ICONA Foundation Study group. Survival in HIV-1 positive individuals with diagnosis of lymphoma compared to general population.  13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
  4. A d'Arminio Monfort , P Lorenzini, A Cozzi-Lepri , C Mussini, A Castagna, F Baldelli, M Puoti, F Mazzotta, N Abrescia, S Lo Caputo, N Gianotti, A Antinori on behalf of Icona Foundation Study Group. Durability and tolerability of first-line combination with 2 NRTI and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation cohort.  13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
  5. G Marchetti, R Bruno, M Shanyinde , C Mussini, P Caramello, M Zaccarelli, M Andreoni, A d’Arminio Monforte and A Cozzi-Lepri for the Icona Foundation Study Group . Are HIV/HCV Co-infected patients more likely to experience multiple lines of antiretroviral therapy (ART) yhan HIV mono-infected patients? 13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
  6. M Shanyinde, G Marchetti, R Bruno, F Ceccherini-Silberstein, A Gori, A De Luca, J VecchietJ, M Lichtner, G Madeddu, P Bonfanti, A d’Arminio Monforte and A Cozzi-Lepri on behalf of the ICONA Foundation Study group. Is ART use associated with increased risk of ALT elevation in HIV/HCV co-infected patients over and above what is expected in HIV mono-infected: a nested case control study approach.  13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
  7. M Smit, R Cassidy, A Cozzi-Lepri, E Girardi, A Mammone, A Antinori, G Angarano, F Bai, S Rusconi, G Magnani, A d’Arminio Monforte, T B Hallet. Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study.  13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
  8. M Zaccarelli, P Lorenzini, N Gianotti, S Rusconi, P Viale, A Chirianni, L Sighinolfi, G Parruti, A d'Arminio Monforte, A Antinori on behalf of ICONA Foundation, Study Group. Reducing Number of Pills or Number of Drugs as Strategy of HIV Treatment Simplification. Data from the Italian Icona Cohort.  13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
  9. C Mussini, A Mammone, G Marchetti, M Lichtner, A De Luca, G Lapadula, S Lo Caputo, A Antinori, A d'Arminio Monforte, E Girardi for the ICONA Foundation Study Group Risk of clinical progression among patients re-entering in care after being lost 21st International AIDS Conference (AIDS 2016); Poster TUPEB058
  10. A d'Arminio Monforte, F. Aragão, A De Luca, F Maggiolo, A Cingolani, F Mazzotta, S Bonora, A Castagna, E Girardi, A Antinori, A Cozzi-Lepri Evolution of comorbidities in HIV patients in Italian ICONA cohort: cross sectional analysis in 2004 and 2014  21st International AIDS Conference (AIDS 2016); Poster TUPEC129
  11. 3. A Cozzi-Lepri, F Aragao, S Lo Caputo, G Guaraldi, A Ammassari, F Mazzotta, S Bonora, A Castagna, E Girardi, A Antinori and A d’Arminio Monforte on behalf of Icona Foundation Study group. Evolution of comorbidities among HIV patients in 2004 and 2014: a cross-sectional analysis from the Italian ICONA Foundation study cohort.  VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016.
  12. B Rossetti, F Bai, A Tavelli, M Galli, A Antinori, F Castelli, G Pellizzer, A Cozzi-Lepri, S Bonora, A d’Arminio Monforte, M Puoti, A De Luca, on behalf of the ICONA Foundation study group Evolution and determinants of the prevalence of HCV infection and HCV genotype distribution among HIV-infected patients entering in care between 1997 and 2015 in Italy: data from a prospective nationwide cohort (ICONA) VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
  13. B Coco on behalf of PITER and ICONA/HepaICONA Studies https://goo.gl/0PYVeR Clinical and virological characteristics of HIV and HCV coinfected versus HCV monoinfected patients: real life evaluation in PITER and ICONA/HepaICONA cohorts VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
  14. A Cozzi-Lepri, A Antinori, M Zaccarelli, F Maggiolo, G Marchetti, A Di Biagio, A Cingolani, A Castagna, A Costantini, R Piolini, A Chiodera and A d’Arminio Monforte for the Icona Foundation Study Group HIV-positive subjects treated with single tablet regimens (STR) when ART-naïve in clinical practice VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
  15. A Di Biagio, P Lorenzini, G Gustinetti, S Rusconi, A De Luca, G Lapadula, S Lo Caputo, S Cicalini, F Castelli, G Marchetti, A Antinori, A D’Arminio Monforte on behalf of the ICONA Foundation study group Outcomes of second line antiretroviral therapy in HIV-infected patients: data from the ICONA cohort VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
  16. A Cozzi Lepri on behalf of PITER and ICONA/HepaICONA Studies Access to new generation DAA treatment in HIV-negative and HIV-positive individuals with F3-F4 stage of liver disease: results from PITER and Icona/HepaICONA cohorts VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
  17. C Mussini, P Lorenzini, A Cozzi-Lepri, G Marchetti, S Rusconi, A Gori, N Gianotti, C Pinnetti, A Antinori, A d’Arminio Monforte CD4/CD8 ratio slope after switching from triple- to double combinations or PI-monotherapy VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
  18. N Gianotti, A Cozzi-Lepri, G Marchetti, A Saracino, A Gori, A Antinori, G Rizzardini, M Lichtner, A Bandera, C Mussini, E Girardi, A d'Arminio Monforte on behalf of the ICONA Foundation Study Group Drop in CD4+ counts below 200 cells/μL after reaching (or starting from) values higher than 350 cells/μL in HIV‐infected patients with virological suppression VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
  19. F Ceccherini-Silberstein; A Cozzi-Lepri; E Merlini; G Marchetti; MR Capobianchi; A De Luca; N Gianotti; A AntinorI; CF Perno; A d'Arminio Monforte. Correlations of Pre-ART HIV-DNA With Outcome in First-Line Treated ART Patients. 23th CROI – Conference on Retrovirus and Opportunistic Infections. Boston, February 22-26, 2016.
· 2015 ·
  1. N Squillace, L Galli, A Bandera, A Castagna, G Madeddu, P Caramello , A Antinori , AM Cattelan, F Maggiolo, A Cingolani, A Gori and A d’Arminio Monforte for the ICONA Foundation study. Low High-Density Lipoprotein Cholesterol (HDL) is associated with the risk of Non-AIDS defining malignancies.  15th European AIDS Conference, Barcelona 21/24 October 2015.
  2. M Puoti, M Shanyinde, A Antinori, A Castagna, E Nicastri, S Bonora, A Di Biagio, C Uberti-Foppa, N Abrescia, P Bonfanti, A d'Arminio Monforte, A Cozzi-Lepri, on behalf of ICONA and Hepaicona Study Group. Challenges of anti HCV treatment in persons living with HIV in the era of Directly Acting Antivirals (DAA) s.  15th European AIDS Conference, Barcelona 21/24 October 2015.
  3. P Scognamiglio, M Shanyinde, A Gori, M Lichtner, A Di Biagio, S Lo Caputo, F Castelli, A Cozzi-Lepri, A Antinori, M Puoti, A d'Arminio Monforte, E Girardi, Icona Foundation Study. Determinants and impact of late HCV diagnosis among persons with newly diagnosed HIV infection.  15th European AIDS Conference, Barcelona 21/24 October 2015.
  4. A Cozzi-Lepri, S Lo Caputo, F Maggiolo, A Antinori, A Ammassari, G Marchetti, C Mastroianni, A Gori, G Di Perri, G Angarano, A Carbone, A d'Arminio Monforte, on behalf of the Icona Foundation Study cohort. High treatment retention and success rates of tenofovir/emtricitabine/rilpivirine (Eviplera) in ART naïve HIV infected persons in clinical practice: a comparative study on determinants of use and treatment outcome.  15th European AIDS Conference, Barcelona 21/24 October 2015.
  5. A Cozzi-Lepri, N Gianotti, A Antinori, A Castagna, A De Luca, BM Celesia, M Galli, C Mussini, C Pinnetti, V Spagnuolo, A d'Arminio Monforte, M Andreoni, on behalf of Icona Foundation Study and mono PI/ r database Study Cohorts. Risk and determinants of failure of a mono PI/ r simplification strategy with LPV/r or DRV/r in clinical practice. 15th European AIDS Conference, Barcelona 21/24 October 2015
  6. G Marchetti, A Cozzi-Lepri, E Merlini, A Castagna, A Costantini, G Orofino, S Lo Caputo, A De Luca, A Antinori, A d'Arminio Monforte, Icona Foundation Study Group PrecART proinflammatory milieu, microbial translocation (MT) and risk of disease progression in HIV Infected patients starting their first cART: data from the Icona Foundation Cohort. 15th European AIDS Conference, Barcelona 21/24 October 2015.
  7. A Antinori, A Cozzi-Lepri, A Ammassari, A Castagna, N Gianotti, S Rusconi, S Lo Caputo, F Baldelli, MS Mura, T Quirino, A Costantini, A d'Arminio Monforte, on behalf of the Icona Foundation Study Cohort. Low-level viremia (LLV) ranging from 50 to 500 copies/mL is associated to an increased risk of AIDS events in the Icona Foundation Cohort. 15th European AIDS Conference, Barcelona 21/24 October 2015.
  8. M Lichtner, A Cozzi Lepri, S Vita, G Marchetti, A Sarracino, A Gori, C Mussini, G Madeddu, A d'Arminio Monforte, Icona Foundation Study Group. “CD4 exploders” and “CD4 peak achievers” under ART in a large Italian cohort of HIV-infected subjects. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, 19/22 luglio 2015.
  9. A Mammone, R Cauda, V Vullo, C Viscoli, P Caramello, F Baldello, P Bonfanti, G Angarano, A Antinori, M Puoti, A d'Arminio Monforte, E Girardi, ICONA Foundation Study Group. Trend and causes of hospitalizations among patients with HIV entering care in Italy: a 15 years study from the ICONA cohort. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, 19/22 luglio 2015.
  10. M Puoti, M Shanyinde, A Cozzi-Lepri, C Pinnetti, A Di Biagio, E Nicastri, G Viale, A De Bona, S Bonora, F Castelli, A d’Arminio Monforte on the behalf of ICONA and HepaICONA study groups. Feasibility of Pegylated Interferon (PegIFN) based therapies in HIV/HCV coinfected individuals seen for care in Italy: an estimate using data from ICONA and HepaICONA cohorts.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  11. S Nozza, A Cozzi-Lepri, S Rusconi, A Gori, P Cinque, A Ammassari, P Caramello, G Tambussi, A d'Arminio Monforte, G Marchetti for ICONA Study Group. Prevalence of recent HIV infection (RHI) and characterisation of the RHI population in a cohort of patients seen for care in Italy over 1997-2014.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  12. M Shanyinde, A Cozzi-Lepri, A Antinori, C Uberti Foppa, N Abrescia, P Bonfanti, G Angarano, S Bonora, A d’Arminio Monforte, MC Moioli on the behalf of ICONA and HepaICONA study groups. Characteristics of HIV/HCV co-infected individuals seen for care in Italy: a description using data from ICONA and HepaICONA cohorts.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  13. A d’Arminio Monforte, A Cozzi Lepri, F Maggiolo, G Rizzardini, PE Manconi, N Gianotti, T Quirino, C Pinetti, S Rusconi, A De Luca, A Antinori on behalf of the Icona Foundation Study cohort. Response to first-line ritonavir-boosted protease inhibitors (PI/r) based regimens in late presenting patients enrolled in a large cohort of HIV-infected individuals.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  14. G Marchetti, A Cozzi-Lepri, M Galli, G Rizzardini, F Maggiolo, A Antinori, T Quirino, PE Manconi, MR Capobianchi, F Ceccherini-Silberstein, A d'Arminio Monforte for the Icona Foundation Study Group. Rates of viral rebound (VR) >200 copies/mL after a viral load (VL) ≤50 copies/mL according to period and duration of viral suppression on first-line cART.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  15. C Mussini, A d’Arminio Monforte, A Antinori, A Castagna, S Lo Caputo, F Maggiolo, M Andreoni, J Vecchiet, C Ferrari, E Nicastri, G Pellizzer, A De Luca and A Cozzi-Lepri for the Icona Foundation Study. Virological response to modern first-line antiretroviral regimens in HIV-infected patients enrolled in a large cohort according to their pre-therapy viral load and type of regimen started.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  16. M Franzetti, A De Luca, F Ceccherini-Silberstein, V Spagnuolo, E Nicastri, C Mussini, A Antinori, L Monno, J Vecchiet, G Rizzardini, V Micheli, I Fanti, A d’Arminio Monforte, C Balotta on behalf of the ICONA Foundation Study Group. Evolution of HIV-1 Transmitted Drug Resistance in Italy in the 2009-2013 Period: a Weighted Analysis.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  17. M Puoti, M Shanyinde, A Cozzi-Lepri, A Antinori, A Castagna, E Nicastri, S Bonora, F Castelli, A Chiodera, C Pinnetti, A d’Arminio Monforte on the behalf of ICONA and HepaICONA study groups. Direct acting anti-viral (DAA) therapeutic options in HIV/HCV co-infected individuals seen for care in Italy: an estimate using data from ICONA and HepaICONA cohorts.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  18. A Mammone, A Cingolani, M Lichtner, A Di Biagio, P Caramello, F Baldelli, P Bonfanti, G Angarano, A Antinori, M Puoti, A d'Arminio Monforte, E Girardi, ICONA Foundation Study Group. Trend and causes of hospitalizations among patients with HIV entering care in Italy: a 15 years study from the Icona cohort.  VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
  19. S Vita, M Lichtner, G Marchetti, C Mascia, E Merlini, P Cicconi, V Vullo, P Luigi Viale, A Costantini, A d'Arminio Monforte. sCD163 increase in HIV/CMV coinfected subjects included in ICONA Cohort. 22nd Conference on Retroviruses and Opportunistic Infections Seattle February 23-26, 2015
  20. A Cozzi-Lepri, A Cingolani, A Antinori, C Pinnetti A De Luca, C Mussini, S Rusconi, M Galli, A d'Arminio Monforte, A Castagna. Viremia copy years and its impact on risk of clinical progression according to shape. 22nd Conference on Retroviruses and Opportunistic Infections Seattle February 23-26, 2015
  21. A Cingolani, P Cicconi, G Taliani, A Cozzi-Lepri, M Puoti, C Pinnetti, P L Viale, A d'Arminio Monforte. Progression of liver disease in HIV/HCV coinfected people according to gender in Icona Cohort: role of age as potential different exposure to estrogens. 22nd Conference on Retroviruses and Opportunistic Infections Seattle February 23-26, 2015
· 2014 ·
  1. G Madeddu, A d'Arminio Monforte, E Girardi, A Di Biagio, S Lo Caputo, R Piolini, G Marchetti, G Pellizzer, A Giacometti, A Galli, A Antinori, A Cozzi Lepri. on the behalf of the Icona Foundation Study Group. CD4 cell count and the risk of infective and non-infective serious non AIDS events in HIV-infected persons seen for care in Italy.  12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
  2. 2. A Cingolani, S Zona, E Girardi, A Cozzi-Lepri, L Monno, E Quiros Roldan, G Guaraldi, A Antinori, A d'Arminio Monforte, S Marcotullio, on the behalf of the Icona Foundation Study Group. Increased incidence of Sexually Transmitted Diseases (STD) in the recent years: data from the ICONA cohort.  12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
  3. S Costarelli, A Cozzi-Lepri, G Lapadula, S Bonora, G Madeddu, F Maggiolo, A Antinori, A Gori, A d'Arminio-Monforte, on the behalf of the Icona Foundation Study Group. Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice.  12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
  4. N Gianotti, A Cozzi-Lepri, A Antinori, A Di Biagio, MC Moioli, S Nozza, A Cingolani, A De Luca, G Madeddu, S Bonora, F Ceccherini-Silberstein, A d’Arminio Monforte, on the behalf of the Icona Foundation Study Group. Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting.  12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
  5. A Cozzi-Lepri, S Lo Caputo, F Maggiolo, A Antinori, A Ammassari, G Marchetti, C Mastroianni, A Gori, G Di Perri, G Angarano, A Carbone, A d'Arminio Monforte, on the behalf of the Icona Foundation Study Group. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy.  12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
  6. A Cozzi-Lepri, A Antinori, S Bonora, A Cingolani, G Cassola, G Angarano, V Vullo, C Mussini, A Gori, F Maggiolo, A Castagna, A d'Arminio Monforte, on the behalf of the Icona Foundation Study Group. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.  12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
  7. A Di Biagio, A Cozzi-Lepri, R Prinapori, G Angarano, A Gori, T Quirino, A De Luca, A Costantini, C Mussini, G Rizzardini, A Antinori, A d'Arminio Monforte on the behalf of the Icona Foundation Study Group. Treatment discontinuation in HIV-1 infected individuals starting their first-line HAART after 2008: data from the Icona Foundation Study Cohort.  12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
  8. A Saracino, P Lorenzini, S Lo Caputo, E Girardi, F Castelli, P Bonfanti, M Galli, P Caramello, N Abrescia, C Mussini, L Monno, A d'Arminio Monforte, on the behalf of the Icona Foundation Study Group. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.  12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
  9. C Mussini, P Lorenzini, A De Luca, M Puoti, M Lichtner, G Lapadula, S DI Giambenedetto, A Antinori, M S Mura, A Cozzi-Lepri and A d'Arminio Monforte for the Icona Foundation. Prognostic value of FIB4 in HIV positive patients of the Icona cohort with or without HCV. 20th International AIDS Conference - July 20-25 2014, Melbourne
  10. A Cingolani, S Zona, E Girardi, A Cozzi-Lepri, L Monno, E Quiros Roldan, G Guaraldi, A Antinori, A d'Arminio Monforte, S Marcotullio for the Community Oriented Study Group of The Icona Foundation Study Group. Increased incidence of Sexually Transmitted Diseases (STD) in the recent years: data from the ICONA cohort.  VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
  11. A Cingolani, P Cicconi, G Taliani, G Marchetti, L Sighinolfi, F Castelli, G Cassola, D Francisci, P Caramello, L Nicolini, M Puoti, A d'Arminio Monforte for Icona Foundation Study Group and Win Study Group. Featuring HIV/HCV coinfected women in the Icona Cohort: epidemiological and clinical aspects according to gender. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
  12. A Cozzi-Lepri, S Lo Caputo, F Maggiolo, A Antinori, A Ammassari, G Marchetti, C Mastroianni, A Gori, G Di Perri, G Angarano, A Carbone and A d'Arminio Monforte for the Icona Foundation. Determinants of the use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in the Icona Foundation Study. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
  13. F Maggiolo, P Lorenzini, A Cozzi-Lepri, G M Corbelli, A Cingolani, E Girardi, A Antinori, A Castagna, A D'Arminio Monforte, S Marcotullio for the ICONA Foundation Study group. Outstanding outcome: in whom and how.  VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
  14. G Madeddu, S Rusconi, A Cozzi-Lepri, S Di Giambenedetto, S Bonora, A Carbone, A De Luca, N Gianotti, A Di Biagio, A Antinori for the Icona Foundation Study Group. Efficacy and tolerability of switching to a dual therapy with darunavir/r+raltegravir in HIV-infected patientswith HIV-1 RNA ≤50 cp/mL. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
  15. S Vita, M Lichtner, G Marchetti, C Mascia, E Merlini, P Cicconi,V Vullo, R Piolini, P Viale, A Costantini, C Mussini, A d'Arminio Monforte for the Icona Foundation Study. Impact of CMV infection on soluble markers of myeloid activation in HIV infected subjects.  VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
  16. G Rozera, I Abbate, E Giombini, A Castagna, A De Luca, F Ceccherini-Silberstein, A Cozzi Lepri, G Cassola, C Torti, A d'Arminio Monforte, G Ippolito and M R Capobianchi on behalf of the ICONA Foundation Group. Analysis of peripheral HIV reservoir, tropism and soluble immune activation markers during long cART in naïve patients. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
  17. C Mussini, P Lorenzini, A De Luca, M Puoti, M Lichtner, G Lapadula, S DI Giambenedetto, A Antinori, M S Mura, A Cozzi-Lepri and A d'Arminio Monforte for the Icona Foundation. Prognostic value of FIB4 in HIV positive patients of the Icona cohort with or without HCV.  VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
  18. C Mussini, P Lorenzini, A Cozzi-Lepri, G Lapadula, G Marchetti, E Nicastri, A Cingolani, M Lichtner, A Antinori, A d’Arminio Monforte for the Icona Foundation Study Group. Incidence of CD4/CD8 Ratio Normalization and Its Role in the Onset of Non-AIDS-Related Events.  21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014 Boston
  19. N Squillace, P Lorenzini, G Lapadula, A Cozzi-Lepri, S Rusconi, M Puoti, A Castagna, A Antinori, A Gori, A d’Arminio Monforte for the Icona Foundation Study Group. Triglycerides/HDL Ratio and Risk of Developing Diabetes Mellitus During Antiretroviral Therapy.  21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014 Boston
· 2013 ·
  1. A Castagna, L Monno, S Carta, L Galli, S Carrara, V Fedele, G Punzi, I Fanti, P Caramello, A Cozzi-Lepri, A De Luca, F Ceccherini-Silberstein, A d'Arminio Monforte, ICONA Foundation Study Group. The Evolution of Viral Tropism by Geno2pheno in HIV-infected Subjects with or without Virological failures after ART Initiation: Results from the ICONA Cohort.  14th European AIDS Conference, Brussels 16/19 October 2013
  2. A Di Biagio, L A Nicolini, P Lorenzini, M Puoti, A Antinori, A Cozzi-Lepri, A Gori, J Vecchiet, C Mussini, M Andreoni, C Viscoli, A d'Arminio Monforte, ICONA Foundation Study Group. Hepatic Safety Profile of Darunavir-based Aniretroviral Treatment (ART) in HIV-1 Infected Patients with or without Hepatitis C Co-infection. 14th European AIDS Conference, Brussels 16/19 October 2013
  3. A d'Arminio Monforte, L Galli, A Castagna, S Lo Caputo, M Lichtner, C Pinetti, N Bobbio, D Francisci, A Costantini, R Cauda, MA Forleo, E Girardi, ICONA Foundation Study Group. Aniretroviral (ART) Regimens of Pregnacy. Data from the Icona Cohort. 14th European AIDS Conference, Brussels 16/19 October 2013
  4. A Cozzi-Lepri, MR Capobianchi, E Girardi, A De Luca, E Nicastri, P Bonfanti, P Viale, CF Perno, A d'Arminio Monforte, and A Antinori for the Icona Foundation Study. Rates of ART switching after first virological rebound >50 copies/mL according to most recent viral load pairs over 2000-2012 in clinical practice. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
  5. A Di Biagio, L Nicolini, P Lorenzini, M Puoti, A Antinori, ACozzi-Lepri, A Gori, J Vecchiet, C Mussini, M Andreoni, C Viscoli, A d'Arminio Monforte for the Icona Foundation Study Group. Liver-related adverse events with darunavir-based antiretroviral treatment in HIV/HCV infected patients. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
  6. MM Santoro, C Alteri, A Bertoli, C Gori, V Borghi, L Fabeni, I Fanti, N Orchi, C Pinnetti, C Tommasi, N Cesta, E Girardi, G D'Offizi, M Giuliani, A d'Arminio Monforte, M Andreoni, C Mussini, A Antinori, CF Perno, F Ceccherini-Silberstein. Low Prevalence of Primary Rilpivirine Mutations in NNRTI-Naïve Patients is Found in B and Most Frequent Non-B HIV-1 Subtypes in Italy. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
  7. S Lo Caputo, A Cozzi-Lepri, P Caramello, T Quirino, L Sighinolfi, R Cauda, S Bonora, V Vullo, A Chiodera, A Castagna, A d'Arminio Monforte for the Icona Foundation Study Group. Gender differences in ICONA cohort: epidemiological and therapeutic aspects in women with HIV infection. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
  8. D Armenia, MM Santoro, A Cozzi Lepri, A Calcagno, F Forbici, R Bellagamba, A Castagna, A Latini, N Petrosillo, A Ammassari, F Castelli, S Di Giambenedetto, M Andreoni, A Antinori, G Di Perri, C Mussini, F Ceccherini-Silberstein, A D'Arminio Monforte, CF Perno. Patients with very high pre-HAART viremia are at highest risk of experiencing virological rebound. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
  9. A Cingolani, A Cozzi-Lepri, C Mussini, A Ammassari, A De Luca, P Caramello, G Castelli, E Girardi, A Antinori, A d'Arminio Monforte, for the ICONA Foundation Study. Patterns of cART regimens use and virological response according to specific AIDS-defining events (ADE) in AIDS-presenter patients over time. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
  10. M Puoti, P Lorenzini, E Girardi, A Cozzi-Lepri, A Gori, C Mastroianni, G Rizzardini, G Mazzarello, A Antinori, A d'Arminio Monforte, and Icona Foundation Study Group1 Incidence and Progression to Cirrhosis of HCV Superinfection in Persons Living with HIV (PLHIV) 20th Conference on Retroviruses and Opportunistic Infections 3-6 March 2013 Atlanta
· 2012 ·
  1. A Cozzi-Lepri, A Antinori, E Magistrelli, F Castelli, G Rizzardini, A Castagna, G Pellizzer, N Abrescia, G Parruti, T Quirino, P Castelli, J Vecchiet, G d'Annunzio, A d'Arminio Monforte. Durability of FTC/TDF-containing cART regimens in a large cohort of HIV-infected patients seen for care in Italy. Eleventh International Congress on Drug Therapy in HIV. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (Oral 313)
  2. M Lichtner, P Cicconi, S Vita, A Cozzi-Lepri, M Galli, S Lo Caputo, G Angarano, A De Luca, F Moioli, F Maggiolo, G Marchetti, V Vullo, A d'Arminio Monforte. CMV co-infection and risk of AIDS and non- AIDS events in a large cohort of HIV-infected patients. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (Oral 415)
  3. A Cingolani, A Cozzi-Lepri, A Ammassari, C Mussini, G Magnani, P Caramello, G Angarano, P Bonfanti, A De Luca, MS Mura, E Girardi, A Antinori, A d'Arminio Monforte. Timing of cART initiation after a first AIDS-defining event (ADE): temporal changes in clinical attitudes in a large cohort of HIV-infected patients. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (Oral 422)
  4. A d'Arminio Monforte, A Cozzi-Lepri, G di Perri, M Andreoni, M Galli, A Poli, F Maggiolo, A Costantini, G Viscoli, L Sighinolfi, G Rizzardini, P Bonfanti, N Gianotti, CF Perno, A Antinori. Durability of lopinavir/r monotherapy in people with viral load ≤ 50 copies/ml. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (P305)
  5. A Ammassari, P Lorenzini, C Mussini, A Cozzi-Lepri, F Baldelli, A Gori, M Andreoni, V Tozzi, G Di Perri, A Lazzarin, T Quirino, G Cassola, A d'Arminio Monforte, A Antinori. Impact of antiretroviral dosing frequency and daily pill burden on virological success rates in patients of the ICoNA cohort starting their first ART. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (P 262)
  6. C Alteri, VC Di Maio, A Artese, G Costa, MM Santoro, S Alcaro, M Andreoni, A Antinori A, F Ceccherini-Silberstein, CF Perno, V Svicher. Structural modifications in HIV-1 RT induced by specific RT polymorphisms tighly modulate the first phase of viraemia decay to first line FTC+TDF containing HAART. International on HIV & Hepatitis virus Drug Resistance Workshop & curative strategies, June 5-9 2012, Melia Sitges, Sitges
  7. G Rozera, I Abbate, E Giombini , A Castagna, A De Luca, F Ceccherini Silberstein, A Cozzi Lepri, G Cassola, G Carosi, G Ippolito, MR Capobianchi. Dynamics of X4 variants in HIV-1 quasispecies over a five years of interval in patients under cart. 10th European Meeting on HIV& Hepatitis Treatment Strategies & Antiviral Drug Resistance, March 28-30 2012, Barcelona, Spain, Reviews in Antiviral Therapy & Infectious Diseases 2/2012 #O_20 p 21 Oral Presentation
  8. C Alteri, VC Di Maio, A Artese, G Costa, S Alcaro, M Andreoni, A Antinori, F Ceccherini-Silberstein, CF Perno, V Svicher. Specific RT Polymorphisms Tightly Modulate Virological Response to First Line FTC+TDF containing HAART and Affect the RT Interaction with FTC and/or TDF. 19 th Conference on Retroviruses and Opportunistic Infections 5-8 March 2012 Seattle
  9. G Lapadula, A Cozzi-Lepri, A Gori, A Antinori, G Marchetti, A Chiodera, P Narciso, G Parruti, M Galli, A d'Arminio Monforte. Risk of AIDS and non AIDS-related events among patients with conserved CD4+ T-cell counts at baseline but blunted immune-response despite virological suppression after antiretroviral treatment. 19 th Conference on Retroviruses and Opportunistic Infections 5-8 March 2012 Seattle
  10. F Sabbatini, A Cozzi-Lepri, A Bandera, G Madeddu, S Bonora, V Tozzi, C Mastroianni, P Bonfanti, A Gori, A d'Arminio Monforte. Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of Italian HIV-Infected People. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012 Seattle (P868)
· 2011 ·
  1. C Mussini, A Cozzi-Lepri, A Antinori, A Castagna, S Lo Caputo, G Pellizzer, F Maggiolo, M Andreoni, J Vecchiet, C Ferrari, L Galli, A d'Arminio Monforte, Icona Foundation. Viro-immunological response to the first cART regimen according to baseline viral load: an observational study. 13th European AIDS Conference/EACS, October 12-15, 2011 Belgrade (PE7.9/4)
  2. A Cozzi-Lepri, C Mussini, S Bonora, MR Capobianchi, A De Luca, V Tozzi, G Parruti, A Giacometti, C Viscoli, A Orani, V Vullo, A d'Arminio Monforte, Icona Foundation Study. The chance of suppressing viral load ≤80 copies/mL according to initial viral load and type of regimen started: an observational study. 13th European AIDS Conference/EACS, October 12-15, 2011 Belgrade (PE7.7/3)
  3. A Cozzi-Lepri, A De Luca, A Castagna, A Antinori, G Cassola, G Rizzardini, T Quirino, N Abrescia, C Torti, G Pagano, A d'Arminio Monfote, Icona Foundation Study. Response to emtricitabine- vs. lamivudine-containing combination antiretroviral therapy (cART) with tenofovir in patients enrolled in a large cohort in Italy. 13th European AIDS Conference/EACS, October 12-15, 2011 Belgrade (PE7.4/1)
  4. S Lo Caputo, A Cozzi-Lepri, A Antinori, M Galli, PL Viale, A Lazzarin, G Carosi, L Sighinolfi, M Montroni, A d'Arminio Monforte for the ICONA Foundation Study Group. HIV treatment guidelines and value of CD4 count at ART initiation. Data analysis of a cohort of HIV patients enrolled in Italy when their CD4 count was >500 cells/mm3. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011 Rome. Abstract TUPBD01
  5. A d'Arminio Monforte, A Cozzi-Lepri, M Puoti, M Arlotti, P Narciso, A Gori, P Caramello, A Chiodera, G Cassola, CM Mastroianni for the Icona Foundation Study group. Durability of emtricitabine vs. lamivudine in patients enrolled in a large cohort in Italy starting tenofovir containing combination antiretroviral therapy (cART). 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011 Rome. Abstract CDB275
  6. R Murri, A Ammassari, MP Trotta, A Antinori, P Lorenzini, A d'Arminio Monforte. Health-care delivery characteristics of clinical centers are correlated with survival of Italian HIV patients.  ICAR 2011, 39(SI):S24
  7. MM Santoro, V Svicher, A Cozzi-Lepri, L Fabeni, B Bruzzone, C Mussini, A De Luca, M Andreoni, I Fanti, A Antinori, M Zazzi, CF Perno, A d'Arminio Monforte, F Ceccherini-Silberstein for Icona Foundation. Impact of natural polymorphisms of HIV-1 reverse transcriptase at position 135 on virologic response to a first line NNRTI-containing HAART. 15th International Workshop on HIV Observational Databases. Prague, Czech Republic, March, 24-26, 2011. Abstract 83
  8. MM Santoro, C Alteri, I Abbate, V Svicher, A Bruselles, B Bartolini, C Gori, G Rozera, MR Capobianchi, CF Perno, F Ceccherini-Silberstein. Sentinel Mutations in Standard Population Sequencing Predict a high prevalence of RTI-resistance minor variants in both RNA plasma and DNA cellular samples from HIV-1 drug naïve patients. SIVIM. 4th National Congress of Italian society of medicine virology oral presentation Milano, 5-7 May, 2011
  9. C Alteri, MM Santoro, L Fabeni, C Gori, V Cento, F Stazi, G Maffongelli, M Viscione, M Zaccarelli, P Narciso, M Andreoni, A Antinori, F Ceccherini-Silberstein, V Svicher, CF Perno. The presence of PR compensatory mutations increases over the years and correlates with a shorter time to virological failure in PI treated patients. 9th European Workshop on HIV & Hepatitis. Cyprus, March 23 -25, 2011. Abstract O_06
  10. G Marchetti, A Cozzi-Lepri, GM Bellistri, E Merlini, F Ceccherini-Silberstein, A De Luca, A Antinori, A Castagna, M Puoti, A d'Arminio Monforte for the Icona Foundation Study Group. Role of Immune Activationand Microbial Translocation in Liver Disease progression in HIV/HCV Co-infected ARV-naïve patients with high CD4+ Count. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 27-March 2 2011. (abs 936)
  11. A Cingolani, A Cozzi-Lepri, A Castagna, D Goletti, A De Luca, P Scarpellini, I Fanti, A Antinori, A d'Arminio Monforte, E Girardi and Icona Foundation, ICC, UCSC, HSR Cohort Study. Impaired CD4 Count response to cART ina ARV-naïve HIV-infected PatientsPresenting with TB as an AIDS-defining Condition. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 27-March 2 2011. (abs 885)
  12. MP Trotta, P Lorenzini, M Bibas, M Galli, G Rizzardini, P Narciso, V Tozzi, L Pucillo, A d'Arminio Monforte, A Antinori and Icona Foundation Study. Relative prognostic value of Serum-Free Light Chains and Effective HAART in Predicting HIV-associated Lymphoma and Mortality. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 27-March 2 2011. (abs 863)
· 2010 ·
  1. G Marchetti, A Cozzi-Lepri, G Bellistrì, E Merlini, F leoncini, F baldelli, G Antonucci, A Castagna, E Raise, L Manzini, PE Manconi, M Puoti, A De Luca, A d'Arminio Monforte for the Icona Foundation Study Group. Role of microbial translocation (MT) and immune Hyperactivation (IH) in liver disease progression of HIV/HCV+ patients with well documented HIV seroconversion date and preserved CD4 count. Infection 2010, 38(SI):85
  2. A Cozzi-Lepri, M Prosperi, S Lo Caputo, C Gervasoni, C Mussini, M Andreoni, A Gori, G Cristini, A d'Arminio Monforte for the Icona Foundation Study. Fib4 is an independent predictor of serious liver disease among HIV-infected patients with or without HBV/HCV co-infection in the Icona Foundation Study. Infection 2010, 38(SI):73
  3. V Svicher, V Cento, C Gori, M Ciccozzi, M Arlotti, M Puoti, N Ladisa, G Rizzardini, A d'Arminio Monforte, CF Perno, and Icona Foundation Study Group. The synergistic interaction between immunological and pharmacological selective pressure in HIV-HBV co-infected patients is a potent driver of HBV evolution and drug resistance emergence. 17th Conference o­n Retroviruses and Opportunistic Infections, San Francisco, February 2010. (abs. 637)
  4. M Borderi, F Vescini, A Cozzi-Lepri, A Di Caro, I Shlacht, G Cassola, G Pellizzer, J Vecchiet, MC Re, A d'Arminio Monforte, for the Icona Foundation Study Group. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large Italian Cohort. 17th Conference o­n Retroviruses and Opportunistic Infections, San Francisco, February 2010. (abs. 751)
  5. G Marchetti, A Cozzi-Lepri, G M Bellistrì, E Merlini, A Chiodera, F Soscia, G Rizzardini, MR Capobianchi, A De Luca, A d'Arminio Monforte, for the Icona Foundation Study Group. Role of microbial translocation and immune hyperactivation in disease progression of HIV+ patients with preserved CD4 count in the absence of ART. 17th Conference o­n Retroviruses and Opportunistic Infections, San Francisco, February 2010. (abs. 333)
· 2009 ·
  1. E Girardi, C Angeletti, P Scognamiglio, MCF Prosperi, A d'Arminio Monforte, A Castagna, A De Luca, C Torti, G Scalise, G Rizzardini, L Caggese, A Antinori, G Ippolito, Icona Foundation. Determinants of access to investigational antiretrovirals among Italian HIV infected patients. 12th European AIDS Conference/EACS, November 11-14, 2009 Cologne (PE10.4/6)
  2. A De Luca, K de Gaetano Donati, A Cozzi-Lepri, M Colafigli, A De Curtis, MR Capobianchi, A Antinori, G Scalise, G Magnani, V Vullo, R Cauda, L Iacoviello, A d'Arminio Monforte, ICoNA Foundation Study Group. Exposure to abacavir and biomarkers associated with cardiovascular disease (CVD) in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. 12th European AIDS Conference/EACS, November 11-14, 2009 Cologne (PE9.5/8)
  3. A d'Arminio Monforte, A Cozzi-Lepri, I Fanti, F Maggiolo, A Castagna, F Prati, V Vullo, T Quirino, P Narciso, S Lo Caputo, E Girardi, C Mussini, A Antinori, Icona Foundation Study Group. Proportion and trend over calendar time of patients with a low CD4 count or AIDS diagnosis at the time of their first contact with clinical care in Italy. 12th European AIDS Conference/EACS, November 11-14, 2009 Cologne (LS 2/2)
  4. A De Luca, M Colafigli, K de Gaetano Donati, A Cozzi-Lepri, A De Curtis, A Gori, F Ghinelli, G Scalise, F Carletti, A D'Avino, L Iacoviello, R Cauda, A d'Arminio Monforte, ICoNA Foundation Study Group. Inflammatory biomarkers predict cardiovascular events in HIV positive patients receiving cART: a case control study. 12th European AIDS Conference/EACS, November 11-14, 2009 Cologne (PS 11/5)
  5. M Zaccarelli, A Antinori, A Cozzi-Lepri, C Mussini, G Palamara, MM Santoro, V Spagnuolo, A d'Arminio Monforte, CF Perno, F Ceccherini-Silberstein. Is there any potential for first line Etravirine use? Analysis from a large dataset of ART-naïve HIV infected patients undergoing resistance test. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2009 CapeTown
  6. A De Luca, K De Gaetano Donati, A Cozzi-Lepri, A De Curtis, MR Capobianchi, A Antinori, G Scalise, G Magnani, V Vullo, R Cauda, L Iacoviello, A d'Arminio Monforte, ICONA Foundation Study Group. Abacavir treatment and biomarkers associated with cardiovascular disease (CVD) in HIV-1 infected patientson effective antiretroviral therapy. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2009 CapeTown
  7. A d'Arminio Monforte, A Cozzi-Lepri, A Antinori, A De Luca, C Mussini, S Lo Caputo, G Cassola, G Pellizzer, J Vecchiet, P Caramello, M Montroni, A Castagna, Icona Foundation Study Group. Framingham risk score in HIV-positive patients living in Italy: the Icona Foundation Study. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2009 CapeTown
  8. A Ammassari, A Cozzi-Lepri, A De Luca, E Girardi, M Arlotti, C Torti, M Ladisa, P Piano, E Raise, C Mussini, A Castagna. A relatively slow risk of diseases progression in HIV-positive patients with indolent infection has been found in the Icona Cohort. Infection 2009, 37(SII):106
  9. MCF Prosperi, A Cozzi-Lepri, A Castagna, C Mussini, R Murri, A Costantini, G Antonucci, A Gori, G Mazzarello, A Antinori, A d'Arminio Monforte for the Icona Foundation Study. The risk and determinants of Malignancies in HIV-infected patients enrolled in the Icona Foundation Study. Infection 2009, 37(SII):30
  10. A Cozzi-Lepri, A Antinori, A De Luca, P Bonfanti, G Cassola, M Andreoni, G Pellizzer, J Vecchiet, G Carnevale, GC Orofino, A d'Arminio Monforte for the Icona Foundation Study Group. An exploratory analysis to ssess the potential effect of art in modifying the Framingham risk score in HIV-infected patients enrolled in the Icona Foundatipn Study. Infection 2009, 37(SII):25
  11. C Alteri, V Svicher, V Cento, C Gori, R Salpini, F Marcucilli, A Bertoli, M Arlotti, M Puoti, N Ladisa, G Rizzardini, M Andreoni, F Ceccherini-Silberstein, A d'Arminio Monforte, CF Perno and the Icona Study Group. Characteristic of Lamivudine resistance profiles in HBV riverse transcriptase from a national collaborative study of HIV+HBV infected individuals on long-exposure to lamivudine including regimens. Infection 2009, 37(SII):32
  12. V Svicher, D Armenia, MM Santoro, F Forbici, B Bruzzone, M Setti, P Corsi, R Maserati, C Mussini, M Zazzi, A De Luca, A Andreoni, P Narciso, A Antinori, CF Perno, F Ceccherini-Silberstein. Impact of mutations at position 135 of HIV-1 reverse transcriptase on virologic response to a first line NNRTI-containing HAART. Infection 2009, 37(SII):33
  13. V Svicher, C Alteri, V Cento, C Gori, R Salpini, F Marcucilli, A Bertoli, M Arlotti, M Puoti, N Ladisa, G Rizzardini, F Ceccherini-Silberstein, A d'Arminio Monforte, CF Perno and the Icona Study Group. Novel patterns of Mutations in HBV Riverse Transcriptase Associated with Lamivudine Resistance in HBV+HIV Co-infected Patients. Antiviral Therapy, 2009 14:S1A68
  14. V Svicher, C Gori, R Salpini, M Trignetti, S Romano, R Longo, M Bernassola, F Marcuccilli, G Rizzardini, GM De Sanctis, F Ceccherini-Silberstein, G Cappiello, A Spanò, A d'Arminio Monforte, C Perno. HIV-driven Immuno-suppression modulates HBV Evolution in HBV/HIV-co-infected Patients. 7th European HIV Drug Resistance Workshop, Stockholm, Sweden, March 25-27 2009
  15. V Svicher, M Trignetti, C Gori, S Romano, A Bonomini, G Rizzardini, F Ceccherini-Silberstein, A Spanò, A d'Arminio Monforte, C Perno, and ICONA Study Group. HIV-driven Immunosuppression Regulates HBV Evolution in HBV/HIV-co-infected Patients. 16th Conference o­n Retroviruses and Opportunistic Infections, Montreal, February 8-11 2009. (abs. 99)
· 2008 ·
  1. M Bongiovanni, A Cozzi-Lepri, A Castagna, A Antinori, A De Luca, C Mussini, S Lo Caputo, C Arici, M Puoti, A d'Arminio Monforte, and ICONA Foundation Study Group. HIV+ Subjects Co-infected with HBV or HCV Have a Higher Risk of Developing AIDSdefining Malignancies. 15th Conference on Retroviruses and Opportunistic Infection, February 3-6 2008, Boston
· 2007 ·
  1. A Castagna, L Galli, C Torti, A d'Arminio Monforte, C Mussini, A Antinori, A Cozzi-Lepri, N Ladisa, A De Luca, A Lazzarin, IDD-HSR Cohort, Master Cohort, Icona Cohort, Modena Cohort. Predicting Magnitude of Short-term CD4 Recovery in HIV Infected Patients during First-line HAART. 11th European AIDS Conference/EACS, Madrid, October 24-27, 2007. (abs. P7.9/07)
  2. A De Luca, A Cozzi-Lepri, A Antinori, C Mussini, C Torti, M Puoti, C Gervasoni, N Abrescia, M Arlotti, A Orani, V Vullo, A Chirianni, A d'Arminio Monforte, ICONA Foundation Study Group. Initiating cART after an AIDS-defining Condition: Treatment Outcomes and their Determinants in ICONA. 11th European AIDS Conference/EACS, Madrid, October 24-27, 2007. (abs. P18.4/08)
  3. F Ceccherini-Silberstein, V Svicher, MM Santoro, MCF Prosperi, F Forbici, A Bertoli, A De Luca, C Mussini, G Palamara, P Narciso, A Antinori, C Balotta, A d'Arminio Monforte, CF Perno, ICoNA Study Group, INMI-Collaborative Group for Clinical Use of HIV Ge Impact of HIV-1 Reverse Transcriptase Polymorphism R83K on Virological Response in Drug-Naïve Patients starting Thymidine Analogue Containing HAART. 11th European AIDS Conference/EACS, Madrid, October 24-27, 2007. (abs. P3.4/19)
  4. P Cicconi, A Cozzi-Lepri, A De Luca, A Antinori, A Castagna, C Mussini, A d'Arminio Monforte, and I.Co.N.A. Cohort. CDB249. Insights into the reasons for discontinuation and changes in the durability of the first line cART over time in Icona (Italian cohort of naïve antiretrovirals). 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sidney, July 22-25, 2007 (abs. CDB249)
  5. F Tordato, P Cicconi, A Cozzi-Lepri, A De Luca, A Antinori, C Mussini, T Quirino, C Arici, A Gori, A d'Arminio Monforte, and I.CO.N.A cohort. Evaluation of glomerular filtration rate (GFR) in naïve HIV positive patients. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sidney, July 22-25, 2007 (abs. CDB166)
  6. M Bongiovanni, A Gori, A Cozzi-Lepri, A Antinori, A De Luca, G Pagano, A Chiodera, M Puoti, A d'Arminio Monforte. Is CD4 percentage a better marker of immune-suppression than CD4 absolute count in HIV-infected subjects with cirrhosis? 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sidney, July 22-25, 2007 (abs. MOPEB063)
  7. A Ammassari, MP Trotta, P Marconi, R Murri, A d'Arminio Monforte, A Antinori for the AdICoNA Study Group. Length of clinic visit affects adherence to antiretroviral therapy. 8th International Conference AIDS Impact. Marseille, France. 1st - 4th July 2007
  8. MP Trotta, A Ammassari, P Marconi, R Murri, A d'Arminio Monforte, A Antinori. Sexual dysfunction in HAART-treated persons: prevalence, determinants and relationship with adherence. 8th International Conference AIDS Impact. Marseille, France. 1st - 4th July 2007.
  9. I Malet, L Fabeni, S Dimonte, S Bono, V Svicher, R D'Arrigo, P Flandre, A Antinori, A d'Arminio Monforte, C Katlama, V Calvez, CF Perno, AG Marcelin, F Ceccherini-Silberstein. Specific mutations associated with in-vitro resistance to HIV-1 integrase inhibitors are present in untreated and NRTI/NNRTI/PI-treated HIV-infected patients. 5th European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications. Cascais, Portugal, March 29-31, 2007. Abstract book: 46 pag 34.
  10. V Svicher, T Sing, A Artese, MM Santoro, C Gori, S Alcaro, A Bertoli, A d'Arminio Monforte, A Antinori, T Lengauer, F Ceccherini-Silberstein, CF Perno. Involvement of Two Additional HIV-1 Reverse Transcriptase Mutations in the Regulation of NNRTI Resistance. 5th European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications. Cascais, Portugal, March 29-31, 2007. Abstract book: 117 pag 92.
  11. A Antinori, A Cozzi-Lepri, P Cinque, M Giancola, A De Luca, C Mussini, C Torti, L Sighinolfi, V Colangeli, A d'Arminio Monforte, and ICoNA Cohort. Could Cerebrospinal Fluid ART Penetration Scores Predict Viral Rebound in ART-naïve Individuals Who Achieve Plasma Viral Load Suppression on Their First Therapy? 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28 2007. (abs. 382a).
  12. A Ammassari, A Cozzi-Lepri, M Trotta, P Marconi, C Torti, A Castagna, A De Luca, V Colangeli, A Antinori, A d'Arminio Monforte, and ICoNA Cohort. Treatment Complexity and Risk of Virological Rebound in Persons Receiving cART. 14th Conference o­n Retroviruses and Opportunistic Infections, Los Angeles, February 25-28 2007. (abs. 522)
· 2006 ·
  1. F Ceccherini-Silberstein, V Svicher, T Sing, MM Santoro, A Bertoli, F Forbici, A Artese, A d’Arminio Monforte, A Antinori, and CF Perno. Additional mutations in HIV-1 reverse transcriptase involved in regulation of NNRTI resistance.  4rd European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications. Monte Carlo, Monaco, March 29 – 31, 2006. (abs. 95)
  2. A Cossarizza, A Riva, B Zanone Poma, P Cicconi, M Nasi, V Broggini, M Pinti, A Cozzi-Lepri, A d’Arminio Monforte, M Galli, and LipoICONA Study Group. FASI-670 and APOC3 polymorphisms as predictors of lipoatrophy in patients receiving antiretroviral therapy. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 5-8 2006. (abs. 767)
  3. P Cicconi, A Cozzi-Lepri, M Puoti, G Antonucci, M Mannazzu, G Pastore, M Mena, A Phillips, A d’Arminio Monforte and I.Co.N.A. Study Group. Is the increased risk of liver enzyme elevation in hepatitis co-infected patients greater in those on HAART than in antiretroviral-naive patients? 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 5-8 2006. (abs. 888)
· 2005 ·
  1. MP Trotta, A Cozzi-Lepri, A Ammassari, P Marconi, D Repetto, G Madeddu, N Ladisa, P Nasta, A Riva, M Lichtner, CM Izzo, M Dalessandro, A d’Arminio Monforte, A Antinori, AdIcona Study Group. Patterns of non-adherence predict virological response differently according to antiretroviral drug classes. X European AIDS Conference/EACS, 17-20 November 2005 Dublin, Ireland (abs. PE10.1/4)
  2. A Cozzi-Lepri, A De Luca, AN Phillips, M Bongiovanni, S Di Giambenedetto, M Mena, C Moioli, M Arlotti, L Sighinolfi, P Narciso, M Lichtner, R Cauda, A d’Arminio Monforte. A comparison between abacavir and efavirez when used as the “third group” with a background therapy of two NRTIs in patients with initially suppressed viral load.  X European AIDS Conference/EACS, 17-20 November 2005 Dublin, Ireland (abs. PE7.4/8)
  3. R Murri, A Cozzi-Lepri, G Vigevani, R Piscopo, D Bertelli, MA Ursitti, A Riva, S Nappa, E Manzillo, A d’Arminio Monforte. Reasons for delaying the starting of antiretroviral therapy (ART) shor an association with clinical outcomes.  X European AIDS Conference/EACS, 17-20 November 2005 Dublin, Ireland (abs. PS1/2)
  4. M Galli, A Cozzi-Lepri, AL Ridolfo, A Cappelletti, P Morelli, E Giannelli, A Radice, S Trovati, F Mazzotta, M Montroni, A Cargbel, A d’Arminio Monforte, C Gervasoni, M Moroni, for LipoIcona Study Group. Triglyceride level predicts lipoatrhphy in patients receiving antiretroviral therapy. X European AIDS Conference/EACS, 17-20 November 2005 Dublin, Ireland (abs. PS5/1)
  5. P Cicconi, L Sighinolfi, A Cozzi-Lepri, C Basilico, G Di Perri, A Chiodera, R Viglietti, M D’Alessandro, A d’Arminio Monforte, and I.Co.N.A. Study Group. Clinical Prognosis of HIV-positive patients older than 50 years in the I.Co.N.A. cohort. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 2005. (abs. MoPe11.6C07)
  6. P Cicconi, M Puoti, A Cozzi Lepri, L Cosco, G Morsica, T Santantonio, F Ancarani, A Cargnel, A d’Arminio Monforte, and I.Co.N.A. Study Group. Risk factors for decompensated cirrhosis and associates morbidity and mortality in I.Co.N.A. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 2005. (abs. TuPe1.1C24)
  7. P Cicconi, A Cozzi Lepri, M Puoti, S Pasquinucci, P Pizzaferri, E Petrelli, F Leoncini, A Alessandrini, A d’Arminio Monforte, and I.Co.N.A. Study Group. Incidence of grade 3 hepato-toxicity (HT) according to different antiretrovirals in a cohort oh HIV-1-positive and HbsAg/HCVAb-negative patients in I.Co.N.A.  3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 2005. (abs. TuPe2.3C16)
  8. V Svicher, F Ceccherini-Silberstein, T Sing, M Santoro, N Beerenwinkel, F Rodriguez, F Forbici, A d’Arminio Monforte, A Antinori, and CF Perno. Additional mutations in HIV-1 reverse transcriptase are involved in the highly ordered regulation of NRTI resistance.  3th European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications, 30 March-1 April 2005, (abs. 63)
  9. MP Trotta, S Bonora, A Cozzi-Lepri, A Ammassari, P Marconi, N Ladisa, P Nasta, L Sighinolfi, M Zaccarelli, A Riva, G Madeddu, P De Longis, A d’Arminio Monforte, G Di Perri, A Antinori and AdICoNA Study Group. Durability of viral suppression according to self-reported non-adherence and antiretroviral plasma levels.  12th Conference on Retroviruses and Opportunistic Infections, 22-25 February, 2005, Boston, USA (abs. 644)
· 2004 ·
  1. A De Luca, A Cozzi-Lepri, A Antinori, M Zaccarelli, A d’Arminio Monforte, M Bongiovanni, S Di Giambenedetto, D Zinzi, P Cicconi, F Resta, B Grisorio, S D’Elia, R Cauda for the ICoNA Study Group. Lopinavir/r or efavirenz plus two NRTI as first-line antiretroviral therapy: a non randomised comparison.  VII International Congress on Drug Therapy in HIV infection, 14-18 November 2004 Glasgow, UK (abs. P26)
  2. A Ammassari, MP Trotta, P Marconi, R Murri, A Cozzi-Lepri, S Melzi, M Zaccarelli, P De Longis, G Bontempo, N Ladisa, L Sighinolfi, P Nasta, G Madeddu, A d’Arminio Monforte, A Antinori. Incorporating patients’ suggestions in individualized intervention program for improving adherence to antiretrovirals.  VII International Congress on Drug Therapy in HIV infection, 14-18 November 2004 Glasgow, UK (abs. P97)
  3. MP Trotta, A Ammassari, A Cozzi-Lepri, P Marconi, R Murri, P De Longis, N Ladisa, M Zaccarelli, G Bontempo, P Nasta, G Madeddu, A d’Arminio Monforte, A Antinori. Changes in adherence to highly active antiretroviral therapy medications and determinants of worsening adherence: results from the AdICoNA Study.  VII International Congress on Drug Therapy in HIV infection, 14-18 November 2004 Glasgow, UK (abs. P117)
  4. F Ceccherini-Silberstein, M Santoro, S Svicher, C Gori, F Gago, T Hermsen, M Ciccozzi, M Ruiz Alvarez, R D'Arrigo, A Bertoli, S Giannella, A Cenci, MP Trotta, C Balotta, A d'Arminio Monforte, A Antinori and CF Perno. High conservation of the HIV-1 reverse transcriptase under drug pressure is maintained despite a continuous appearamce of mutations. HIV Medicine 2004; 5 (abstract 39)
  5. G Antonucci, A Cozzi-Lepri, E Petrelli, G Carnevale, PA Grossi, P Viganò, A d'Arminio Monforte, MR Capobianchi, M Solmone, E Girardi, F Carletti, G Ippolito for the ICoNA Study Group. The role of GBV-C viraemia and HCV viraemia in the response to antiretroviral therapy in a cohort of HIV-infected subjects.  XV International AIDS Conference, 11-16 July 2004, Bangkok - Thailand (abs. WeOrB1328)
  6. M Galli, A Cozzi-Lepri, AL Ridolfo, V Vullo, M Montroni, A Cappelletti, P Morelli, A d'Arminio Monforte, C Gervasoni, M Moroni. Correlates of risk of concomitant presentation of lipoatrophy, lipohypertrophy and hypertriglyceridemia in HIV-positive patients on first-line antiretroviral therapy. XV International AIDS Conference, 11-16 July 2004, Bangkok - Thailand (abs. WePeB5936)
  7. A d'Arminio Monforte, P Cicconi, A Cozzi-Lepri, A Matteelli, G Orlando, A Alessandrini, M Mena, MC Moioli, P Ortolani, D Bertelli, M Montroni, M Moroni for the ICoNA Study Group. Sexually transmitted diseases (STD) in the I.Co.N.A (Italian CohortNaive Antiretrovirals) study: prevalence and incidence on 5422 patients.  XV International AIDS Conference, 11-16 July 2004, Bangkok - Thailand (abs. WeOrB1330)
  8. F Ceccherini-Silberstein, M Santoro, S Svicher, C Gori, F Gago, M Ciccozzi, M Ruiz Alvarez, R D’Arrigo, A Bertoli, S Giannella, A Cenci, MP Trotta, A d’Arminio Monforte, A Antinori an CF Perno. High conservation of the HIV-1 reverse transcriptase under drug pressure. 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004, San Francisco, USA (abs. 643)
· 2003 ·
  1. E Girardi, MS Aloisi, C Arici, P Pezzotti, D Serraino, R Balzano, GM Vigevani, F Alberici, M Ursitti, M D’Alessandro, A d’Arminio Monforte, G Ippolito for the I.CO.N.A. Behavioural Epidemiology Study Group. Delayed presentation and late testing for HIV: demographic and behavioural risk factors in a multicenter study in Italy.  9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. F5/2)
  2. A De Luca, A Cozzi-Lepri, CF Perno, C Balotta, S Di Giambenedetto, A Orani, C Mussini, M Toti, A d’Arminio Monforte for the I.CO.N.A. Study Group. The prognostic value to predict virological outcomes of 14 distinct systems used to interpret the results of genotypic HIV-1 drug resistance testing in untreated patients starting their first HAART. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. F6/7)
  3. M Galli, A Cozzi-Lepri, AL Ridolfo, A Cappelletti, P Morelli, E Gianelli, M Piazza, F Mazzotta, M Montroni, U Tirelli, A Cargnel, A d’Arminio Monforte, C Gervasoni, M Moroni for the LipoICONA Study Group. Are the early manifestations of Lypodistrophy predicted by serum triglyceride level in patients receiving antiretroviral therapy? 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. F16/1)
  4. C Riva, M Violin, A Cozzi-Lepri, R Velleca, F Forbici, R Novati, F Castelli, M Bonasso, V Colangeli, G Rezza, G Ippolito, CF Perno, A d’Arminio Monforte, M Moroni, C Balotta for the I.CO.N.A. Study Group. Transmitted resistance mutations in a cohort of recent seroconvertes in Italy: temporal pattern and prevalence accordino to HIV-1 subtype. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. 3.1/3)
  5. A d’Arminio Monforte, A Cozzi-Lepri, C Balotta, R Velleca, C Gori, A Antinori, G Angarano, F Mazzotta, GP Cadeo, R Maserati, CF Perno for the I.CO.N.A Study Group. The degree of viral suppression predicts the probabilità of accumulatine new drug-mutations at virological failure to the first PI-HAART regimen. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. 3.4/11)
  6. 6. MP Trotta, A Ammassari, A Cozzi-Lepri, P Marconi, S Melzi, M Zaccarelli, R Murri, P De Longis, G Bontempo, N Ladisa, L Sighinolfi, F Castelli, G Madeddu, N Abrescia, M Lichtner, J Vecchiet, G Orofino, A d’Arminio Monforte, A Antinori for the AdICoNA2 Study Group. Relationship between four adherence measurements and CD4 count response. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. 10.1/19)
  7. A Ammassari, MP Trotta, A Cozzi-Lepri, A De Luca, S Melzi, M Zaccarelli, F Castelli, P Narciso, F Soscia, R Murri, A Scasso, CM Izzo, F Baldelli, A d’Arminio Monforte, A Antinori for the AdICoNA2 Study Group. HAART non-adherence and HCV/HIV co-infection.  9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. 13.2/20)
  8. A d'Arminio Monforte, A Cozzi-Lepri, R Murri, R Novati, A Antinori, C Arici, V Colangeli, A De Luca, N Ladisa, E Girardi, M Moroni for the I.Co.N.A. Study Group The effect of HAART interruptions on clinical progression: evidence from I.CO.N.A.. cohort. Antiviral Therapy 2003; 8(suppl 1): S219
  9. A Cozzi-Lepri, S Kinloch, C Arici, AN Phillips, D Santoro, P Narciso, F Lompe and A d'Arminio Monforte for the I.CO.N.A. Study Group The pre-therapy CD4 count and the duration of safe HAART interruption (HI) in patients (pts) who discontinue all their drugs with a CD4 count > 200 cells/mmc. Antiviral Therapy 2003; 8(suppl 1): S350
  10. MP Trotta, A Ammassari, A Cozzi-Lepri, S Melzi, P Marconi, N Abrescia, P De Longis, V Vullo, M Zaccarelli, A Scalzini, V Tozzi, R Murri, E Boumis, A d'Arminio Monforte and A Antinori Sexual dysfunction (SD) in HAART-treated persons: prevalence, determinants and relationship with adherence (ADH). Antiviral Therapy 2003; 8(suppl 1): S399
  11. MS Aloisi, C Arici, P Noto, R Piscopo, G Filice, F Menichetti, A d'Arminio Monforte, G Ippolito, E Girardi and Behepi Study Group. Behavioural correlates of adherence to antiretroviral therapy. AIDS impact 2003, 6th International Conference on Biopsychosocial Aspects of HIV infection, 7-10 July 2003, Milan, Italy
  12. MS Aloisi, L Gennero, S Di Cesare, S Nappa, A La Gala, A Antinori, G Ippolito, A d'Arminio Monforte, F Starace and Neuroicona Study Group. One-year incidence of minor cognitive impairment in a cohort of HIV patients: findings from the Neuroicona Study. AIDS impact 2003, 6th International Conference on Biopsychosocial Aspects of HIV infection, 7-10 July 2003, Milan, Italy
  13. CF Perno, A Cozzi-Lepri, C Balotta, F Forbici, A De Luca, S Rusconi, MS Mura, MC Moioli, A Scalzini, M Lichtner, AN Phillips, A d’Arminio Monforte for the I.CO.N.A. Study Group. Mutation M36I in the HIV protease before starting therapy is predictive of L90M primary mutation at the time of first PI-HAART failure. 1st European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications, March 6-8, 2003, Luxembourg. (abs. 1:P1.1)
  14. M Violin, R Velleca, C Riva, S Corvasce, M Montroni, N Petrosillo, G Antonucci, A Poggio, F Forbici, CF Perno, A d’Arminio Monforte, M Moroni and C Balotta. Analysis of HIV-1 mutants with unreported variants at position 215 of RT region.  1st European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications, March 6-8, 2003, Luxembourg. (abs. 2:P1.2)
  15. C Riva, M Violin, A Cozzi-Lepri, R Velleca, PA Grossi, E Raise, D Santoro, A Sinicco, G Rezza, CF Perno, A d’Arminio Monforte, M Moroni and C Balotta. HIV-1 non-B subtypes and circulating recombinant forms increased in Italy in recently infected individuals over the 1996-2002 period. 1st European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications, March 6-8, 2003, Luxembourg. (abs. 58:P4.7)
  16. CF Perno, A Cozzi-Lepri, C Balotta, F Forbici, M Violin, A De Luca, S Rusconi, G Ballardini, E Petrelli, E Tufo, AN Phillips, A d’Arminio Monforte. Mutation 36I of the protease region bifore starting therapy facilitates the appearance of L90M in patients failing their first PI-HAART regimen. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, USA. (abs. 602)
  17. F Ceccherini-Silberstein, A Bertoli, F Forbici, F Erba, L Marcon, S Aquaro, C Balotta, S Giannella, R D’Arrigo, MC Bellocchi, C Gori, MP Trotta, A d’Arminio Monforte, A Antinori, CF Perno. Identification of the minimal conserved structure of the HIV-protease under the presence and absence of drug pressare.  10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, USA. (abs. 595)
  18. G Nasti, R Talamini, A Antinori, F Martellotta, M Fasan, F Chiodo, G Ballardini, L Stoppini, G Di Perri, M Mena, M Tavio, E Vaccher, A d’Arminio Monforte, U Tirelli. AIDS-related Kaposi’s Sarcoma in 211 patients: assessment of the AIDS clinical trial group staging classification prognostic value in the era of HAART. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, USA. (abs. 815)
· 2002 ·
  1. R Murri, A Cozzi Lepri, AP Phillips, E Girardi, G Nasti, S Ferrara, MS Mura, C Mussini, E Petrelli, M Arlotti, C De Stefano, P Viganò, L Gennero, B Salassa, G Antonucci, P Narciso, S Chigiotti, T prestileo, R Novati, A Cargnel, A d’Arminio Monforte. Access to antiretroviral treatment, incidence of sustained therapy interruptions and risk of clinical events according to gender:evidence from the I.CO.N.A. study.  6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. PL6.4)
  2. A Ammassari, A Cozzi Lepri, MP Trotta, A Cappelletti, S Melzi, P De Longis, M Zaccarelli, V Vullo, R Murri, P Piano, S Lo Caputo, S Nappa, F Baldelli, A d’Arminio Monforte, A Antinori, M Galli for the AdICONA and the LipoICONA Study Group. Adherence (ADH) to HAART is predictive of developing of adipose tissue alterations (ATA) and is negatively affected by patient-reported fat accumulation. 6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. P85)
  3. MP Trotta, A Ammassari, R Murri, A Cozzi Lepri, C Minardi, G Orofino, L Tacconi, F Alberici, P Noto, G Nasti, M Ciardi, A d’Arminio Monforte, A Antinori. Patient-report, physician-estimate and drug plasma levels as measures for adherence to HAART in the AdICONA study.  6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. P89)
  4. A Antinori, A Cozzi Lepri, MP Trotta, GC Fibbia, P Narciso, E Manzillo, J Vecchiet, A Vincenti, M De Marco, C Mussini, A d’Arminio Monforte, A Ammassari for the AdICONA Study Group. Predictive value of self-reported non-adherence (non-adh) and drug plasma levels on viral rebound in HAART-treated patients with undetectable viremia.  6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. P177)
  5. M Galli, AL Ridolfo, A Cozzi Lepri, A d’Arminio Monforte, C Gervasoni, M Vaccarezza, A Cappelletti, A Chirianni, F Mazzotta, U Tirelli, A Scalzini, P Morelli, E Gianelli, M Piazza, M Moroni. Risk factors for the development of hypercholesterolaemia, hypertriglyceridaemia and abnormal glucose levels in the LipoICONA cohort.  6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. P131)
  6. M Galli, A Cozzi-Lepri, C Gervasoni, AL Ridolfo, F Mazzotta, C De Stefano, N Piersantelli, E Pizzigallo, E Gianelli, M Piazza, M Vaccarezza, A Cappelletti, A d’Arminio Monforte, M Moroni for the LipoICONA Study Group. Triglyceridaemia, but not cholesterolaemia and glycaemia, is a predictor of lipodystrophy: the results of LipoICONA longitudinal study.  4TH International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego (USA) 22-25 September 2002 (abs. 41)
  7. M Violin, A Cozzi-Lepri, R Piscopo, A Giacometti, CF Perno, A d’Arminio Monforte, C Balotta for the I.CO.N.A. Study Group. The pattern of primary resistance to antiretrovirals in Italy after HAART therapy.  XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. ThPeB7217)
  8. E Girardi, C Arici, M S Aloisi, D Serraino, F Delfanti, M C Moioli, M Ciardi, M De Marco, E Manzillo, G Ippolito on behalf of ICONA-BehEpi Study. Determinants of delayed presentation to medical care after testing HIV positive. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. WePeC6158)
  9. MS Aloisi, E Girardi, D Serraino, M Ferrara, P Ortolani, G Tositti, L Tacconi, GC Fibbia, L Sighinolfi, G Ippolito on behalf of ICONA-Behavioural Epidemiology (BEHEPI) Study. Sexual risk behaviours after initiating HAART therapy among people living with HIV.  XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. ThPeD7765)
  10. G Antonucci, A Cozzi-Lepri, M Solmone, A De Luca, C Pastecchia, G Madeddu, P Piano, A Vincenti, F Carletti. No difference in virological and immunological response to HAART according to HCV genotype and viral load in a cohort of HIV/HCV co-infected patients.  XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. WePeB6029)
  11. A Antinori, M P Trotta, A Cozzi Lepri, M Zaccarelli, L Minardi, P Narciso, L Ravasio, R Murri, F Baldelli, P Piano, S Lo Caputo, P De Longis, P Noto, S Nappa, M Dalessandro, AW Wu, M Moroni, G Ippolito, A d'Arminio Monforte, A Ammassari. Adherence to antiretroviral therapy: comparative analysis of protease inhibitors-based and non-nucleoside reverse transcriptase inhibitors-based regimens.  XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. WePeB5852)
  12. A Antinori, A Cozzi-Lepri, A Ammassari, MP Trotta, R Hoetelmans, L Ravasio, M Zaccarelli, L Minardi, R Murri, V Tozzi, P Santopadre, A Scasso, F Soscia, C Izzo, M Ciardi, J Vecchiet, P Caramello, N Abrescia, AW Wu, G Ippolito, M Moroni, A d'Arminio Monforte. Self-reported non-adherence but not drug plasma levels is predictive of viral rebound in HAART-treated patients with undetectable viraemia. Results of the AdICoNA Study Group. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. MoPpB2011)
  13. C Riva, M Violin, A Cozzi-Lepri, R Velleca, A Bertoli, P Viganò, L Minoli, A Orani, G Rizzardini, T Zauli, CF Perno, A d'Arminio Monforte and C Balotta for the I.Co.N.A. Study Group Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral-naive patients starting highly active antiretroviral therapy. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. 124)
· 2001 ·
  1. A De Luca, A Cozzi-Lepri, C Arici, R Piscopo, G Cadeo, A Orani, ML Soranzo, A d’Arminio Monforte for the ICONA Study Group. The effect of age, drug class, HCV coinfection and viral inhibition on the long term immunologic recovery of antiretroviral-naïve subjects undergoing HAART. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P22)
  2. S Corvasce, R Mazzucchelli, A Cozzi-Lepri, F Ghinelli, G Pagano, G Ippolito, A d’Arminio Monforte, M Moroni G Rezza and C Balotta for the ICONA Study Group. Role of CCR5-delta32, CCR2-641 and SDF 1-3’A alleles in a population of HIV-1 patients with known date of seroconversion.  8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P30)
  3. A Cozzi-Lepri, AN Phillips, A d’Arminio Monforte, E Raise, E Rinaldi, V Colangeli, P Narciso, L Bonazzi and M Moroni or the ICONA Study Group. Virological and immunological response to nevirapine or efavirenz in combination with two nucleoside analogues in the ICONA Study. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P45)
  4. R Bugarini, A d’Arminio Monforte, G Nasti, P Viganò, S Mancuso, C Moioli, N Petrosillo, G Antonucci, E Petrelli for the ICONA Study Group. Determinants of the choice of the first HAART regimen. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P51)
  5. A Ammassari, A Antinori, P Pezzotti, MS Aloisi, MP Trotta, R Murri, P De Longis, L Ravasio, G D’Offizi, M Zaccarelli, CM Izzo, S Nappa, A d’Arminio Monforte, G Ippolito, AW Wu, F Starace and the AdICONA and NeuroICONA Study Groups. Relationship of depression, neurocognitive impairment and HAART adherence.  8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P79)
  6. R. Murri, A. Ammassari, P Pezzotti, MP Trotta, R Hoetelmans, L Ravasio, P De Longis, S Lo Caputo, P Narciso, S Pauluzzi, G Carosi, S Nappa, PE Manconi, CM Izzo, P Santopadre, A Scasso, F Soscia, S D’Elia, P Caramello, J Vecchiet, A Scalzini, G Rezza, G Ippolito, A d’Arminio Monforte, AW Wu, A Antinori for the AdICoNA Study Group. Patient-physician concordance on adherence to HAART: prevalence and determinants.  8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. LB/P7)
  7. MS Aloisi, R Murri, E Girardi, M Ferrara, D Serraino, A d’Arminio Monforte, M Moroni, G Ippoliti and ICONA-BEHEPI Study Group. Assessment of mental health (MH)among antiretroviral naive women living with HIV in Italy: The ICONA-BEHEPI Study. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P355)
  8. M Galli, AL Ridolfo, C Gervasoni, L Ravasio, L Corsico, E Giannelli, M Vacarezza, A Cargnel, A d’Arminio Monforte, M Moroni for the LipoICONA Study Group. Socio-behavioural factors and HCV coinfection influence the risk of presenting fat tissue alterations in first line antiretroviral therapy.  8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P108)
  9. A Ammassari, R Murri, P Pezzotti, MP Trotta, R Hoetelmans, L Ravasio, P De Longis, S Lo Caputo, P Narciso, S Pauluzzi, G Carosi, S Nappa, P Piano, CM Izzo, M Lichtner, G Rezza, G Ippolito, A d’Arminio Monforte, Aw Wu, A Antinori for the AdICONA Study Group. Symptoms and medication side effects as determinant of self-reported non-adherence to HAART are related to antiretroviral plasma levels. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P152)
  10. A d’Arminio Monforte, A Cozzi Lepri, C Balotta, F Forbici, M Violin, A Bertoli, G Facchi, V Colangeli, A Vincenti, A De Luca, F Soscia, G Ippolito, CF Perno. 3TC-related mutations and response to therapy. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 4-8, 2001 (abs. 447)
· 2000 ·
  1. M Galli, A Cozzi-Lepri, AL Ridolfo, C Gervasoni, L Ravasio, L Corsico, E Gianelli, V Vullo, A Cargnel, L Minoli, F Gritti, G Scalise, A Antinori, G Antonucci, A d'Arminio Monforte, M Moroni for the LipoICONA Study Risk of developing adipose tissue alterations after starting antiretroviral therapy in naive patients. 2nd International Workshop on Adverse Drug Reactions and lipodystrophy in HIV. Toronto, Canada, 13-15 September 2000, (abs. P60)
  2. A d’Arminio Monforte, R Bugarini, Pezzotti, A Sinicco, F Menichetti, S Pauluzzi, A Chirianni, P Grima, F Resta for the I.CO.N.A Study Group. Changes in triglycerides and cholesterol in response to HAART in Italian Cohort Naive Antiretrovirals (I.CO.N.A). XIII International AIDS Conference, Durban 9-13 July 2000 (abs. WePeB4242)
  3. P Pezzotti, R Bugarini, A Aceti, F Alberici, G Filice, A Scalzini, F Ghinelli, A Alessandrini, F Leoncini for the I.CO.N.A Study Group. Incidence and factors associated with the occurrence of severe hepatic cytolysis in the ICONA study. XIII International AIDS Conference, Durban 9-13 July 2000 (abs. TUPpB1161)
  4. A d’Arminio Monforte, A Cozzi-Lepri, C Balotta, G Facchi, F Forbici, A Colomba, M Arlotti, A Antinori, CF Perno. Prevalence of antiretroviral drugs-related mutations in a large cohort of HIV-1 positive antiretroviral-naive patients and its correlation with viral load and CD4 count at the time of genotypic testing. XIII International AIDS Conference, Durban 9-13 July 2000 (abs. TuPeB3273)
  5. C Balotta, M Violin, S Van Dooren, A Berlusconi, G Facchi, F Forbici, A Bertoli, G Rezza, CF Perno, A d’Arminio Monforte, AM Vandamme, M Moroni for the I.CO.N.A. Study Group. Increasing prevalence of non-clade B HIV-1 strains in Italy, as monitored by the analysis of the RT and protease sequences.  4th International Workshop on HIV Drug Resistance & Treatment Strategies. Sitges, 12-16 June 2000 (abs. 181)
  6. C Balotta, M Violin, G Facchi, A Berlusconi, E Manzillo, C Minardi, S Garavaglia, L Cremonini, G Tositti, A Cozzi-Lepri, G Rezza, CF Perno, A d’Arminio Monforte for the I.CO.N.A. Study Group. Risk of HAART failure is related to the presence of trasmitted mutations conferring resistance to RT inhibitors in HIV-1 newly infected individuals.  4th International Workshop on HIV Drug Resistance & Treatment Strategies. Sitges, 12-16 June 2000 (abs. 187)
  7. C Balotta, A Cozzi-Lepri, M Violin, G Facchi, M Salemi, A Berlusconi, F Gritti, M Montroni, B Grisorio, CF Perno, A Lazzarin, G Angarano, G Rezza and A d’Arminio Monforte for the I.CO.N.A. Study Group. HIV-1 primary transmitted mutations and HIV-1 subtyping in a cohort of induviduals recently infected with HIV-1. Second Frankfurt Symposium on the clinical implications of HIV drug resistance. Frankfurt, 25-27 February 2000 (abs. 8)
  8. CF Perno, C Balotta, A Cozzi-Lepri, F Forbici, M Violin, A Bertoli, PE Manconi, A Poggio, P Caramello, F Soscia, L Monno, G Ippolito, A d’Arminio Monforte for the I.CO.N.A. Study Group. Selected secondary mutations in the protease region can be independent predictors of virological failure in antiretroviral naive patients treated with protease inhibitors containing HAART regimens.  Second Frankfurt Symposium on the clinical implications of HIV drug resistance. Frankfurt, 25-27 February 2000 (abs. 4)
  9. A d’Arminio-Monforte, CF Perno, C Balotta, A Cozzi-Lepri, F Forbici, A Bertoli, M Violin, P Pezzotti, F Mazzotta, E Raise, L Monno, G Angarano, F Dianzani, G Ippolito and M Moroni for the I.Co.N.A. Study Group. Prevalence of pol gene Mutations In A Cohort of Antiretroviral-Naïve Patients: Correlation with HIV RNA and CD4 Count at the Time of Genotypic Testing.  VII Conference on Retroviruses and Opportunistic Infections. San Francisco, January 30-February 2, 2000 (abs. 747)
  10. CF Perno, A d’Arminio-Monforte, A Cozzi-Lepri, C Balotta, F Forbici, A Bertoli, P Pezzotti, G Facchi, L Monno, G Angarano, P Bottura, V Vullo, A Cargnel, MR Capobianchi, G Ippolito, and M Moroni for the I.CO.N.A. Study Group. Mutations at Codons 10 and 36 of Protease Region in Absence of Primary Mutations May Correlate with Virological Outcome in Naive Patients Starting a PI-Containing HAART Regimen.  VII Conference on Retroviruses and Opportunistic Infections. San Francisco, January 30-February 2, 2000 (abs. 728)
· 1999 ·
  1. A d’Arminio Monforte, A Cozzi Lepri, P Pezzotti, G Rezza, AN Phillips, N Abrescia, L Bonazzi, GP Cadeo, A Cargnel, F De Lalla, C De Stefano, M Piazza, S Ranieri, ML Soranzo, V Vullo for the I.CO.N.A. Study Group. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen and its determinants.  Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon 23-27 October, 1999 (abs. 121)
  2. P Pezzotti, R Bugarini, A d'Arminio Monforte, G Rezza, A Aceti, A Chirianni, B De Rienzo, W Grillone, P Grima, F Mazzotta, M Montroni, S Pauluzzi, E Raise, A Scalzini, P Viganò for the I.CO.N.A. Study Group. Factors associated to immunologic and virologic response in the first 24 months of combination therapy in a large observational cohort study. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon 23-27 October, 1999 (abs. 221)
  3. G Rezza, A Cozzi-Lepri, P Pezzotti, A d'Arminio Monforte, P Cadrobbi, G Carnevale, S D'Elia, T Ferraro, GP Fiori, R Piscopo, E Pizzigallo, G Scalise, A Scasso, F Suter, M Toti, for the I.CO.N.A. Study Group. Lower levels of HIV-RNAin women compared to men in a population of antiretroviral naïve patients (I.CO.N.A. Study) with known duration of HIV infection.  Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon 23-27 October, 1999 (abs. 410)
· 1998 ·
  1. A d’Arminio Monforte, C Arici, G Ippolito, G Rezza, F Dianzani, M Moroni, for the I.CO.N.A. Group. Issues of Italian Cohort Naive Antiretroviral (ICONA) study and enrollment data. 12th World AIDS Conference. Geneva, June 28-July 3 1998; (abs. 60929).
  2. MS Aloisi, E Girardi, M Carballo, A d’Arminio Monforte, C Arici, G Ippolito. Patient perspective of clinical disease and care in cohort of people with HIV/AIDS antiretrovirals therapies naives. 12th World AIDS Conference. Geneva, June 28-July 3 1998; (abs. 12452)
  3. MS Aloisi, E Girardi, M Carballo, A d’Arminio Monforte, C Arici, G Ippolito. Perception of the risk of transmitting HIV among people living with HIV/AIDS presently cared for in the italian health system. 12th World AIDS Conference. Geneva, June 28-July 3 1998; (abs.23521)
  4. MS Aloisi, E Girardi, M Carballo, A d’Arminio Monforte, G Ippolito for the ICONA Behepi-study. Assessment of behavioural patterns a cohort of naive antiretrovirals HIV-infected persosns. 2eme Conférence européenne sur les methodes et les résultats des Recherches en sciences sociales sur le SIDA. Parigi, 12-15 Janvier 1998; (abs. Wo 15.1)

ART Cohort Collaboration

· 2019 ·
  1. L Gras, M May, LP Ryder, A Trickey, M Helleberg, N Obel, R Thiebaut, J Guest, J Gill, H Crane, V Dias Lima, A dʼArminio Monforte, TR Sterling, J Miro, S Moreno, C Stephan, C Smith, J Tate, L Shepherd, M Saag, A Rieger, D Gillor, M Cavassini, M Montero, SM Ingle, P Reiss, D Costagliola, FWNM Wit, J Sterne, F de Wolf, R Geskus; Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy.  Antiretroviral Therapy Cohort Collaboration (ART-CC). J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):292-300. doi: 10.1097/QAI.0000000000001913.
· 2018 ·
  1. R A Hughes, M T. Maya, K Tilling, N Taylorc, L Wittkop, P Reiss, J Gill, P Schommers, D Costagliolal J L. Guest, V D. Lima, A d’Arminio Monforte, C Smith, M Cavassini, M Saag, J L. Castilho and J AC Sterne. Long terms trends in CD4R cell counts, CD8R cell counts, and the CD4R :CD8R ratio.  AIDS. 2018 Jun 19;32(10):1361-1367. doi: 10.1097/QAD.0000000000001848
  2. Pettit A, Giganti M, Ingle SM, May MT, Shepherd BE, Gill MJ, Fatkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JAC, Sterling TR, Antiretroviral Therapy Cohort Collaboration (ART-CC). Increased Non-AIDS Mortality among Persons with AIDS Defining Events after Antiretroviral Therapy Initiation.  J Int AIDS Soc, 21 (1); 15 Jan 2018
· 2017 ·
  1. J Young, C Smith, R Teira, P Reiss, I Jarrín Vera I, H Crane, JM Miro, A d'Arminio Monforte, M Saag, R Zangerle, HC Bucher; Antiretroviral Therapy Cohort Collaboration (ART-CC). Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection. HIV Med. 2018 Feb;19(2):132-142. doi: 10.1111/hiv.12562.
  2. 1. Trickey A, May MT, Schommers P, Tate J, Ingle S, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, d'Arminio Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola C, Sterne JAC, on behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC). CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).  Clinical Infectious Diseases 65 (6); 15 Sep 2017
  3. 1. Trickey A, May MT, Vehreschild J-J, Obel N, Gill MJ, Crane HM, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, d'Arminio Monforte A, van Sighem A, Saag MS, Lampe FC, Hernando V, Montero M, Zangerle R, Justice AC, Sterling TR, Ingle S, & Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.  The Lancet HIV, epub before print; 10 May 2017
· 2016 ·
  1. Balestre E, Ekouevi DK, Tchounga B, Eholie SP, Messou E, Sawadogo A, Thiébaut R, May MT, Sterne JA, Dabis F; International Epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration. Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.  J Int AIDS Soc. 19(1):20044; 8 Feb 2016
  2. Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, d'Arminio Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLoS One. 11(8):e0160460; 15 Aug 2016
  3. 2. May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, d'Arminio Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miro JM, Sterne JA. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study  Clin Infect Dis. 62(12):1571-7; 15 Jun 2016
  4. Antiretroviral Therapy Cohort Collaboration (ART-CC), Canadian Observational Cohort Collaboration (CANOC), The UK Collaborative HIV Cohort Study (UK CHIC), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.  AIDS 30(3):503-13; 28 Jan 2016
  5. 1. Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill MJ, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H15, Hogg RS16, Rybniker J17, Sabin CA18, Jose S18, Del Amo J19, Moreno S20, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, Monforte AD, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA; Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.  IJE 44 (6); 31 Dec 2015
· 2015 ·
  1. Antiretroviral Therapy Cohort Collaboration (ART-CC). Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.  Antivir Ther. 2015;20(1):21-8. doi: 10.3851/IMP2768.
  2. MA Vandenhende, S Ingle, M May, G Chene, R Zangerle, A Van Sighem, MJ Gill, C Schwarze-Zander, B Hernandez-Novoa, N Obel, O Kirk, S Abgrall, J Guest, H Samji, A d'Arminio Monforte, JM Llibre, C Smith, M Cavassini, GA Burkholder, B Shepherd, HM Crane, J Sterne, P Morlat Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015 Jan 28;29(3):373-83
  3. M Helleberg, MT May, SM Ingle, F Dabis, P Reiss, G Fätkenheuer, D Costagliola, S d'Arminio Monforte, M Cavassini, C Smith, AC Justice, J Gill, JA Sterne, N Obel. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.  AIDS. 2015 Jan 14;29(2):221-9
· 2014 ·
  1. FN Engsig, R Zangerle, O Katsarou, F Dabis, P Reiss, J Gill, K Porter, C Sabin, A Riordan, G Fätkenheuer, F Gutiérrez, F Raffi, O Kirk, M Mary-Krause, C Stephan, PG de Olalla, J Guest, H Samji, A Castagna, A d'Arminio Monforte, A Skaletz-Rorowski, J Ramos, G Lapadula, C Mussini, L Force, L Meyer, F Lampe, F Boufassa, HC Bucher, S De Wit, GA BurkholderA, R Teira, AC Justice, TR Sterling, H M Crane, J Gerstoft, J Grarup, M May, G Chêne, SM Ingle, J Sterne, N Obel; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV positive individuals virally suppressed for more than three years with incomplete CD4 recovery  CID 58(9): 1312-21. May 2014
  2. SM Ingle, MT May, MJ Gill, MJ Mugavero, C Lewden, S Abgrall, G Fätkenheuer, P Reiss, MS Saag, C Manzardo, S Grabar, M Bruyand, D Moore, A Mocroft, TR Sterling, A d'Arminio Monforte, V Hernando, R Teira, J Guest, M Cavassini, HM Crane, JAC Sterne & for the Antiretroviral Therapy Cohort Collaboration. Impact of risk factors for specific causes death in the first and subsequent years of ART among HIV-infected patients.  CID 59(2): 287-97. 15 July 2014
  3. The IeDEA and ART Cohort Collaborations Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2014;65:e8-e16
  4. A Boulle, M Schomaker, MT May, R Hogg, BE Shepherd, S Monge, O Keiser, F Lampe, J Giddy, J Ndirangu, D Garone, M Fox, SM Ingle, P Reiss, F Dabis, D Costagliola, A Castagna, K Ehren, C Campbell, MJ Gill, M Saag, AC Justice, J Guest, H Crane, M Egger, Sterne JAC. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe or North America: a collaborative analysis of prospective studies .  PLoS Med 11(9): e1001718. 9 Sept 2014
· 2013 ·
  1. JP Tate, AC Justicea, MD Hughesb, F Bonnetc, P Reissd, A Mocrofte, J Nattermannf, FC Lampee, HC Bucherg, TR Sterlingh, HM Cranei, MM Kitahataj, M Mayk and JAC Sterne. An internationally generalizable risk index for mortality after one year of antiretroviral therapy AIDS 2013, 27:563-572
  2. J Kaulich-Bartz, W Dam, MT May, B Lederberger, U Widmer, AN Phillips, S Grabar, A Mocroft, J Vilaro, A van Sighem, S Moreno, F Dabis, AD Monforte, R Teira, SM Ingle, JA Sterne. Writing committee for the Antiretroviral Cohort Collaboration. Insurability of HIV positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS. 2013; 27:1641-1655
  3. The Antiretroviral Therapy Cohort Collaboration (ART-CC) Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis AIDS 2013, 27:1321-1329
  4. The Antiretroviral Therapy Cohort Collaboration (ART-CC) Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States. Clin Infect Dis. (2013) 56 (12): 1800-1809
· 2012 ·
  1. MT May, RS Hogg, AC Justice, BE Shepherd, D Costagliola, B Ledergerber, R Thiébaut, MJ Gill, O Kirk, A van Sighem, MS Saag, G Navarro, P Sobrino-Vegas, F Lampe, S Ingle, JL Guest, HM Crane, A d'Arminio Monforte, JJ Vehreschild, JA Sterne; the Collaboratin Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol. 2012 Dec;41(6):1807-1820
· 2011 ·
  1. MJ Mugavero, M May, HJ Ribaudo, RM Gulick, SA Riddler, R Haubrich, S Napravnik, S Abgrall, A Phillips, R Harris, MJ Gill, F de Wolf, R Hogg, HF Günthard, G Chêne, A d'Arminio Monforte, JL Guest, C Smith, J Murillas, J Berenguer, C Wyen, P Domingo, MM Kita Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. JAIDS 58(3):253-260
  2. M Murray, R Hogg, V Lima, M May, D Moore, S Abgrall, M Bruyand, A d'Arminio Monforte, C Tural, M Gill, R Harris, P Reiss, A Justice, O Kirk, M Saag, C Smith, R Weber, J Rockstroh, P Khaykin, J Sterne; for the Antiretroviral Therapy Cohort Collaboration (ART-CC) The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine 13(2):89-97
· 2010 ·
  1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010 May 15;50(10):1387-96
· 2009 ·
  1. DM Moore, R Harris, V Lima, B Hogg, M May, B Yip, A Justice, A Mocroft, P Reiss, F Lampe, G Chêne, D Costagliola, L Elzi, MJ Mugavero, AD Monforte, C Sabin, D Podzamczer, G Fätkenheuer, S Staszewski, J Gill, JA Sterne; Antiretroviral Therapy Cohort Collab Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):357-63
  2. Antiretroviral Cohort Collaboration (ART-CC) Writing committee: RJ Harris, JAC Sterne, S Abgrall, F Dabis, P Reiss, M Saag, AN Phillips, G Chêne, JM Gill, AC Justice, J Rockstroh, CA Sabin, A Mocroft, HC Bucher, RS Hogg, A d'Arminio Monforte, M May, M Egg Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in eight industrialized countries. Int J Epidemiol. 2009 Dec, 38(6):1624-33
  3. RJ Harris, JA Sterne, S Abgrall, F Dabis, P Reiss, M Saag, AN Phillips, G Chêne, JM Gill, AC Justice, J Rockstroh, CA Sabin, A Mocroft, HC Bucher, RS Hogg, AD Monforte, M May, M Egger; Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries. Antiviral Therapy 2009;13: 959-967
  4. Antiretroviral therapy cohort collaboration (ART-CC), E Lanoy, M May, A Mocroft, A Phillip, A Justice, G Chêne, H Furrer, T Sterling, AD Monforte, L Force, J Gill, R Harris, RS Hogg, J Rockstroh, M Saag, P Khaykin, F de Wolf, JA Sterne, D Costagliola. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 2009 Oct 23;23(16):2199-208
  5. When To Start Consortium Writing Committee: JAC Sterne, M May, D Costagliola, F de Wolf, AN Phillips, R Harris, MJ Funk, RB Geskus, J Gill, F Dabis, JM Miro, AC Justice, B Ledergerber, G Fatkenheuer, RS Hogg, A d'Arminio Monforte, M Saag, C Smith, S Stasz Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009 Apr 18;373(9672):1352-63
  6. The ART Cohort Collaboration Writing committee: A Mocroft, J Sterne, M Egger, M May, S Grabar, H Furrer, C Sabin, G Fatkenheuer, A Justice, P Reiss, A d'Arminio Monforte, J Gill, R Hogg, F Bonnet, M Kitahata, S Staszewski, J Casabona, R Harris, M Saag. Variable impact on mortality of AIDS defining events diagnosed during combination antiretroviral therapy: Not all AIDS Defining Conditions are Created Equal. Clinical Infectious Diseases 2009 Apr 15;48(8):1138-51
· 2008 ·
  1. The ART Cohort Collaboration Writing committee: R Harris, R Hogg, D Costagliola, M May, F de Wolf, J Gill, G Fätkenheuer, C Lewden, M Saag, S Staszewski, A d'Arminio Monforte, J Casabona, F Lampe, A Justice, V von Wyl, M Egger. Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries. Antivir Therapy 2008; 13(8):959-67
  2. The ART Cohort Collaboration: Writing committee: R Hogg, V Lima, JAC Sterne, S Grabar, M Battegay, M Bonarek, A d'Arminio Monforte, A Esteve, MJ Gill, R Harris, A Justice, A Hayden, F Lampe, A Mocroft, MJ Mugavero, S Staszewski, JC Wasmuth, A van Sighem, Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299
  3. The ART Cohort Collaboration: Writing committee: MJ Mugavero, M May, R Harris, MS Saag, D Costagliola, M Egger, A Phillips, H Günthard, F Dabis, R Hogg, F de Wolf, G Fatkenheuer, J Gill, A Justice, A d'Arminio Monforte, F Lampe, JM Miró, S Staszewski, M K Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS 2008; 22: 2481-2492
· 2007 ·
  1. The Antiretroviral Therapy Cohort (ART) Collaboration- Writing committee: JAC Sterne, MT May, CA Sabin, AN Phillips, D Costigliola, J Chene, AC Justice, F De Wolf, RS Hogg, M Battegay, A d'Arminio Monforte, G Fatkenheuer, S Staszewski, J Gill, M Egger. Importance of baseline prognostic factors with increasing time since initiation of Highly Active Antiretroviral Therapy. Collaborative analysis of cohorts of HIV-1 infected patients. J Acquir Defic Syndr. 2007; 46: 607-615
  2. The ART Cohort Collaboration - Writing committee: M May, J Sterne, C Sabin, D Costagliola, A Justice, R Thiébaut, J Gill, A Phillips, P Reiss, R Hogg, B Ledergerber, A d'Arminio Monforte, N Schmeisser, S Staszewski, M Egger. Prognosis of HIV-1 infected patients up to five years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197
· 2006 ·
  1. ART Cohort Collaboration Study- Writing committee: MT May, JAC Sterne, D Costagliola, CA Sabin, AN Phillips, AC Justice, F Dabis, J Gill, J Lundgren, RS Hogg, F de Wolf, G Fätkenheuer, S Staszewski, A d'Arminio Monforte, M Egger for The Antiretroviral The HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006 Aug 5;368(9534):451-8.
· 2005 ·
  1. A d'Arminio Monforte, CA Sabin, A Phillips, JAC Sterne, M May, AC Justice et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch.Intern Med 2005; 165:416-23
  2. E Girardi, CA Sabin, A d'Arminio Monforte, B Hogg, AN Phillips, MJ Gill, F Dabis, P Reiss, O Kirk, E Bernasconi, S Grabar, A Justice, S Staszewski, G Fatkenheuer, JA Sterne for the Antiretroviral Therapy Cohort Collaboration. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-1782
  3. M May, P Kholoud, JAC Sterne, P Royston, M Egger, ART-CC (The Antiretroviral Therapy Cohort Collaboration) and CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe). Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol 2005; 58:1033-1041
  4. C Sabin, B Hogg, F Dabis, MJ Gill, AN Phillips, P Reiss, G Fätkenheuer, S Grabar, J Lundgren, A Justice, B Ledergerber, A d'Arminio Monforte, A Staszewski and Sterne JAC for The ART Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?  AIDS 2005 19: 1995-2000
· 2004 ·
  1. M May, P Royston, M Egger, AC Justice, JAC Sterne, ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Statistic in Medicine 2003; 23:2375-98
· 2003 ·
  1. The Antiretroviral Therapy (ART) Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003, 362:679-86
· 2002 ·
  1. M Egger, M May, G Chêne, AN Phillips, B Ledergerber, F Dabis, D Costagliola, A d'Arminio Monforte, F de Wolf, P Reiss, JD Lundgren, AC Justice, S Staszewski, C Leport, RS Hogg, CA Sabin, M J Gill, B Salzberger, JAC Sterne and the ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29

CASCADE

· 2017 ·
  1. J Ghosn, T Bayan, K Meixenberger, L Tran, P Frange, A d’Arminio Monforte, R Zangerle, C de Mendoza, E Krastinova, K Porter, L Meyer and ML Chaix on behalf of the CASCADE Collaboration in EuroCoord. CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. J Antimicrob Chemother; doi:10.1093/jac/dkx247
· 2014 ·
  1. N Pantazis, K Porter, D Costagliola, A De Luca, J Ghosn, M Guiguet, A Johnson, A Kelleher, C Morrison, R Thiebaut, L Wittkop, G Touloumi, for the CASCADE Collaboration in EuroCoord. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility. An observational cohort study. Lancet HIV 2014; doi:10.1016/S2352-3018(14)00002-2
  2. J van der Helm, R Geskus, S Lodi, L Meyer, H Schuitemaker, B Gunsenheimer-Bartmeyer, A d'Arminio Monforte, A Olson, G Touloumi, C Sabin, K Porter, M Prins, on behalf of CASCADE Collaboration in EuroCoord. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. September 19, 2014
· 2013 ·
  1. S Lodi, M Fisher, A Phillips, A De Luca, J Ghosn, R Malyuta, R Zangerle, S Moreno, P Vanhems, F Boufassa, M Guiguet, K Porter, for CASCADE Collaboration in EuroCoord. Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection.  PLoS ONE 2013;8:e78642
  2. G Touloumi, N Pantazis, ML Chaix, HC Bucher, R Zangerle, AM Kran, R Thiebaut, B Masquelier, C Kucherer, A d'Arminio Monforte, L Meyer, K Porter; for CASCADE Collaboration in EuroCoord. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. PLoS One. 2013 Jul 30;8(7):e71174.
  3. Y Madec, F Boufassa, K Porter, M Prins, C Sabin, A d'Arminio Monforte, P Amornkul, B Bartmeyer, M Sannes, A Venet, O Lambotte, L Meyer; on behalf of the CASCADE Collaboration in Eurocoord. Natural history of HIV-control since seroconversion. AIDS. 2013 Aug 1. [Epub ahead of print]
  4. S Lodi, J del Amo, A d'Arminio Monforte, S Abgrall, C Sabin, C Morrison, H Furrer, R Muga, K Porter, E Girardi; CASCADE collaboration in EuroCoord. Risk of tuberculosis following HIV seroconversion in high-income countries.  Thorax. 2013 Mar;68(3):207-13.
· 2012 ·
  1. I Jarrin, N Pantazis, MJ Gill, R Geskus, S Perez-Hoyos, L Meyer, M Prins, G Touloumi, A Johnson, O Hamouda, PG de Olalla, K Porter, J del Amo; CASCADE Collaboration in EuroCoord. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis. 2012 Jan 1;54(1):111-8.
· 2011 ·
  1. C Mussini, A Cossarizza, C Sabin, A Babiker, A De Luca, A Heiner, C Bucher, M Fisher, G Rezza, K Porter, M Dorrucci. Decline of CD4+ T cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals.  AIDS 2011; 15;25:1041-1049
  2. H Jaffe, B De Stavola, L Carpenter, K Porter and D Cox. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults.  AIDS 2011; 25:1395-1403
  3. L Wittkop, H Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kücherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F García, A Judd, K Porter, R Thiébaut, H Castro, AL van Sighem, C Colin, J Kjaer, JD Lundgren, R Paredes, A Pozniak, B Clotet, A Phillips, D Pillay, G Chêne, for the EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.  Lancet Infect Dis 2011;11:363-371

CHAIN

· 2015 ·
  1. A Cozzi-Lepri, M Noguera-Julian, F Di Giallonardo, R Schuurman, M Daumer, S Aitken, F Ceccherini-Silberstein, A d'Arminio Monforte, AM Geretti, CL Booth, R Kaiser, C Michalik, K Jansen, B Masquelier, P Bellecave, RD Kouyos, E Castro, H Furrer, A Schultze, HF Gunthard, F Brun-Vezinet, R Paredes, KJ Metzner. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.  J Antimicrob Chemother. 2015;70:930-940.
· 2012 ·
  1. A Lai, FR Simonetti, G Zehender, A De Luca, V Micheli, P Meraviglia, P Corsi, P Bagnarelli, P Almi, A Zoncada, S Paolucci, A Gonnelli, G Colao, D Tacconi, M Franzetti, M Ciccozzi, M Zazzi, C Balotta HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America. PLoS One. 2012;7(8):e42223. Epub 2012 Aug 2
  2. K Theys, K Deforche, J Vercauteren, P Libin, DA van de Vijver, J Albert, B Asjo, C Balotta, M Bruckova, RJ Camacho, B Clotet, S Coughlan, Z Grossman, O Hamouda, A Horban, K Korn, LG Kostrikis, C Kucherer, C Nielsen, D Paraskevis, M Poljak, E Puchhammer-Stockl, C Riva, L Ruiz, K Liitsola, JV Schmit, R Schuurman, A Sonnerborg, D Stanekova, M Stanojevic, D Struck, K van Laethem, AM Wensing, CA Boucher, AM Vandamme Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology 2012, 9:81 doi:10.1186/1742-4690-9-81
  3. V Cento, C Mirabelli, S Dimonte, R Salpini, Y Han, P Trimoulet, A Bertoli, V Micheli, G Gubertini, G Cappiello, A Spano, R Longo, M Bernassola, F Mazzotta, GM De Sanctis, XX Zhang, J Verheyen, A d'Arminio Monforte, F Ceccherini-Silberstein, CF Perno, V Svicher Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. J Gen Virol. 2012 Oct 10
  4. MM Santoro, D Armenia, L Fabeni, M Santoro, C Gori, F Forbici, V Svicher, A Bertoli, L Dori, M Surdo, E Balestra, G Palamara, E Girardi, G Angarano, M Andreoni, P Narciso, A Antinori, F Ceccherini-Silberstein, CF Perno The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. Clin Microbiol Infect.;18(8):E289-98 (2012)
  5. MM Santoro, C Alteri, L Ronga, P Flandre, L Fabeni, F Mercurio, R D'Arrigo, C Gori, G Palamara, A Bertoli, F Forbici, R Salpini, E Boumis, V Tozzi, U Visco-Comandini, M Zaccarelli, M Van Houtte, T Pattery, P Narciso, A Antinori, F Ceccherini-Silberstein, CF Perno Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy. AIDS Res Hum Retroviruses 28(10):1285-93 (2012)
  6. D Armenia, I Vandenbroucke, L Fabeni, H Van Marck, V Cento, R D'Arrigo, L Van Wesenbeeck, F Scopelliti, V Micheli, B Bruzzone, S Lo Caputo, J Aerssens, G Rizzardini, V Tozzi, P Narciso, A Antinori, L Stuyver, CF Perno, F Ceccherini-Silberstein Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis.; 205(4):557-67 (2012)
· 2011 ·
  1. L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kücherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F García, A Judd, K Porter, R Thiébaut, H Castro, AI van Sighem, C Colin, J Kjaer, JD Lundgren, R Paredes, A Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011 May;11(5):363-371
  2. V Svicher, C Alteri, A Artese, JM Zhang, G Costa, F Mercurio, R D'Arrigo, S Alcaro, G Palù, M Clementi, M Zazzi, M Andreoni, A Antinori, A Lazzarin, F Ceccherini-Silberstein, CF Perno; on behalf of the OSCAR study group. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. Antivir Ther. 16(7):1035-1045 (2011)
  3. I Malet, S Fourati, C Charpentier, L Morand-Joubert, D Armenia, M Wirden, S Sayon, M Van Houtte, F Ceccherini-Silberstein, F Brun-Vézinet, CF Perno, D Descamps, A Capt, V Calvez, AG Marcelin The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype J Antimicrob Chemother. Sep 21. 66 (12): 2827-2830 (2011). IF 4.659, Citazioni 4
  4. C Alteri, MM Santoro, I Abbate, G Rozera, A Bruselles, B Bartolini, C Gori, F Forbici, N Orchi, V Tozzi, G Palamara, A Antinori, P Narciso, E Girardi, V Svicher, F Ceccherini-Silberstein, MR Capobianchi, CF Perno Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. J Antimicrob Chemother. 66(11):2615-23 (2011)
  5. AM Vandamme, RJ Camacho, F Ceccherini-Silberstein, A de Luca, L Palmisano, D Paraskevis, R Paredes, M Poljak, JC Schmit, V Soriano, H Walter, A Sönnerborg; European HIV Drug Resistance Guidelines Panel. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. Apr-Jun; 13(2):77-108 (2011)
  6. I Malet, M Wirden, S Fourati, D Armenia, B Masquelier, L Fabeni, S Sayon, C Katlama, CF Perno, V Calvez, AG Marcelin, F Ceccherini-Silberstein F Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother. Jul; 66(7):1481-3 (2011)
  7. V Svicher, E Balestra, V Cento, L Sarmati, L Dori, I Vandenbroucke, R D'Arrigo, AR Buonomini, H Van Marck, M Surdo, P Saccomandi, W Mostmans, J Aerssens, S Aquaro, LJ Stuyver, M Andreoni, F Ceccherini-Silberstein, CF Perno HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res. Apr; 90(1):42-53 (2011)
· 2010 ·
  1. A De Luca, M Prosperi, L Bracciale. Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options. Curr Opin HIV AIDS. 2010 Jan;5(1):27-37
  2. F Ceccherini-Silberstein, K Van Baelen, D Armenia, M Trignetti, E Rondelez, L Fabeni, F Scopelliti, M Pollicita, L Van Wesenbeeck, V Van Eygen, L Dori, L Sarmati, S Aquaro, G Palamara, M Andreoni, LJ Stuyver, CF Perno. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naïve patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48.
  3. F Ceccherini-Silberstein, I Malet, L Fabeni, S Dimonte, V Svicher, R D'Arrigo, A Artese, G Costa, S Bono, S Alcaro, A d'Arminio Monforte, C Katlama, V Calvez, A Antinori, AG Marcelin, CF Perno. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naïve to integrase inhibitors. J. Antimicrob. Chemother. 2010 Nov; 65(11):2305-18
· 2009 ·
  1. F Ceccherini-Silberstein, V Svicher, M Van Houtte. New Horizons in Resistance Interpretation. HIV and AIDS 2009; 10 June 2009, in press.
  2. MC Puertas, MJ Buzòn, A Artese, S Alcaro, L Menendez-Arias, CF Perno, B Clotet, F Ceccherini-Silberstein, J Martinez-Picado. Effect of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility. Journal of Virology 2009; 83(15):7434-7439.

COHERE

· 2014 ·
  1. FN Engsig, R Zangerle, O Katsarou, F Dabis, P Reiss, J Gill, K Porter, C Sabin, A Riordan, G Fätkenheuer, F Gutiérrez, F Raffi, O Kirk, M Mary-Krause, C Stephan, PG de Olalla, J Guest, H Samji, A Castagna, A d'Arminio Monforte, A Skaletz-Rorowski, J Ramos, G Lapadula, C Mussini, L Force, L Meyer, F Lampe, F Boufassa, HC Bucher, S De Wit, GA Burkholder, R Teira, AC Justice, TR Sterling, H M Crane, J Gerstoft, J Grarup, M May, G Chêne, SM Ingle, J Sterne, N Obel; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.  Clin Infect Dis. 2014 May;58(9):1312-21. Epub 2014 Jan 22. abstract
  2. The Natural History Project Working Group for COHERE in EuroCoord. Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naive individuals. AIDS. 2014 June 1;28(9):1351-1356 article
  3. Socio-economic inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord.  AIDS, 2014. 28(15): p.2297-306.
· 2013 ·
  1. A Mocroft, JD Lundgren, M Sabin, A d'Arminio Monforte, N Brockmeyer, J Casabona, A Castagna, D Costagliola, F Dabis, S De Wit, G Fätkenheuer, H Furrer, AM Johnson, O Kirk, for the Late Presenters Working Group, on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).  PLoS Med. 2013 10(9): e1001510
· 2012 ·
  1. Pursuing Later Treatment Options II (PLATO II) project team; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9
  2. D Costagliola for the PLATO II group for COHERE in EuroCoord. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis. 2012 Feb;12(2):119-27
  3. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in Eurocoord. CD4 cell count and the risk of AIDS or death in HIC-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Medicine March 2012; 9(3) e1001194
  4. C Lewden, V Bouteloup, S De Wit, C Sabin, A Mocroft, JC Wasmuth, A van Sighem, O Kirk, N Obel, G Panos, J Ghosn, F Dabis, M Mary-Krause, C Leport, S Perez-Hoyos, P Sobrino-Vegas, C Stephan, A Castagna, A Antinori, A d'Arminio Monforte, C Torti, C Mussini, All-cause mortality in treated HIV-infected adults with CD4 >500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int. J. Epidemiol. 2012; 41:433-445
· 2011 ·
  1. F Nakagawa for the PLATO II group for COHERE in EuroCoord. Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9
  2. H Castro, A Judd, DM Gibb, K Butler, RK Lodwick, A van Sighem, JT Ramos, J Warsawski, C Thorne, A Noguera-Julian, N Obel, D Costagliola, PA Tookey, C Colin, J Kjaer, J Grarup, G Chene, A Phillips. Pursuing Later Treatment Options II (PLATO II) project tea Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011 May 7;377(9777):1580-7
  3. L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kucherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F Garcia, A Judd, K Porter, R Thiébaut, H Castro (née Green), AI van Sighem, C Colin, J Kjær, JD Lundgren, R Paredes, A Pozniak, B Clotet, A Phillips, D Pillay, G Chêne. Impact of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy - a European multi-cohort study. The EuroCoord-CHAIN joint project.  Lancet Infectious Diseases. 2011 May;11(5):363-371. Epub 2011 Feb 25
· 2010 ·
  1. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HV infection and a CD4 cell count <200 cells/mL? Clinical Infectious Diseases. 2010;51(5), 1 september
  2. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Triple class virologic failure in HIV-infected patients on antiretroviral therapy for up to 10 years. Archives of Internal Medicine 2010, March 8; 170(5):410-19
· 2009 ·
  1. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study. Antiviral Therapy 2009, 14(8):1065-74
  2. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009 Sep 24;23(15):2029-37
· 2008 ·
  1. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22(12):1463-1473

D:A:D

· 2019 ·
  1. L Shepherd, L Ryom, M Law, K Petoumenos, CI Hatleberg, A d'Arminio Monforte, C Sabin, M Bower, F Bonnet, P Reiss, S de Wit, C Pradier, R Weber, W El-Sadr, J Lundgren, A Mocroft; Data Collectionon Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.  Clin Infect Dis. 2019 Feb 1;68(4):650-657. doi: 10.1093/cid/ciy508.
· 2018 ·
  1. Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d’Arminio Monforte A, Kovari H, Law, M, Lundgren JD, Sabin C, On behalf of the Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.  Journal of the International AIDS Society 2018
  2. Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group. Abacavir use and risk of recurrent myocardial infarction. AIDS. 2018; 32(1):79-88.
  3. L Ryom, JD Lundgren, W El-Sadr, P Reiss, O Kirk, M Law, A Phillips, R Weber, E Fontas, A d’ Arminio Monforte, S de Wit, F Dabis, CI Hatleberg, C Sabin, A Mocroft. On behalf of the D:A:D Study group. Association between Cardiovascular Disease & Use of Contemporary Protease Inhibitors: The D:A:D Study. Lancet HIV 2018.
  4. CI HatlebergI, L Ryom, A d'Arminio Monforte, E Fontas, P Reiss, O Kirk, W El-Sadr, A Phillips, S de Wit, F Dabis, R Weber, M Law, JD Lundgren, C Sabin; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.  HIV Med. 2018 Oct;19(9):605-618. doi: 10.1111/hiv.12639. Epub 2018 Jul 18.
· 2017 ·
  1. MA Boyd, A Mocroft, L Ryom, AD Monforte, C Sabin , WM El-Sadr, CI Hatleberg, S De Wit, R Weber, E Fontas, A Phillips, F Bonnet, P Reiss, J Lundgren, M Law. Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.  PLoS Med. 2017;14(11):e1002424
  2. L Ryom, A Mocroft, O Kirk, P Reiss, M Ross, C Smith, O Moranne, P Morlat, CA Fux; C Sabin, A Phillips, M Law, JD Lundgren. On behalf of the D:A:D Study group. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.  AIDS. 2017; 31(9):1261-1270.
  3. L Shepherd, L Ryom, M Law, C Ingrid Hatleberg, S de Wit, A d'Arminio Monforte, M Battegay, A Phillips, F Bonnet, P Reiss, C Pradier, A Grulich, C Sabin, J Lundgren, A Mocroft. Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma. J Natl Cancer Inst. 2017
· 2016 ·
  1. CA Sabin, P. Reiss, L Ryom, AN Phillips, R Weber, M Law, E Fontas, A Mocroft, S de Wit, C Smith, F Dabis, A d’Arminio Monforte, W El-Sadr, J D Lundgren for the D:A:D Study Group. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.  BMC Medicine 2016 14:61 DOI: 10.1186/s12916-016-0588-4.
  2. A Mocroft, JD Lundgren, M Ross, CA Fux P Reiss, O Moranne, P Morlat, A d'Arminio Monforte, O Kirk, L Ryom, on behalf of The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.  Lancet HIV. 2016 Jan; 3(1):e23-32.
  3. L Ryom, JD Lundgren, S De Wit, H Kovari, P Reiss, M Law, W El-Sadr, A D’Arminio Monforte, Amanda Mocroft, C Smith, E Fontas, F Dabis, A Phillips and C Sabin for the D:A:D Study Group. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS. 2016 Jul 17;30(11):1731-43
  4. DC Boettiger, CA Sabin, A Grulich, L Ryom, F Bonnet, P Reiss, A d’ArminioMonforte, O Kirk, A Phillips, M Bower, G Fätkenheuer, JD Lundgren, M Law on behalf of the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group. Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals?  AIDS. 2016 Jun 19;30(10):1629-37.
  5. 5. CI Hatleberg, L Ryom, W El-Sadr, C Smith, R Weber, P Reiss, E Fontas, F Dabis, M Law, A d’Arminio Monforte, Stephane De Wit, A Mocroft, A Phillips, J D. Lundgren and C Sabin for the D:A:D Study Group. Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals AIDS. 2016 Jun 19; 30(10):1583-96.
  6. Amit C Achhra; Amanda Mocroft; Peter Reiss; Caroline Sabin; Lene Ryom; Stephane de Wit; Colette J Smith; Antonella d´arminio Monforte; Andrew Phillips; Rainer Weber; Jens Lundgren; Matthew G Law; The D:A:D Study Group. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.  HIV Med. 2016 Apr;17(4):255-68.
  7. N Friis-Møller, L Ryom, C Smith, R Weber, P Reiss, F Dabis, S De Wit, A D’Arminio Monforte, O Kirk, E Fontas, C Sabin, A Phillips, J Lundgren, M Law, on behalf of the D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV- positive persons.  European Journal of Eur J Prev Cardiol. 2016 Jan;23(2):214-23
  8. DA Kamara, CA Sabin, L Ryom, P Reiss, M Rickenbach, CJ Smith, A Phillips, A Mocroft, S De Wit, M Law, A d’Arminio Monforte, F Dabis, C Pradier, JD Lundgren. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study.  Antivir Ther. 2016; 21(6):495-506.
  9. L Ryom, JD Lundgren, M Ross, O Kirk, M Law, P Morlat, C Smit, E Fontas, CA Fux, CI Hatleberg, S de Wit, CA Sabin and A Mocroft for the D:A:D Study Group. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study.  J Infect Dis. 2016 Oct 15;214(8)
· 2015 ·
  1. M Bruyand, L Ryom, L Shepherd, G Fatkenheuer, A Grulich, P Reiss, S de Wit, A d ‘Arminio Monforte, H Furrer, C Pradier, J Lundgren, C Sabin; D:A:D study group. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-577.
  2. N Friis-Møller, L Ryom, C Smith, R Weber, P Reiss, F Dabis, S De Wit, A d’Arminio Monforte, O Kirk, E Fontas, C Sabin, A Phillips, J Lundgren, M Law, on behalf of the D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons.  Eur J Prev Cardiol. 2015 Apr 16. pii: 2047487315579291
  3. A Mocroft, JD Lundgren, M Ross, M Law, P Reiss, O Kirk, C Smith, D Wentworth, J Neuhaus, CA Fux, O Moranne, P Morlat, MA Johnson, L Ryom on behalf of the Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT, SMART and ESPRIT study group. Development and validation of a risk-score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.  PlOS Medicine 2015 Mar 31; 12 (3)
· 2014 ·
  1. K Petoumenos, P Reiss, L Ryom, M Rickenbach, C Sabin, W El-Sadr, A d'Arminio Monforte, A Phillips, S De Wit, O Kirk, F Dabis, C Pradier, J Lundgren, M Law; D:A:D Study Group. Increased risk of cardiovascular disease (CVD) with age in HIV positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.  HIV Med. 2014 Nov;15(10):595-603. abstract
  2. L Ryom, A Mocroft, O Kirk, M Ross, P Reiss, CA Fux, P Morlat, O Moranne, C Smith, W El-Sadr, M Law, JD Lundgren et al. for the D:A:D study group. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons in the D:A:D study. AIDS. 2014 Jan 14;28(2):187-99
  3. DA Kamara, L Ryom, M Ross, O Kirk, P Reiss, P Morlat, O Moranne, CA Fux, A Mocroft, C Sabin, JD Lundgren, CJ Smith. . Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study BMC Nephrol. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51.
  4. CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, JD Kowalska, S De Wit, M Law, W el Sadr, O Kirk, N Friis-Moller, A d’Arminio Monforte, AN Phillips, C Sabin, JD Lundgren, D:A:D Study Group. Trends in underlying causes of death in poeple with HIV from 1999-2011 (D:A:D): a multicohort collaboration. Lancet. 2014 jul 19:384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8
· 2013 ·
  1. CA Sabin, L Ryom, S De Wit, A Mocroft, AN Phillips, SW Worm, R Weber, A d’Arminio Monforte, P Reiss, D Kamara, W El-Sadr, C Pradier, F Dabis, M Law, J Lundgren. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 13 November 2013; Volume 27; Issue 17; 2735-2748
  2. SW Worm, M Bower, P Reiss, F Bonnet, M Law, G Fätkenheuer, A d'Arminio Monforte, DI Abrams, A Grulich, E Fontas, O Kirk, H Furrer, S De Wit, A Phillips, JD Lundgren, CA Sabin. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013 Oct 9;13(1):471
  3. H Kovari, C Sabin, B Ledergerber, L Ryom, SW Worm, C Smith, A Phillips, P Reiss, E Fontas, K Petoumenos, S De Wit, P Morlat, JD Lundgren, R Weber. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.  Clin Infect Dis. 2013 Mar;56(6):870-9.
  4. C Sabin, L Ryom, H Kovari, O Kirk, S de Wit, M Law, P Reiss, F Dabis, C Pradier, W El Sadr, A d’Arminio Monforte, D Kamara, AN Phillips, JD Lundgren JD. Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: The D: A: D Study.  J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):456-63.
  5. d'Arminio Monforte A, P Reiss, L Ryom, W El-Sadr, F Dabis, S De Wit, SW Worm, MG Law, R Weber, O Kirk, C Pradier, AN Phillips, JD Lundgren, CA Sabin. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS 2013 Jan 28;27(3):407-15.
· 2012 ·
  1. K Petoumenos, SW Worm, E Fontas, R Weber, S De Wit, M Bruyand, P Reiss, W El-Sadr, A d'Arminio Monforte, N Friis-Møller, JD Lundgren, MG Law, On behalf of the D:A:D Study Group. Predicting the short term risk of diabetes in HIV positive patients: The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. J Int AIDS Soc. 2012 Oct 10;15(2):17426.
  2. SW Worm, DA Kamara, P Reiss, E Fontas, S De Wit, W El-Sadr, Ad'Arminio Monforte, M Law, A Phillips, L Ryom, F Dabis, R Weber, C Sabin, JD Lundgren on behalf of the D:A:D Study Group. Evaluation of HIV protease inhibitor usage and the risk of sudden death or non-haemorrhagic stroke. JID 2012 Feb;205(4):535-9
· 2011 ·
  1. DA Kamara, SW Worm, P Reiss, M Rickenbach, A Phillips, O Kirk, A d'Arminio Monforte, M Bruyand, M Law, S De Wit, C Smith, C Pradier, JD Lundgren, C Sabin. The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: The D:A:D Study. J Infect Dis. 2011 Aug;204(4):521-525.
  2. JD Kowalska, N Friis-Møller, O Kirk, W Bannister, A Mocroft, C Sabin, P Reiss, J Gill, C Lewden, A Phillips, A d'Arminio Monforte, M Law, J Sterne, S De Wit, JD Lundgren; CoDe Working Group; D:A:D Study Group. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology. 2011 Jul;22(4):516-23
  3. SW Worm, DA Kamara, P Reiss, O Kirk , W El-Sadr, C Fux, E Fontas, A Phillips, A d'Arminio Monforte, S De Wit, K Petoumenos, N Friis-Mller, P Mercie, JD Lundgren, C Sabin. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011 Jul 31;25(12):1497-504
  4. K Petoumenos, S Worm, P Reiss, S de Wit, A d'Arminio Monforte, C Sabin, N Friis-Møller, R Weber, P Mercie, C Pradier, W El-Sadr, O Kirk, J Lundgren, M Law; for the D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med. 2011 Aug;12(7):412-21
· 2010 ·
  1. R Weber, C Sabin, P Reiss, S de Wit, SW Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, W El-Sadr, O Kirk, M Rickenbach, A Phillips, B Ledergerber, J Lundgren. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther. 2010;15(8):1077-86
  2. C Smith, SW Worm, N Friis-Møller, CA Sabin, A Sjøl, JD Lundrgen, R Salbøl-Brandt, M Rickenbach, P Pezzotti, E Krum, L Gras, E Balestre, A Sundström, M Delforge, E Fontas, F Torres, K Petoumenos, J Kjær, S Collins, S Storpher, G Pearce, R Rode, I Weller. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS. 2010 Jun 19;24(10):1537-48
  3. N Friis-Møller, R Thiébaut, P Reiss, R Weber, AD Monforte, S De Wit, W El-Sadr, E Fontas, S Worm, O Kirk, A Phillips, CA Sabin, JD Lundgren, MG Law; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501
  4. SW Worm, S Sabin, R Weber, P Reiss, W El-Sadr, F Dabis, S De Wit, M Law, A d'Arminio Monforte, N Friis-Møller, E Fontas, I Weller, A Phillips, J Lundgren. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010 Feb 1;201(3):318-30
  5. SW Worm, N Friis-Møller, M Bruyand, A d'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin; for the D:A:D study group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010 Jan 28;24(3):427-35
· 2009 ·
  1. SW Worm, S De Wit, R Weber, CA Sabin, P Reiss, W El-Sadr, AD Monforte, O Kirk, E Fontas, F Dabis, MG Law, JD Lundgren, N Friis-Møller. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the DATA Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation. 2009 Feb 17;119(6):805-11
  2. SW Worm, CA Sabin, P Reiss, W El-Sadr, AD Monforte, C Pradier, R Thiebaut, M Law, M Rickenback, S De Wit, JD Lundgren, NF Møller Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) than the sum of its components in HIV-infected individuals. Data Collection on Adverse Events of Anti-HIV Drugs (The D:A:D study). Diabetes Care. 2009 Mar;32(3):474-80
· 2008 ·
  1. A d'Arminio Monforte, D Abrams, C Pradier, R Weber, P Reiss, F Bonnet, O Kirk, M Law, S De Wit, N Friis-Møller,  AN Phillips, CA Sabin, JD Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008 Oct 18;22(16):2143-53
  2. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, CA Sabin, A d'Arminio Monforte, N Friis-Moller, R Weber, WM El-Sadr, P Reiss, O Kirk, P Mercie, MG Law, S De Wit, C Pradier, AN Phillips, JD Lundgren. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis. 2008 Apr 1;46(7):1101-10
  3. The D:A:D: Study Group- Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W El Sadr, F Dabis, S De Wit, M Law, A d'Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, I Weller, AN Phillips, JD Lundgren. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008 371 (9622): 1417-26
  4. S de Wit, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, W El-Sadr, A d´Arminio Monforte, E Fontas, MG Law, N Friis-Møller, JD Lundgren. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. Diabetes Care. 2008 Jun;31(6):1224-9
· 2007 ·
  1. The D:A:D: Study Group- Writing committee: N Friis-Møller, P Reiss, CA Sabin, R Weber, A d'Arminio Monforte, WM. El-Sadr, R Thiébaut, S De Wit, O Kirk, E Fontas, MG Law, AN Phillips, and JD Lundgren. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35
· 2006 ·
  1. MG Law, N Friis-Møller, WM El-Sadr, R Weber, P Reiss, A d'Arminio Monforte, R Thiébaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, CA Sabin, AN Phillips, and JD Lundgren for the D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.. HIV Med. 2006; 7:218-230.
  2. D:A:D: Study- Writing committee: R Weber, CA Sabin, N Friis-Møller, P Reiss, WM. El-Sadr, O Kirk, F Dabis, MG Law, C Pradier, S De Wit, B Åkerlund, G Calvo, A d'Arminio Monforte, M Rickenbach, B Ledergerber, AN Phillips, and JD Lundgren. Liver-related deaths among persons infected with the human immunodeficiency virus: The D:A:D Study. Arch Intern Med. 2006;166:1632-164.
  3. M Puoti, A Cozzi-Lepri, C Arici C, NF Moller, JD Lundgren, B Ledergerber, M Rickenbach, I Suarez-Lozano, M Garrido, F Dabis, M Winnock, L Milazzo, A Gervais, F Raffi, J Gill, J Rockstroh, N Ourishi, C Mussini, A Castagna, A De Luca, A d’Arminio Monforte; HBV-HIV International Intercohort Study Group. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther. 2006;11(5):567-74
· 2005 ·
  1. R Thiébaut, W El-Sadr, N Friis-Moller, M Rickenbach, P Reiss, A d'Arminio Monforte, L Morfeldt, E Fontas, O Kirk, S De Wit, G Calvo, MG Law, F Dabis, CA Sabin, JD Lundgren, for the D :A :D : Study Group Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005; 10(7) :811-23.
· 2004 ·
  1. E Fontas, F van Leth, CA Sabin, N Friis-Møller, M Rickenbach, A d'Arminio Monforte, O Kirk, M Dupon, L Morfeldt, S Mateu, K Petoumenos, W El-Sadr, S de Wit, JD Lundgren, C Pradier, P Reiss. Lipid profiles in HIV-1 infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-1075
  2. A d'Arminio Monforte, CA Sabin, AN Phillips, P Reiss, R Weber, O Kirk, W El-Sadr, S De Wit, S Mateu, K Petoumenos, F Dabis, C Pradier, L Morfeldt, JD Lundgren, N Friis-Møller, WRITING Commettee of the D :A :D : Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004;18(13):1811-7
· 2003 ·
  1. M Law, N Friis-Moller, R Weber, P Reiss, R Thiebaut, O Kirk, A d'Arminio Monforte, C Pradier, L Morfeldt, G Calvo, W El-Sadr, S De Wit, CA Sabin, JD Lundgren; DAD Study Group. Modelling the three year risk of myocardial infarction among participants in the D:A:D study. HIV Medicine 2003; 4(1):1-10.
  2. N. Friis-Møller, R Weber, P Reiss, R Thiebaut, O Kirk, A d'Arminio Monforte, C Pradier, L Morfeldt, G Clavo, M Law, W El-Sadr, S De Witt, C Sabin, AN Phillips, J Lundgren for the D:A:D Study Group. Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study. AIDS 2003; 17(8):1179-1193.
  3. The D:A:D Study Group. Combination antiretroviral therapy and risk of myocardial infarction. The Data Collection Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. N Engl J Med 2003; 349:1993-2003.

EuroCoord

· 2019 ·
  1. G Vourli, A Pharris, F Cazein, D Costagliola, F Dabis, J Del Amo, V Delpech, A Díaz, E Girardi, A Gourlay, B Gunsenheimer-Bartmeyer, V Hernando, G Nikolopoulos, K Porter, M Rosińska, C Sabin, B Suligoi, V Supervie, F Wit, G Touloumi. Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?  AIDS. 2019 Jan 27;33(1):133-143. doi: 10.1097/QAD.0000000000002034.

Altre collaborazioni

· 2020 ·
  1. G Vourli, T Noori, A Pharris, K Porter, M Axelsson, J Begovac, F Cazein, D Costagliola, S Cowan, S Croxford, A d'Arminio Monforte, V Delpech, A Diaz, E Girardi, B Gunsenheimer-Bartmeyer, V Hernando, G Leierer, F Lot, O Nunez, N Obel, E Op de Coul, D Paraskeva, S Patrinos, P Reiss, D Schmid, A Sonnerborg, B Suligoi, V Supervie, A van Sighem, R Zangerle, G Touloumi Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress? Clin Infect Dis 2020 Dec 31;71(11):2905-2916. doi: 10.1093/cid/ciaa696
· 2019 ·
  1. F Olearo, H Nguyen, F Bonnet, S Yerly, G Wandeler, M Stoeckle, M Cavassini, A Scherrer, D Costagiola, P Schmid, HF Günthard, E Bernasconi, J Boeni, A d'Arminio Monforte, M Zazzi, B Rossetti, D Neau, P Bellecave, B Rijnders, P Reiss, F Wit, R Kouyos, A Calmy. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment Experienced Patients. Open Forum Infect Dis. 2019 Jul 12;6(10):ofz330. doi: 10.1093/ofid/ofz330. eCollection 2019 Oct.

Amici di ICONA

×

Accesso all'Area riservata

×

Password dimenticata

Inserisca il suo indirizzo email per ricevere le sue credenziali di accesso.

Ok

×